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THESIS ABSTRACTS 
 
 
Chapter 1 
Inhalable drugs formulated as dry powders are more stable than the liquid dosage forms, do 
not require refrigeration, and are more efficient for the delivery of large doses likely required 
for anti-tubercular drugs. This chapter contains a literature review examining published 
techniques for producing inhalable anti-tuberculosis (anti-TB) dry powder formulations. The 
review also covers the current innovations of dry powder inhalers (DPIs) and potential risk of 
delivering therapeutic drugs directly to the lungs. 
  
This chapter has been published in Advanced Drug Delivery Reviews, 2016; 102: 83-101, with 
the title ‘Dry powder inhalable formulations for anti-tubercular therapy’. Authors: 
Parumasivam T, Chang RYK, Abdelghany S, Ye TT, Britton WJ, Chan H-K. 
 
Chapter 2  
Efflux pumps are broadly recognised as one of the key contributors to the development of drug 
resistance in Mycobacterium tuberculosis. It has been demonstrated in preclinical studies that 
co-administration of drugs that inhibit these efflux pumps (efflux pump inhibitors) with the 
anti-TB regimen could significantly enhance the efficacy of the treatment. Verapamil is an 
example of an efflux pump inhibitor which appears to be promising adjunctive anti-TB therapy. 
The drug has also been approved by the U.S. Food and Drug Administration (FDA) for the 
treatment of hypertension. Verapamil, however, has poor bioavailability when administered 
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orally with rifamycins (i.e. rifampicin and rifapentine), thereby limiting its clinical 
effectiveness. This is because rifamycins induce the hepatic enzyme CYP3A4 which 
metabolises verapamil in the liver. To overcome this limitation, an inhalable dry powder 
consisting of amorphous verapamil and crystalline rifapentine was produced. The powder was 
found suitable for aerosol delivery with a respirable fraction (< 5 µm) greater than 70 %. The 
combination also showed higher killing of M. tuberculosis within the macrophages compared 
to either verapamil or rifapentine alone. The combination showed an acceptable half maximal 
inhibitory concentration (IC50) of 62.5 µg/mL on both human monocytic (THP-1) and lung 
alveolar basal epithelial (A549) cell lines. The powder required a moisture-free packaging for 
long-term storage stability. 
 
This chapter has been published in Molecular Pharmaceutics, 2016; 13: 979-989, with the title 
‘In vitro evaluation of inhalable verapamil-rifapentine particles for tuberculosis therapy’. 
Authors: Parumasivam T, Chan JGY, Pang A, Quan DH, Triccas JA, Britton WJ, Chan H-K. 
 
Chapter 3  
The next publication explores the development of an inhalable dry powder consisting of 
thioridazine and rifapentine. Similar to verapamil, thioridazine is an efflux pump inhibitor that 
has potential in the treatment of tuberculosis (TB). Thioridazine is an FDA-approved anti-
psychotic drug. However, the drug can induce adverse cardiac effects in TB patients when used 
at an efficacious oral dose of 200 mg/day. The total dose could be reduced via an inhaled route 
of delivery while increasing pulmonary drug concentrations. Inhalable dry powders consisting 
of thioridazine and rifapentine were produced: (I) Formulation 1 is a combination of amorphous 
thioridazine and crystalline rifapentine, and (II) Formulation 2 containing both drugs in 
amorphous forms. Both powder formulations were found suitable for aerosol delivery with a 
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respirable fraction (< 5 µm) between 68 and 76 %. Formulation 1, however, exhibited greater 
chemical stability after storage for 3 months at a low humidity (vacuum) condition. The 
thioridazine and rifapentine in combination showed better bactericidal activity on M. 
tuberculosis within the macrophages compared to the single drug treatments. In regards to 
cytotoxicity, the combination exhibited an IC50 of 31.25 µg/mL on both THP-1 and A549 cell 
lines. 
 
This chapter has been published in European Journal of Pharmaceutics and Biopharmaceutics, 
2016; 107: 205-214, with the title ‘In vitro evaluation of novel inhalable dry powders consisting 
of thioridazine and rifapentine for rapid tuberculosis treatment’. Authors: Parumasivam T, 
Chan JGY, Pang A, Quan DH, Triccas JA, Britton WJ, Chan H-K. 
          
Chapter 4 
In the following chapter, the potential of polymeric particles for aerosol delivery of anti-
tubercular drugs was investigated. Poly(lactic-co-glycolic acid) (PLGA) is an FDA-approved 
polymer for medical application because of its biocompatibility and biodegradation. However, 
limited data are available on the effects of monomer ratio (lactic and glycolic acid) and 
molecular weight (MW) on the aerosol performance of the powder. The suitability of PLGAs 
for delivering rifapentine was assessed by evaluating PLGAs with monomer ratios of 50:50, 
75:25 and 85:15, and molecular weight (MW) ranging between 24 and 240 kDa. Regardless of 
the monomer ratio and MW, the particles were within the inhalable size of less than 5 µm, and 
the fine particle fraction (FPF) (particles with an aerodynamic diameter < 5 µm relative to the 
total recovered drug mass) ranged between 52 and 57 %. These powders were also non-toxic 
to THP-1 and A549 cells at concentrations up to 1.5 mg/ml. PLGA 85:15 particles exhibited 
the highest likelihood of phagocytosis by THP-1 monocyte-derived macrophages, followed by 
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75:25 and 50:50. These findings suggest that the monomer ratio and MW of PLGA did not 
have any significant effect on the aerosol performance and toxicity, yet may have an indirect 
influence on enhancing the killing of the intracellular M. tuberculosis.      
 
This chapter has been published in European Journal of Pharmaceutical Sciences, 2016; 88: 1-
11, with the title ‘Rifapentine-loaded PLGA microparticles for tuberculosis inhaled therapy: 
preparation and in vitro aerosol characterization’. Authors: Parumasivam T, Leung SSY, Quan 
DH, Triccas JA, Britton WJ, Chan H-K. 
 
Chapter 5 
Many capsule-based DPIs have been optimised to deliver a small amount of drugs, generally 
less than 20 mg, for the treatment of asthma and chronic obstructive pulmonary disease 
(COPD). When delivering higher doses using these inhalers, patients need to load and inhale 
multiple capsules, resulting in a tedious dose administration process. To overcome the 
requirement of loading multiple capsules, an Aerolizer® dry powder device was modified to 
accommodate a size 0 capsule for delivery of high doses to the lungs in a single capsule with 
multiple inhalation manoeuvres. In addition to a large capsule size, in some devices, the four 
piercing pins (0.6 mm diameter) were replaced with a single centrally located 1.2 mm pin and 
1/3 reduced air inlet relative to full inlet of the original design. The in vitro aerosol performance 
of rifapentine and another two drugs, viz. colistin and tobramycin, was evaluated at capsule 
loadings of 30, 50 and 100 mg, respectively. The device with a single pin and 1/3 air inlet 
showed superior performance dispersing rifapentine and colistin. Subsequently, a device with 
a similar configuration but with an expanded capacity to accommodate a size 00 capsule was 
manufactured to increase the drug payload further. When the device was tested at inhalation 
conditions achievable by cystic fibrosis (CF) patients, a capsule loading of 100 mg rifapentine 
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and colistin showed optimal performance at 60 L/min with an air volume of 2.0 L and 45 L/min 
with an air volume of 1.5 – 2.0 L, respectively. These results demonstrate the potential of the 
modified Aerolizer® device to deliver high doses of dry powder systems including anti-
tubercular drugs. 
 
This chapter has been published in The AAPS Journal, 2016; 19: 191-202, with the title ‘The 
delivery of high dose dry powder antibiotics by a low-cost generic inhaler’. Authors: 
Parumasivam T, Leung SSY, Tang P, Mauro C, Britton WJ, Chan H-K. 
 
Chapter 6 
The penultimate chapter of the thesis addresses the potential in vivo inflammatory risk of 
delivering rifapentine particles directly to the lungs. A single dose of 20 mg/kg rifapentine dry 
powder was delivered to 6 - 8-week old BALB/c mice by intratracheal insufflation. The mice 
were euthanised at 12 h, 24 h and 7 days post-treatment, and the lungs and bronchoalveolar 
lavage (BAL) fluid were collected. The control mice were untreated (Nil). The lung and BAL 
were processed for total cell counts and immune cell characterisation via flow cytometry. One 
right lobe of the lung was fixed in 10 % neutral buffered formalin, and stained with hematoxylin 
and eosin (H&E) for histopathological examination. Pulmonary delivery of rifapentine caused 
a significant influx of neutrophils in the lungs by 12 h that had resolved over 7 days. In the 
BAL, there was a significant increase in the abundance of alveolar macrophages at 24 h, and 
this also resolved by day 7. The histopathological patterns were consistent with these findings: 
pulmonary congestion and a massive increase in the abundance of macrophages was observed 
at 12 and 24 h post-treatment. In conclusion, pulmonary delivery of rifapentine particles caused 
a transient neutrophil-associated inflammation in the lungs that resolved over 7 days. This 
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finding suggests that inhalation of rifapentine is suitable for delivering once a week at a dose 
of 20 mg/kg or less. 
 
This chapter has been published in Molecular Pharmaceutics, 2017; 14: 328-335, with the title 
‘Inhalation of respirable crystalline rifapentine particles induces pulmonary inflammation’. 
Authors: Parumasivam T, Ashhurst AS, Nagalingam G, Britton WJ, Chan H-K. 
 
Chapter 7 
The major findings from the previous chapters are summarised in this chapter.  
 Novel inhalable dry powders consisting of efflux pump inhibitors (verapamil 
and thioridazine) and rifapentine were successfully formulated and were shown 
to be suitable for aerosol administration. 
 Inhalable polymeric PLGA particles containing rifapentine were shown suitable 
for targeting intracellular M. tuberculosis and were relatively non-toxic to 
respiratory cells.  
 A modified Aerolizer® dry powder inhaler device which can accommodate a 
size 00 capsule was shown capable of aerosolising high dose dry powder 
antibotics at doses up to 100 mg in a single capsule. 
 Pulmonary delivery of rifapentine caused a neutrophil-associated inflammatory 
response in the lungs that had resolved over 7 days. 
 
Finally, future projects and challenges that accelerate the progress of inhaled anti-TB therapy 
are discussed.  
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INTRODUCTION 
 
 
It is estimated that one-third of the global population has been infected with Mycobacterium 
tuberculosis, a deadly lung pathogen. Approximately, 10 % of infected individuals will develop 
active tuberculosis (TB). Unlike common respiratory infections that typically require one to 
two weeks of oral antibiotics, successful treatment of TB requires at least six months of 
multiple oral antibiotics administered daily. This lengthy treatment duration leads to poor 
patient adherence and severe side effects which has fuelled the development of multi-drug 
resistant (MDR) and extremely drug resistant (XDR) strains of M. tuberculosis. Therefore, 
there is an urgent need for an improved therapeutic option that can address these limitations in 
treating TB infection. 
 
Rifapentine is an antibiotic approved by the U.S. Food and Drug Administration (FDA) since 
June 1998 for the treatment of pulmonary TB and is administered orally. Recent murine 
preclinical efficacy studies suggest that if the currently approved dose of 10 mg/kg twice-
weekly was increased to 20 mg/kg daily, TB can be treated in just three months or less [1]. 
However, these shorter treatment times were not replicable in the human clinical trial [2]. This 
was attributed to a multitude of physiological barriers when rifapentine is administered orally 
in human, including poor absorption and liver metabolism that led to low systemic drug 
concentrations and limited access of rifapentine to the lungs [2, 3]. It is hypothesised that if 
rifapentine is delivered directly to the pulmonary site of infection, these limitations could be 
overcome and the treatment duration can be shortened. 
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The pulmonary route of drug delivery, which mimics the natural route of M. tuberculosis 
infection, has attracted significant attention for treatment of TB as it offers several advantages 
compared to systemic delivery. These including: (i) delivering high drug concentrations to the 
lungs, (ii) avoiding hepatic first-pass metabolism, (iii) potentially the slow release in the lungs 
may reduce the dosing frequency, and (iv) directly targeting the primary site of infection that 
harbours M. tuberculosis. Indeed, inhaled antibiotics have established clinical efficacy in 
treating a variety of respiratory infections, such as CF and pneumonia. However, no inhaled 
medications are currently approved for treatment of TB. Nonetheless, anti-TB drugs 
administered via the pulmonary route have demonstrated favourable pharmacokinetic and 
pharmacodynamic in a number of preclinical studies, and in one Phase 1 study with inhaled 
capreomycin [4].  
 
The nebuliser, pressurised metered-dose inhaler (pMDI) and dry powder inhaler (DPI) are 
popular models of pulmonary delivery devices. The nebuliser generates aerosol medication 
from liquid or suspension formulations in the form of mist using compressed gas or ultrasonic 
waves. The aerosolisation mechanism of pMDI is driven by propellants, such as 
chlorofluorocarbon or hydrofluorocarbon. The drug is dissolved in the propellant under 
pressure and releases a metered volume of drug-propellant suspension when activated. DPI is 
a breath-activated device ideal for dry powder delivery. The powder is dispersed into inhalable 
particles by the inspiratory flow generated by the user. For treatment of TB, patients may need 
to inhale a large total dose (over a hundred milligrams) of an antibiotic for an effective clinical 
outcome. pMDI delivers microgram doses of drugs and requires hand-breath coordination, 
making them unsuitable. While the nebuliser can deliver a high dose, the process is time-
consuming and the devices are relatively bulky and require a source of electrical power. 
Currently, DPIs are designed for delivering tens of milligrams of powders and so with the 
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higher doses likely to be required for TB treatment, patients may need to go through more 
tedious multi-dose inhalations. Therefore, device enhancements and/or design of tailored 
devices for high powder doses need to be developed to ensure that inhaled dry powder 
antibiotic therapy for TB is viable. Furthermore, dry powders have superior chemical stability 
and bacterial resistance compared to liquid dosage forms.  
 
Although inhaled therapy holds potential for rapid treatment of TB, there are also some risks 
that need to be balanced. For example, direct deposition of particles in the already inflamed 
lungs of the patients could exacerbate the pulmonary inflammation and lung damage. 
Therefore, these risks should be evaluated during the inhaled product development.  
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OBJECTIVES AND AIMS 
 
 
The core objective of the studies covered in this thesis is to demonstrate the potential and any 
related challenges of inhaled therapy for the treatment of TB using the inhalation of rifapentine 
as a model. The thesis embarks on the following specific objectives: 
 
1. To summarise the recent advances in inhaled dry powder formulations, including 
vaccine and drug candidates for treatment and prevention of TB. 
2. To investigate the limitations of the current oral rifapentine TB treatment, and provide 
reasoning to develop inhalable drug powders. 
3. To produce novel inhalable dry powders containing rifapentine either as pure drug or 
in combination with other drugs or with carriers, such as polymers, to overcome the 
limitations identified in Objective 2. 
4. To develop a novel DPI that can deliver high doses of rifapentine and other drugs. 
5. To assess the murine inflammatory response when dry powder rifapentine is delivered 
to the lungs   
 
The overall research flow to achieve these objectives is outlined in Figure 1. Chapter 1 
summarises the key findings and updates on the dry powder formulations for treatment and 
prevention of TB. It also covers the current development in the DPI designs and challenges 
pertaining to inhaled delivery in the context of TB treatment. Chapters 2 and 3 are about two 
novel formulations consisting of rifapentine in combination with efflux pump inhibitor drugs 
which hold a high potential to prevent the emergence of drug resistance during treatment and 
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hence shorten the duration of anti-TB regimen. Chapter 4 examines the potential of inhaled 
rifapentine-loaded PLGA particles for targeting intracellular M. tuberculosis. The following 
Chapter 5, evaluates a modified Aerolizer® device as a low-cost generic inhaler for delivery of 
high dose dry powder antibiotics, including rifapentine. The final chapter (Chapter 6) examines 
the pulmonary inflammatory response to respirable rifapentine particles in murine toxicity 
studies.           
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Figure 1. Flowchart of research progress. 
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CHAPTER 1 
 
 
DRY POWDER INHALABLE FORMULATIONS FOR ANTI-
TUBERCULAR THERAPY 
 
  
 
 
 
 
 
This chapter has been published in Advanced Drug Delivery Reviews, 2016; 102: 83-101, with 
the title ‘Dry powder inhalable formulations for anti-tubercular therapy’ Authors: 
Parumasivam T, Chang RYK, Abdelghany S, Ye TT, Britton WJ, Chan H-K. 
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ABSTRACT 
 
 Tuberculosis (TB) is an infectious disease caused by the airborne bacterium, Mycobacterium 
tuberculosis. Despite considerable research efforts, the treatment of TB continues to be a great 
challenge in part due to the requirement of prolonged therapy with multiple high-dose drugs 
and associated side effects. The delivery of pharmacological agents directly to the respiratory 
system, following the natural route of infection, represents a logical therapeutic approach for 
treatment or vaccination against TB. Pulmonary delivery is non-invasive, avoids first-pass 
metabolism in the liver and enables targeting of therapeutic agents to the infection site. Inhaled 
delivery also potentially reduces the dose requirement and the accompanying side effects. Dry 
powder is a stable formulation of drug that can be stored without refrigeration compared to 
liquids and suspensions. The dry powder inhalers are easy to use and suitable for high-dose 
formulations. This review focuses on the current innovations of inhalable dry powder 
formulations of drug and vaccine delivery for TB, including the powder production method, 
preclinical and clinical evaluations of inhaled dry powder over the last decade. Finally, the 
risks associated with pulmonary therapy are addressed. A novel dry powder formulation with 
high percentages of respirable particles coupled with a cost effective inhaler device is an 
appealing platform for TB drug delivery.               
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1. INTRODUCTION 
 
Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium tuberculosis that 
results in more deaths than any other communicable disease [1, 2]. Recently, the World Health 
Organization (WHO) declared 1.5 million deaths globally out of an estimated 9 million people 
who developed TB in 2013 [1]. The threat is exaggerated by co-infection with the human 
immuno-deficiency virus (HIV) and the emergence of multi-drug-resistant (MDR) and 
extensively drug-resistant (XDR) strains of M. tuberculosis. In 2013, 1.1 million TB cases were 
reported among HIV-positive patients, 480 000 new cases of MDR-TB and nearly 50 000 
people with XDR-TB [1]. These numbers may be underestimated due to lack of drug-resistance 
testing and treatment facilities across high-risk regions, such as sub-Saharan Africa, Asia, and 
Eastern Europe [3].     
 
M. tuberculosis is transmitted predominantly through small airborne droplets or droplet nuclei 
created by the coughing or sneezing of a person with pulmonary or laryngeal TB. Once the M. 
tuberculosis in droplet nuclei reaches the terminal airways, they are quickly surrounded and 
engulfed by alveolar macrophages. The bacterial cells within the macrophages are then exposed 
to multiple microbicidal mechanism including reactive oxygen and nitrogen species, acidic pH, 
lysosomal enzymes, and toxic peptides [4, 5]. Furthermore, the macrophages initiate 
production of proteolytic enzymes and cytokines to degrade these pathogenic microorganisms. 
The release of cytokines consequently attracts T lymphocytes to the infected site [6]. In an 
immunocompetent person, granulomas will be formed through accumulation of activated T 
lymphocytes and macrophages around the M. tuberculosis to contain the infection [4, 7]. These 
tumour necrosis factor (TNF)-dependent granulomas create a microenvironment that limits the 
replication and spreading of M. tuberculosis [8, 9]. This condition results in latent TB infection 
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(LTBI), where the infection is not active and cannot be transmitted [10, 11]. Nonetheless, these 
dormant cells can be reactivated when the host immune system is suppressed (e.g. by HIV 
infection) [11, 12]. On the other hand, in immunocompromised patients the granuloma 
formation fails to trap or contain the bacteria [13]. Therefore, the M. tuberculosis will be able 
to escape and spread to other alveoli and organs that lead to progressive primary TB [14].   
 
Until the present, the only approved TB vaccine is an attenuated form of Mycobacterium bovis, 
bacilli Calmette-Guerin (BCG) developed by Calmette and Guérin in 1908 [15]. BCG is a live 
attenuated strain of M. bovis that was isolated from a cow with tuberculous mastitis [15]. BCG 
vaccination has been successfully carried out in children five years and under for over a 
century. The vaccine is relatively cheap and safe, and is administered as a single intradermal 
injection. BCG is protective against childhood and disseminated TB, but less effective against 
adult pulmonary TB [16, 17]. In addition, in clinical trials the efficacy of BCG demonstrated 
the protection wanes over time and only lasts up to 10 years after vaccination [18, 19]. A 
number of meta-analyses have further revealed that the efficacy of BCG immunisation for 
prevention of adult pulmonary TB depends on the geographical location where the vaccination 
was carried out [17, 20, 21]. BCG confered a strong protection against TB to people living in 
the UK (77 %), but was less efficacious in South India, suggesting the host response to BCG 
is strongly modulated by environmental and genetic factors [16]. As a result, the protective 
efficacy of BCG has varied dramatically between different parts of the world and its impact on 
the global control of TB remains ambiguous [17, 20, 21].   
 
The WHO recommended TB therapy requires large doses of antibiotics in combination to be 
taken orally every day for at least six months. In general, during the initial phase the patients 
receive three to four first-line drugs (isoniazid, rifampicin, pyrazinamide, and ethambutol) 
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daily for two months for a rapid amelioration of clinical symptoms [22, 23]. In the continuation 
period, two to three drugs (isoniazid, rifampicin or ethambutol) are given intermittently for 
four to seven months to eliminate the remaining M. tuberculosis cells and reduce the relapse 
rate [22, 23]. The current treatment of MDR-TB requires at least eight months for the initial 
phase with a regimen containing 2 - 3 injectable second-line drugs, such as aminoglycosides 
(kanamycin or amikacin) and polypeptides (capreomycin or viomycin), and then three oral 
drugs including a fluroquinolone, ethambutol and possibly ethionamide for up to 20 months 
[24]. The treatment of XDR-TB is substantially longer (> 12 months) and requires 
administration of the third-line anti-TB drugs (clofazimine, linezolid, amoxicillin plus 
clavulanate and imipenem plus cilastatin), which are expensive and more toxic [24, 25]. The 
long duration of medication and unpleasant side effects of the drugs often lead to high rates of 
noncompliance with the consequence of increased mortality rate. The recent emergence of 
totally drug-resistant TB (TDR-TB) cases has exacerbated the problem. Hence, there is a strong 
demand for a simpler, affordable and more effective medication approach for treatment of TB.           
  
Over the past decade, there have been increasing research interests towards pulmonary route 
for treatment and prevention of TB [21, 26-28]. Compared to conventional administrations, the 
advent of inhalation as a potential route for treatment of TB has the following advantages for 
the second and third line drugs: 
(i) Noninvasive therapy avoids the necessity of injections for second and third-line 
anti-TB drugs and avoids the requirement for the disinfection of injection sites 
and disposal of the needles [29], 
(ii) Allows a high drug concentration in the lung which can reduce the frequency of 
dosing [29, 30], 
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(iii) May require smaller inhaled doses compared to those required for oral route  
[28],  
(iv) Targets alveolar macrophages which harbour M. tuberculosis cells [31-34],  
(v) Activates the innate bactericidal machinery of infected macrophages [35],   
(vi) Aerosol vaccination may best mimic the immune response in the pulmonary 
region followed by systemic immunity [27, 36-39], and 
(vii) Direct absorption of active agents into systemic circulation bypassing hepatic 
first-pass metabolism could avoid the degradation of drug or vaccine by the 
acidic environment in the stomach [40]. 
 
Despite these advantages compared to the current anti-TB regimen, no commercial inhaled 
medication is currently approved for treatment of TB, and this may be due to the following 
factors: 
1. Issues in dose estimation and dosing reproducibility as many parameters could 
affect the lung deposition, i.e. breathing pattern, relative humidity (RH), particle 
morphology, surface, density or shape, and inhaler device design [41, 42], 
2. Inhaled medication and inhaler devices are potentially more costly, and may not 
be affordabable in low-income countries [41],  
3. Lack of trained staff to instruct on the proper use of devices for administration 
[42], and 
4. Insufficient patient compliance and adherance to new inhaled treatments [43]. 
5. While most of these issues can be addressed ultimately, in the authors’ own 
opinions, there are other hurdles which may be more important:  1. TB 
physicians may not utilise inhaled therapy owing to the uncertainty of whether 
(i) the inhaled drugs will penetrate into the  site of infection, including into 
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granulomas, and (ii) delivery of inhaled drugs into already inflammed lungs 
would cause unwanted adverse effects. 2. Global organisations for TB treatment 
may favour oral administration and new drug discovery rather than repurposing 
old drugs for an alternative inhalation route. 
 
This review mainly focuses on recent advances in inhaled dry powder formulations, including 
drug and vaccine candidates for treatment and prevention of TB. Issues and challenges 
pertaining to the development of dry powder formulation with promising aerosol performance 
and long-term physicochemical stability are addressed. In addition, the current development in 
the inhaler device design for delivering a high dose antibiotic amongst TB patients is covered. 
Finally, the clinical and safety aspects of dry powder inhalation are discussed.  
 
2. POWDER FORMULATION APPROACHES USING PARTICLE ENGINEERING 
TECHNIQUES 
 
Dry powder formulations may offer greater physiochemical stability over liquid or suspension-
based formulations. Moreover, they do not require refrigeration and are easy to transport. In 
general, the powder requires moisture-free packaging to protect them from humidity (and light) 
for long-term storage. For inhalation, particles aerodynamically within 1 - 5 µm in size are 
considered suitable for deposition in the lungs.  
 
The traditional way of producing dry powders for aerosol delivery involves crystallisation, 
micronisation through milling, followed by blending with coarse carrier particles [44-46]. 
Lactose is a commonly used carrier for improving the flowability of a powder mixture for better 
capsule emptying and enhanced deposition of therapeutic particles in the lungs [47]. A typical 
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drug-to-carrier proportion is 1:67.5 [48]. Because of the large dose likely to be required for 
inhaled treatment for TB, the lactose carrier system may not be suitable. As a result, alternative 
methods, such as spray drying and spray freeze drying have been utilised. These techniques are 
advantageous in terms of easy production scalability and better control over particle size 
distribution for enhanced aerodynamic performance [44]. Other approaches involving 
liposomal and polymeric formulations may improve the physicochemical stability and offer 
protection for the active ingredient, although the cost can be a barrier for large-scale production. 
Tables 1 and 2 summarise the key findings of dry powder formulations of anti-TB drugs and 
vaccines, respectively.      
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Table 1: Summary of inhaled TB antibiotic powder formulations with the processing parameters and the key findings. 
Drug Production 
method 
Excipient Formulation description Inhaler 
device 
Flow 
rate 
(L/min) 
FPF (%) Key findings Refs  
Amikacin 
sulfate 
Freeze drying Hydrogenated 
soybean 
phosphatidylcholine, 
cholesterol 
saturated soybean 
phosphatidylglycerol  
or stearylamine and 
lactose carrier 
 
Liposomal formulation Rotahaler  30, 60 
and 90 
21.9-34.2  Addition of lactose carrier was 
crucial to enhance the 
flowability of liposome powder 
[49] 
Spray drying 
(inlet, 125-
130°C; outlet, 
65-70°C; fd, 
2mL/min; asp, 
100 %, atom, 
1.5 kg/cm2) and 
freeze drying 
 
Hydrogenated soya 
phosphatidylcholine, 
leucine and 
Poloxamer 188 
Liposomal formulation Rotahaler  28.3 
 
Spray dried, 
65.1;  
freeze 
dried, 50.5 
(< 5 µm) 
 
Spray dried particles found to 
have better aerosol 
performance compared to 
freeze dried powder due to less 
device and capsule retention  
[50] 
Capreomycin 
sulfate 
Spray drying 
(inlet, 186-
189°C; outlet, 
65°C; fd, 80 
mL/min; asp, 
79-82 kg/h; 
atom, 29-31 
g/min) 
 
Leucine  Large porous particles  A hand-
held, dry 
powder, 
breath-
activated 
inhaler 
device  
28.3 50 (< 5.8 
µm) and 10 
(< 3.3 µm) 
Longer half-life in guinea pigs 
 
Significantly reduced the 
bacterial count in the lung of 
guinea pigs challenged with M. 
tuberculosis 
 
Inhalation of single dose 300 
mg achieved serum 
concentration above MIC of M. 
tuberculosis and the dose well 
tolerated in humans 
[29, 
51, 
52] 
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Supercritical 
precipitation 
and spray drying 
(inlet, 60°C; 
asp, 30 L/min) 
 
Leucine  Crumpled particles PuffHaler 
and 
Aerolizer 
28.3 
and 60  
> 21.6 (< 
3.3 µm)   
Contained low moisture 
content and retained the anti-
TB activity after processed 
[53] 
 Nano spray 
drying (inlet, 
100-120°C; 
atom, 100 %) 
 
Lactose Spherical particles with a 
smooth surface and 
smaller size  
HandiHaler 60 11-30 Drug particles needed lactose 
to improve respirability  
[54] 
Frozen in liquid 
nitrogen and 
freeze drying 
PLGA, leucine and 
mannitol 
Double emulsion (w/o/w) 
and polymeric particle 
Spinhaler  100 54.3 (< 5 
µm) 
Encapsulated drug showed 
enhanced killing compared to 
free drug treatment in M. 
tuberculosis infected THP-1 
cells 
 
[55] 
Freeze drying PLGA Double emulsion (o/w/o) 
and porous polymeric 
microparticles 
n/a n/a n/a The method was not easy to 
scalable and the powder 
required further analysis on 
aerosol performance 
 
[56] 
Spray drying 
(inlet, 70-80°C; 
fd, 2 mL/min; 
asp, 27 m3/h; 
atom, 414 L/h) 
and nano spray 
drying (inlet, 
80-90°C; fd, 1; 
spray, 100 %; 
asp, 100 L/min) 
 
 
 
 
Oleate, linoleate and 
linolenate 
Hydrophobic ion-pair and 
nanopowder 
n/a n/a n/a Capreomycin oleate was less 
toxic and showed comparable 
antimycobacterial activity to 
capreomycin alone 
[57] 
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Clofazimine  Spray drying 
(n/a) 
Leucine  None  n/a n/a n/a Treatment of infected mice 
resulted in significant 
reduction in bacterial count 
than the oral administration 
 
[58] 
Isoniazid  Supercritical 
precipitation 
and spray drying 
(inlet, 60°C; 
asp, 30 L/min) 
 
Leucine  Spheres, crystals and 
some cube-like particles 
PuffHaler 
and 
Aerolizer 
28.3 
and 60 
> 21.6 (< 
3.3 µm)   
Contained low moisture 
content and intact anti-TB 
activity after processed 
[53] 
 Spray drying 
(inlet, 110°C; 
outlet, 88-92°C; 
fd, 3 mL/min; 
atom, 800 kPa) 
L-α soybean 
phosphatidylcholine, 
cholesterol and 
mannitol  
Proliposome formulation 
with mannitol as carrier 
A dispersion 
device made 
in-house 
60 15-35 (< 
4.4 µm) 
Powder was non-toxic to 
respiratory cells including 
human epithelial cells and 
alveolar macrophages and did 
not activate inflammatory 
mediators of alveolar 
macrophages 
 
[59] 
Spray drying 
(inlet, 140°C; 
outlet, 70-80°C; 
fd, 5 mL/min; 
asp, 45 m3/h; 
atom, 3 kg/cm2) 
 
Chitosan, 
tripolyphosphate, 
lactose and leucine 
Chitosan/tripolyphosphate 
particles 
Cyclohaler  28.3 67 High FPF with sustained drug 
release profile  
[60] 
Spray drying 
(inlet, 110°C; 
fd, 20 %; asp, 
80 %; atom, 600 
L/h)  
 
 
 
 
 
Chitosan and 
tripolyphosphate, 
with lactose, 
mannitol and 
maltodextrin alone 
or with leucine 
Chitosan/tripolyphosphate 
nanoparticles 
Cyclohaler 60 7-45  Nanoparticles showed lower 
MIC than the free isoniazid 
against Pseudomonas 
aeruginosa and Staphylococcus 
aureus. Nanoparticles blended 
with lactose and leucine 
showed highest FPF 
 
[61] 
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Kanamycin Supercritical 
precipitation 
and spray drying 
(inlet, 60°C; 
asp, 30 L/min) 
 
Leucine  Crumpled particles PuffHaler 
and 
Aerolizer 
28.3 
and 60 
> 21.6 (< 
3.3 µm)   
Contained low moisture 
content and retained the drug 
anti-TB activity 
[53] 
Levofloxacin  Spray drying 
(inlet, 90°C; fd, 
3 mL/min; 
atom, 800 kPa) 
L-α soybean 
phosphatidylcholine, 
cholesterol and 
porous mannitol  
 
Proliposome formulation 
with porous mannitol as 
carrier 
A dispersion 
device made 
in-house 
60 13-38 (< 
4.4 µm) 
Proliposomes had enhanced 
activity against M. bovis than 
the free levofloxacin. No renal 
and liver toxicity was observed 
in the rats repeatedly treated 
with levofloxacin-liposomes 
 
[62] 
PA-824 Spray drying 
(inlet, 107°C; 
fd, 60 mL/min; 
atom, 25 g/min) 
Leucine and 
phospholipid 1,2-
dipalmitoyl-sn-
glycero-3-
phosphocholine 
Porous particles   Hand-held, 
breath-
activated, 
capsule-
based dry 
powder 
inhaler 
device  
n/a 53.3 (< 5.8 
µm) 
Drug concentration in the lungs 
of guinea pigs treated with 
pulmonary route showed drug 
concentration that remained for 
32 h post-exposure, whereas 
those given the drug orally 
cleared the drug more rapidly 
 
Infected animals treated with 
inhalation of PA-824 showed a 
lower number of viable 
bacteria than the untreated 
group. Greater bacterial 
reduction was reported in the 
lungs and spleen of animals 
given oral treatment 
 
[63, 
64] 
Para-
aminosalicylic 
acid (PAS) 
Spray drying 
(inlet, 78°C; 
outlet, 42-55°C; 
fd, 80 mL/min; 
asp, 100 %; 
atom, 570 NI/h) 
Ammonium 
carbonate 
Irregular crystal 
agglomerates to spherical 
crystal clusters and 
porous microparticles 
 
Spinhaler  60  24.5 (< 
6.4 µm) 
The lower inlet temperature 
(78°C) prevented the 
conversion of PAS into acidic 
form during spray drying 
[65] 
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Spray drying 
(n/a) 
1,2-Dipalmitoyl-sn-
glycero-3-
phosphocholine 
Large porous particles AIR  60 59-63 (< 
5.6 µm), 
31-39 (< 
3.4 µm) 
 
Rapid systemic drug onset and 
high concentration in the lung 
lining fluid rats 
 
[66] 
Frozen in liquid 
nitrogen and 
freeze drying 
PLGA, leucine and 
mannitol 
Single emulsion (o/w) 
and polymeric particle 
Spinhaler  100 54.3 (< 5 
µm) 
No significant difference 
between encapsulated and free 
drug treatment in M. 
tuberculosis infected THP-1 
cells 
 
[55] 
Pyrazinamide  Spray drying 
(inlet, 90°C; fd, 
3 mL/min; 
atom, 800 kPa) 
Soybean 
phosphatidylcholine, 
cholesterol, and 
porous mannitol  
Proliposome formulation 
with porous mannitol as 
carrier 
A dispersion 
device made 
in-house 
60 20-30 (< 
4.4 µm) 
Proliposomes were less toxic to 
respiratory cell lines and did 
not activate inflammatory 
response in alveolar 
macrophage 
 
[67] 
Rifampicin Supercritical 
precipitation 
(CO2 flow, 20 
g/min; CO2 
temp, 38-42°C) 
and spray drying 
(inlet, 38-42; fd, 
1 mL/min; asp, 
2 g/min) 
 
Lactose Spherical and 
polymorphic mixture 
n/a n/a n/a No chemical reaction between 
rifampicin and lactose 
[68] 
Recrystallisation 
and spray drying 
(inlet, 70°C; fd, 
5 mL/min; asp, 
40 m3/h; atom, 
500 L/h) 
 
 
 
None  A very thin flaky 
structure and crystalline 
Aerolizer or 
HandiHaler 
60 HandiHaler, 
63.8; 
Aerolizer, 
68.5 (< 5 
µm) 
Flaky morphology reduced the 
agglomeration tendency and 
chemically stable up to 9 
months 
[69] 
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Recrystallisation 
and spray drying 
(inlet, 70°C; 
outlet, 40-50°C; 
fd, 8 mL/min; 
asp, 40 m3/h; 
atom, 600 L/h) 
 
PLA or PLGA Thin flaky Rifampicin 
dihydrate coated with 
PLA or PLGA 
Aerolizer 60 24-45 (< 5 
µm) 
The coated rifampicin 
dihydrates showed slower 
release than the uncoated. No 
significant chemical 
degradation in the rifampicin 
crystals compared to 
amorphous form  
[70] 
Spray drying 
(inlet, 150°C; 
fd, 5 mL/min; 
atom, 2.5 
kg/cm2) 
 
Chitosan  Porous and wrinkled 
particles 
n/a 60 58-62 (5 
µm) 
Sustained drug release (Tmax 8 
h) in vivo animal study 
[71] 
Spray drying 
(inlet, 150°C; 
fd, 5 mL/min; 
atom, 2.5 
kg/cm2) 
Chitosan and 
hydroxyl propyl 
methyl cellulose 
(HPMC) and 
blended with Inhalac 
230  
 
Wrinkle surfaced porous 
microparticles with 
Inhalac 230 as a carrier 
Aerolizer 60 51.5-72.7 (5 
µm) 
Inhalac 230 improved the 
dispersibility of powder on 
inspiration 
[72] 
Freeze drying PLGA Single emulsion (w/o)-
solvent evaporation  with 
premix membrane 
homogenisation PLGA 
microspheres 
A Model 
DP-4 dry 
powder 
insufflatorTM  
(for rat) 
30 46.7-69.9 
(1-5 µm) 
Premix membrane 
homogenisation can be used to 
prepare monodisperse particles 
with extended drug release and 
suitable aerodynamic 
performance for intratracheal 
delivery in rats 
 
[73, 
74] 
Freeze drying L-α soybean and 
phosphatidylcholine,  
cholesterol with 
mannitol, trehalose 
or lactose as a 
cryoprotectant 
Proliposome formulation  A dispersion 
device made 
in-house 
60 Mannitol, 
66.8; 
Trehalose, 
32.0; 
Lactose, 
27.8 (< 5 
µm) 
Mannitol as a cryoprotectant 
produced crystalline powder 
with good aerosol performance 
compared to trehalose and 
lactose which are moisture 
sensitive 
 
[75, 
76] 
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Liposome with mannitol was 
not toxic to lung epithelial or 
alveolar macrophages, and did 
not activate inflammatory 
response in alveolar 
macrophages  
 
Spray drying 
(inlet, 60°C; 
outlet, 35-39°C; 
fd, 2.5 mL/min; 
atom, 20 L/min) 
Mannitol, 
ethylcellulose and 
PLGA, either alone 
or in combination 
with 
polyethylenimine  
Rifampicin-PLGA 
submicron particle 
dispersed in mannitol 
microparticles 
Jethaler 28.3 7  Single step process to produce 
PLGA nanoparticles 
 
Rifampicin-PLGA recognised 
by alveolar macrophages that 
increased the rifampicin uptake 
 
[77, 
78] 
Freeze drying PLGA Single emulsion (w/o)-
solvent evaporation  
a Model 
DP-4 dry 
powder 
insufflatorTM  
(Penn 
Century, 
PA) 
 
30 52 (1-5 µm) Non-biodegradable polyvinyl 
alcohol replaced with 
degradable sucrose palmitate. 
The particles efficiently 
phagocytosed by alveolar 
macrophages   
 
[79] 
Spray drying 
(inlet, 50°C) 
PLA and PLGA Polymeric microparticles Cyclohaler  28.3 
(1.1-5.8 
µm) 
PLA, 55-
70; 
PLGA, 22-
32 
PLA showed faster release than 
PLGA. The microspheres 
showed lack of cytotoxicity 
profile and prolonged drug 
release in animal 
pharmacokinetic study 
 
[80] 
Frozen in liquid 
nitrogen and 
freeze drying 
 
 
 
 
PLGA, leucine and 
mannitol 
Single emulsion (o/w) 
and polymeric particle 
Spinhaler  100 54.3 (< 5 
µm) 
No significant difference 
between encapsulated and free 
drug treatment in M. 
tuberculosis infected THP-1 
cells 
 
[55] 
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Spray drying 
(inlet, 60°C; 
outlet, 40°C; fd, 
16.7 mL/min; 
asp, 15; atom, 
700 Nl/h)  
PLGA Polymeric microparticles n/a n/a n/a Spray drying superior to single 
emulsion to obtain high drug 
payload particles compared to 
single emulsion technique 
 
Guinea pigs insufflated with 
single emulsion rifampicin-
PLGA significantly reduced 
the bacterial load, reduced 
inflammation and lung damage 
compared to untreated group 
 
[81, 
82] 
Supercritical 
precipitation 
(CO2 flow, 1.5 
g/mL) 
 
PLA Polymeric microparticles n/a n/a n/a Inhalable particles can be 
produced using supercritical 
technique 
[83] 
Spray drying 
(inlet, 40°C; 
outlet, 33°C; fd, 
2.5 mL/min; 
asp, 40 Nm3/h; 
atom, 0.8 
kg/cm2) 
 
Stearic acid and 
branched 
polyethyleneimine 
blended with Inhalac 
230 as a carrier 
 
Cationic lipopolymeric 
nanomicelle with Inhalac 
230 as a carrier 
 Rotahaler  28.3 67.9 (1.1–
5.8 μm) 
Process parameter optimisation  [84] 
 Spray drying 
(inlet, 170°C; 
fd, 45 mL/min; 
asp, 25 g/min; 
atom, 33 psi) 
 
 
 
 
 
 
Leucine Large porous particles n/a n/a 53 (< 5.8 
µm) 
Pulmonary delivery using one-
half of the oral dose achieved 
systemic concentration similar 
to oral dose and 3-4-fold 
higher drug concentration in 
bronchoalveolar lavage than 
the oral delivery in guinea pigs 
 
[85] 
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 Spray drying 
(inlet, 150°C; 
outlet, 65°C; fd, 
10 rpm; asp, 40 
%; atom, 1.5 
kg/m3) 
 
Chitosan particles 
blended with 
inhalable lactose 
Chitosan formulation with 
Lactohale® 100 and 
Lactohale 300® 
Lupihaler 28.3 
 
10- 25 % 
(<5 µm) 
The rifampicin loaded particles 
were less toxic to the lungs 
than the free drug treatment in 
rats 
 
[86] 
 
 
 
 
Freeze drying  Thiobarbituric acid Uniform and amorphous 
rifampicin microspheres 
- - - The particles were mono-
dispersed between 1 and 3 µm, 
and readily phagocytosed by 
macrophages 
[87] 
Rifapentine  Recrystallisation 
and spray drying 
(inlet, 60°C; 
outlet, 39°C; fd, 
2 mL/min; asp, 
40 m3/h; atom, 
650 L/h) 
None  Elongated crystalline Aerolizer 100 83.2 (< 5 
µm) 
The powder well tolerated by 
alveolar macrophage and 
epithelial cell lines 
 
High drug concentration in the 
lung compared to 
intraperitoneal delivery in 
mouse model 
 
[30, 
88] 
Spray drying 
(inlet, 115-
125°C; outlet, 
60-65°C; fd, 1.2 
mL/min; asp, 35 
%; atom, 1.8 
bar) 
Hydrogenated soya 
phosphatidylcholine  
Smooth, spherical 
particles of proliposomes 
Rotahaler 60 92.5 (< 4.4 
µm) 
Longer retention of drug in the 
lungs of albino rats pulmonary 
pharmacokinetic 
 
Rifapentine loaded liposomes 
safe at 1 and 5 mg/kg. Higher 
dose (10 mg/kg) caused liver 
and kidney damage in rat 
model 
 
[89, 
90] 
 Spray drying 
(inlet, 60°C; 
outlet, 39°C; fd, 
15 mL/min; asp, 
40 m3/h; atom, 
672 L/h) 
PLGA Polymeric particles Osmohaler 100  52-57 (< 5 
µm) 
The molecular weight and 
monomer ratio is not crucial 
factors determining the aerosol 
performance of PLGA particles 
[91] 
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Rifabutin Spray drying 
(inlet, 150°C; 
outlet, 65°C; fd, 
10 rpm; asp, 40 
%; atom, 1.5 
kg/m3) 
 
Chitosan particles 
blended with 
inhalable lactose 
Chitosan formulation with 
Lactohale® 100 and 
Lactohale 300® 
Lupihaler 28.3 
 
10- 25 % 
(<5 µm) 
The rifabutin loaded particles 
were less toxic to the lungs 
than the free drug treatment in 
rats 
[86] 
Isoniazid, 
rifampicin, 
and 
pyrazinamide  
Spray drying 
(inlet, 60°C; 
outlet, 39°C; fd, 
2 mL/min; asp, 
40 m3/h; atom, 
500 L/h) 
 
None  Spherical with a surface 
composed primarily of 
rifampicin 
Aerolizer 100 45 (< 5 µm) Combination powder displayed 
better physical stability than 
the antibiotics spray dried 
alone 
[92] 
Isoniazid, 
rifampicin, 
and 
pyrazinamide 
Freeze drying Sucrose as a 
cryoprotectant and 
lactose core carrier 
Thin film hydration 
method and liposomal 
nanoparticles coated with 
mannan as ligand 
n/a n/a n/a Rapid high drug concentration 
in the lungs and the high drug 
concentration retained over 
long period (nearly 24 h) when 
compared to free drug 
treatment  
 
[93] 
Isoniazid and 
rifabutin 
 
 
 
 
 
 
 
 
 
 
 
 
 
Spray drying 
(inlet, 53-55°C; 
outlet, 32-34°C; 
fd, 4.5 mL/min; 
atom, 700-800 
Nl/H) 
PLA Polymeric particles Animal 
nose-only 
exposure 
chamber  
20 78.91 (< 4.6 
μm) 
Drug concentration in the lungs 
20 times higher in 
microparticles inhaled animals 
compared to drug solution 
administered mice group 
 
Prolonged half-life of the drugs 
after single inhalation in rhesus 
macaques 
 
[94, 
95] 
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Moxifloxacin, 
rifapentine, 
and 
pyrazinamide 
Spray drying 
(inlet, 60°C; 
outlet, 39°C; fd, 
1.4 mL/min; 
asp, 40 m3/h; 
atom, 540 L/h) 
With or without 
leucine 
Spherical and largely 
amorphous 
Aerolizer 100 55.5 ± 1.9% 
(without 
leucine) and 
63.6 ± 2.0% 
(with 
leucine) 
 
Leucine protects the particles 
from moisture to prevent 
recrystallisation of 
pyrazinamide 
[96] 
Rifapentine 
and verapamil 
Recrystallisation 
and spray drying 
(inlet, 60°C; 
outlet, 39°C; fd, 
2 mL/min; asp, 
40 m3/h; atom, 
650 L/h) 
Leucine Elongated rifapentine and 
corrugated verapamil 
particles 
Osmohaler 100  72-75 % 
(<5 µm) 
Verapamil enhanced the killing 
of M. tuberculosis within the 
infected macrophages. The 
powder stable up to 3 months 
stored in 0 % relative humidity 
 
[97] 
n/a: not available; inlet: inlet temperature; outlet: outlet temperature; fd: feed rate; asp: aspirator; atom: atomiser; CO2 flow: carbon dioxide flow rate 
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Table 2: Summary of inhaled powder vaccine formulations with the processing parameters and the key findings. 
Drug  Production 
method  
Excipient  Formulation 
description 
Inhaler 
device 
Flow 
rate 
(L/min) 
FPF 
(%) 
Key findings   Refs  
Ad35-vectored 
TB AERAS-
402 
 
 
 
 
Spray drying 
(inlet, 65-
125°C; outlet, 
34-50°C; fd, 
4.5 mL/min; 
asp, 439–538 
m3/h L/h; atom, 
35 m3/h)   
 
Mannitol, trehalose, 
leucine, sucrose, 
cyclodextrin, dextran, 
inositol, histidine, 
polyvinylpyrrolidone, 
and tween 80 
Mannitol 
based dry 
powder 
n/a n/a n/a Trehalose with dextran formed 
dispersible particles and appeared to be 
good vaccine stabiliser 
[98] 
Bacillus 
Calmette–
Guérin (BCG) 
Spray drying 
(inlet, 100-
125°C; outlet, 
40°C; fd, 7.0 
mL/min; asp, 
35 L/h) and 
freeze drying 
Leucine  Bacteria in a 
matrix of 
leucine 
A hand-held 
dry powder 
inhaler and 
newborn 
inhaler 
device 
28.3 n/a Spray drying superior to freeze drying 
due to former reduced loss of viable 
bacteria 
 
Inhaled powder displayed enhanced 
immunogenicity compared to 
equivalent dose of subcutaneous 
administration in guinea pigs 
 
[99, 
100] 
Culp 1-6 and 
MPT 83 
conjugated to 
Lipokel  
 
 
 
 
 
 
 
 
Spray drying 
(inlet, 50°C; 
outlet, < 35°C; 
fd, 1.0 
mL/min; asp, 
38 m3/h; atom, 
700-800 L/h) 
 
Mannitol  Mannitol with 
1 % protein 
n/a n/a n/a Intact protein concentration after spray 
dried. Intratracheal insufflations in 
mice showed a significant influx of 
neutrophils and antigen presenting 
cells in the lungs 
 
[39] 
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 Mtb Antigen 
85B (Ag85B) 
and trehalose 
dibehenate 
(TDB) 
Spray drying 
(inlet, 65°C; 
outlet, 41-
43°C; fd, 4.5 
mL/min; asp, 
600 L/h; atom, 
3.0 bar)   
PLGA  Polymeric 
microparticles 
 Insufflator 
DP-3 (Penn 
Century, 
PA)  
60 68.9 
(< 
5 μm)  
PLGA-rAg85B induced hybridoma 
cells to produce IL-2 at intensity that 
was two orders higher than response by 
free rAg85B 
 
PLGA-rAg85B effective in boosting 
the primary BCG immunisation against 
M. tuberculosis in guinea pigs 
 
[101, 
102] 
n/a: not available; inlet: inlet temperature; outlet: outlet temperature; fd: feed rate; asp: aspirator; atom: atomiser 
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2.1 Formulations by spray drying  
 
Spray drying is a widely explored technique for the production of respirable particles owing to 
its advantages of cost-effectiveness and ready capacity for scale-up. It has been successfully 
used to develop commercially available inhaled medications, such as insulin (Exubera®, 
Pfizer), tobramycin (Tobi® Podhaler, Novartis) and mannitol (Aridol®, Pharmaxis) [103-105]. 
Spray drying is a single step process that directly converts drug solutions or suspensions into 
particles. Details of the spray drying process and its mechanism were reviewed by Vehring 
[106]. Briefly, a drug solution or suspension is atomised into a drying chamber where the 
sprayed droplets are rapidly dried into solid particles by a heated gas. The size distribution and 
physical properties of the particles can be optimised through modifying process parameters 
such as the feed rate, atomisation pressure, inlet air temperature and aspirator gas flow.  
 
Spray dried drug particles often exist in an amorphous state, which is usually cohesive, 
hygroscopic and has higher surface energy than the crystalline form. A conventional approach 
to improve aerosolisation of cohesive powders is spray drying with surface coating materials 
to reduce inter-particulate forces [106, 107]. Amino acids especially leucine is a well-
recognised dispersion enhancer in spray dried powders [106, 108, 109]. Leucine is able to 
recrystallise on the surface of the particles, forming a shell to reduce inter-particle interaction 
and enhance the flow and dispersibility of the powder [108, 110]. Chan et al. reported that 
leucine could prevent water-induced recrystallisation of hygroscopic pyrazinamide in an 
inhalable formulation containing rifapentine, moxifloxacin and pyrazinamide [96]. Due to the 
low water solubility of leucine (24 g/L), this surface coating was also shown to delay the 
dissolution rate of the drug particles [111]. In the context of TB treatment, the slow release 
may prolong the drug action in the lungs and enhance the internalisation by macrophages. In 
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addition, surface coating with lipophilic excipients, such as magnesium stearate and sodium 
stearate, was demonstrated to reduce interparticulate contact area and deagglomeration for 
enhanced aerosol performance [112, 113].  
 
Over the last decade, inhalable dry powder formulations consisting of first-line, second-line or 
a combination of both classes of anti-TB drugs have been studied to reflect current treatment 
regimens for the treatment of MDR and XDR cases [92, 94, 96, 114, 115]. There are also few 
studies reported on spray dried BCG and novel vaccine candidates [39, 99, 116]. Some of the 
well-established spray dried drug or vaccine formulations will be discussed. 
 
2.1.1 Capreomycin sulphate 
 
Capreomycin sulphate is a polypeptide antibiotic and a first choice of the second-line drugs in 
MDR-TB chemotherapy. Capreomycin is administered intramuscularly or intravenously up to 
1.0 g daily for 5 days a week [117] and these routes of administration showed a low peak serum 
drug concentration [118]. Garcia et al. reported pioneering study on inhaled capreomycin, 
showing a thin-walled porous particles produced by spray drying of 80 % capreomycin with 
20 % leucine in ethanol:water cosolvent system [52]. The particles had a mass median 
aerodynamic diameter (MMAD) of about 5 µm with a reasonably high fine particle fraction 
(FPF < 5.8 µm) of 47.7 % when tested at a flow rate of 28.3 L/min using a hand-held dry 
powder inhaler [52]. A single-dose insufflation of the formulation into guinea pigs resulted in 
a low serum drug concentration, but a longer half-life compared to intramuscular or intravenous 
administrations [52]. No significant changes in drug content, physical diameter and aerosol 
performance was observed after storing the powder at 4°C or room temperature and 10.5 % 
relative humidity (RH) [51]. In addition, the study investigated the influence of leucine 
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concentration on the aerosol performance of capreomycin. No significant difference were 
observed in the FPF (< 5.8 µm) of the formulations with 10 to 50 % leucine, suggesting 10 % 
was sufficient to improve powder dispersion [51]. Interestingly, denser particles were reported 
when leucine concentration was reduced from 50 to 30 % (0.36 g/mL for 50 % leucine; 0.68 
g/mL for 30 % leucine), but the particles became less dense when the leucine concentration 
was further reduced from 20 to 10 % (0.64 g/mL for 20 % leucine; 0.32 g/mL for 10 % leucine) 
[51]. 
 
More recently, Shoubben et al. produced a capreomycin formulation using a nano-spray dryer 
[54]. The initial powder was cohesive, resulting in a low respirable fraction of only 14 % at 60 
L/min using HandiHaler®. When the powder was blended with lactose (1:50 
capreomycin:lactose) the respirable fraction was increased to 26 %, highlighting the need of 
lactose to improve the dispersability of the capreomycin. As mentioned earlier, the bulky 
composition of lactose carrier may not be practical for delivering a large dose of capreomycin 
required for TB therapy. In regards to the differences between conventional and nano spray 
dryer, the latter has an advantage of achieving high powder recovery with low amount of 
materials or/and low volumes of samples to allow formulation optimisation during early 
product development [119].       
 
2.1.2 Rifamycins (rifampicin and rifapentine) 
 
Rifampicin is a semi-synthetic derivative of rifamycin and the most potent sterilising agent in 
the current anti-TB regimen. The drug is orally administered at a recommended dosage of 600 
mg daily [120]. Rifapentine is a long-acting derivative of rifampicin that was subsequently 
approved by Food and Drug Administration (FDA). Rifapentine may be administered weekly 
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at an oral dose of 600 mg during the continuation period of TB therapy in low risk and HIV-
negative TB patients [23].  
 
Rifampicin 
 
Son and McConville produced a spray dried, flake-like rifampicin dihydrate for inhalation [69]. 
The rifampicin crystalline powder possessed superior dispersion properties with FPF (< 5 µm) 
above 60 % when dispersed using both Aerolizer® and HandiHaler® devices at 60 L/min. This 
formulation was chemically stable for up to nine months at ambient conditions, compared to 
approximately 26 % degradation in amorphous rifampicin under the same conditions [69]. In 
a subsequent study, the dihydrate crystals were coated with poly (lactic-co-glycolic acid) 
(PLGA) and polylactic acid (PLA) polymers using a three-fluid spray nozzle to reduce the 
initial drug release, and this was shown to protect the microcrystals from water absorption [70]. 
However, this coating adversely affected the aerosol performance of the crystals as the FPF 
was reduced to less than 45 %, probably owing to the larger particle size after coating [70]. 
 
Ohashi et al. produced PLGA-rifampicin nanocomposite particles dispersed in mannitol 
microspheres without any stabiliser using a four-fluid nozzle spray dryer, as reviewed in Ozeki 
and Tagami [121]. Briefly, rifampicin/PLGA in acetone:methanol (2:1), aqueous mannitol and 
compressed air were simultaneously supplied through different passages of the four-fluid 
nozzle, mixed at a high turbulence at the nozzle tip and then spray dried [122]. In vitro studies 
in rat macrophages showed that these rifampicin nanoparticles were rapidly phagocytosed by 
alveolar macrophages leading to increased drug uptake [78]. These studies confirmed that it is 
possible to produce polymeric nanocomposites for efficient delivery of rifampicin to the lungs 
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using the four-fluid nozzle spray dryer in a single step process. This is potentially a rapid and 
readily scalable method to produce inhalable nanocomposite particles. 
 
Rifapentine 
 
When compared with rifampicin, rifapentine has the advantages of a longer serum half-life, 
greater bactericidal activity and higher intracellular accumulation [88, 123]. Chan et al. 
compared dispersibility of solvent spray dried amorphous and crystalline form of rifapentine 
produced through acetone-water cosolvent system [88]. Both forms were suitable for inhalation 
with a FPF (< 5 µm) of more than 70 % when dispersed at 100 L/min using the Aerolizer®. 
The crystalline form, however, exhibited a greater chemical stability than the amorphous 
rifapentine after storage at both 0 % and 60 % RH for at least 3 months. In another study, Patil-
Gadhe et al. produced inhalable hydrogenated soya phosphatidylcholine (HPSC) proliposomes 
loaded with rifapentine using a single-step spray drying of hydroalcoholic solution containing 
rifapentine, HPSC, and cholesterol. The proliposomes have a low MMAD (1.56 ± 0.16 µm) 
and high FPF (< 4.4 µm, 92.5 ± 1.5 %) [89]. The powder also showed a good tolerability at 
doses up to 5 mg/kg with improved pulmokinetic parameters in rats [89, 90].   
 
2.1.3 Para-aminosalicylic acid (PAS) 
 
There has been growing interest in formulating para-aminosalicylic acid (PAS) into an 
inhalable form, in part due to the requirement of relatively large dose (8 - 12 g) when 
administered orally. Tsapis et al. formulated porous and partly crystalline micron-sized 
particles by spray drying PAS with 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) in 
ethanol solution [66]. These particles were suitable for optimal lung deposition (FPF < 5.6 µm, 
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59 - 63 % at 60 L/min using AIR® inhaler) and were physically stable up to four weeks at 40°C 
and 15 % RH [66]. On the other hand, Gad et al. produced nanoporous microparticles by spray 
drying with ammonium carbonate that underwent thermal decomposition in the hot drying 
chamber into gaseous ammonia, carbon dioxide and water thus producing a novel salt/complex 
form of PAS [65]. The particles were crystalline and agglomerated into non-uniform rough 
surface sphericals. When the powder was dispersed using the Spinhaler® device at 60 L/min, 
approximately 25 % drug deposited in the lower region of the impinger (< 6.4 µm) [65]. The 
FPF of this pure drug formulation will need to be improved further to permit greater lung 
exposure to PAS with a lower inhalable dose than the typical oral dose.   
 
2.1.4 Pretomanid (PA-824) 
 
Pretomanid (PA-824) is a nitroimidazopyran anti-TB drug, currently in Phase II clinical trial 
as part of a combination with standard oral regimen for drug sensitive TB [124]. Sung et al. 
produced thin-walled, porous particles composed of PA-824, leucine and phospholipid 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) for inhalation using spray drying technique 
[63]. The MMAD, geometrical standard deviation (GSD), and FPF (< 5.8 µm) was 4.74 ± 0.04 
µm, 1.53 ± 0.02 and 53.3 ± 2.7 %, respectively which support the suitability of the powder for 
inhalation [63]. The powder also exhibited intact physical, chemical and aerodynamic stability 
for a year under refrigerated condition (4°C), and for six months at room temperature (25°C) 
and 10 % RH [63]. Furthermore, the powder exhibited an elevated drug concentration in the 
lungs of the guinea pigs when given via the pulmonary route compared to the oral delivery 
[63].     
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2.1.5 Isoniazid 
 
There are various reports on inhalable isoniazid. Severe hepatotoxicity is an infrequent but 
important adverse effect of oral isoniazid, and direct drug delivery to the lungs is a rational 
approach to reduce this toxicity. Rojanarat et al. showed that spray dried isoniazid-loaded 
proliposomes possessed a relatively low FPF (< 4.4 µm) of 15 to 35 % when dispersed at 60 
L/min using a locally-made dispersion device [59]. In contrast, an FPF (< 5 µm) of more than 
60 % was reported for spray dried chitosan particles dispersed using Cyclohaler® at 28.3 L/min 
[60]. The poor dispersion of proliposomes was due to strong agglomeration force between the 
particles compared to the less cohesive chitosan particles. In addition, Pourshahab et al. 
produced isoniazid-loaded chitosan/tripolyphosphate nanoparticles via an ionic gelation 
method and spray dried into microparticles using lactose and leucine as carriers [61]. The in 
vitro deposition data indicated the spray dried powder has a high FPF of 45 % at 60 L/min 
using Cyclohaler®. Furthermore, the nanoparticles showed enhanced in vitro anti-
mycobacterial activity compared to isoniazid solution, and this was attributed to the 
nanoparticles binding to the negatively charged bacterial cell surface [61]. 
 
2.1.6 Combination formulations 
 
For multi-drug formulations, the combination ratios were determined based on the 
recommended oral dose [92, 96]. Chan et al. produced an excipient-free dry powder consisting 
of pyrazinamide, rifampicin and isoniazid at a ratio of 5:2:1 (w/w) following the oral doses of 
25 mg/kg, 10 mg/kg and 5 mg/kg, respectively [92]. The TOF-SIMS analysis of these particles 
showed that rifampicin predominantly concentrated on the surface of the particles. This 
observation suggested that during spray drying, the hydrophobic and heavier rifampicin 
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molecules tend to remain on the surface of the drying droplets to form the outer layer compared 
to the hydrophilic and smaller molecules of pyrazinamide and isoniazid. The combination 
formulation also displayed better physical stability than the spray dried individual drugs [92]. 
By contrast, previous studies reported that when rifampicin was combined with either 
isoniazid, pyrazinamide or both, it resulted in formation of adduct-rifamycin isonicotinyl 
hydrazone [125]. A similar phenomenon was also reported in polymeric formulations [126]. In 
the following study, Chan et al. replaced isoniazid and rifampicin with moxifloxacin and 
rifapentine, respectively, and spray dried with or without leucine as an excipient. The powder 
was chemically stable for up to 3 months storage at 25°C and 60 % RH and showed no extra 
peaks in the HPLC data [96]. The combination of spray dried drugs also retained their in vitro 
anti-mycobacterial activity. However, the stabilisation with leucine was necessary to prevent 
recrystallisation of pyrazinamide for long-term storage. Overall, these studies demonstrated the 
feasibility of spray drying drugs in combination into respirable powders without altering or 
degrading their chemical constitution or anti-mycobacterial properties.   
 
2.1.7 Vaccine candidates 
 
The general principle for spray drying vaccine formulations is similar to that for drugs, except 
that careful attention is required on the processing parameters, such as excipient selection and 
drying temperature, to prevent denaturation of antigens. These aspects of spray drying vaccines 
along with stabilisation process were systematically reviewed by McAdams et al. [127].  
 
For inhalational delivery, live M. bovis BCG (5 % w/w) was formulated into an inhalable 
powder containing a larger fraction of L-leucine (95 % w/w) to improve the flowability and 
dispersibility of the powder [99, 100]. The powder showed intact bacterial viability upon 
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storage at 4°C and 20 % RH in high moisture protection vials up to 3 months [99]. The dry 
powder form of BCG delivered intra-tracheally to guinea pigs induced protection against 
pulmonary TB [100]. 
 
Recently, Tyne et al. successfully produced dry powders containing the M. tuberculosis 
antigens, cutinase-like proteins (Culp) 1 and 6 and MPT83, conjugated to Pam2Cys (Lipokel), 
a TLR2 ligand, with excipient mannitol [39]. Mannitol was chosen because unlike other sugars, 
such as sucrose and lactose, spray dried mannitol is largely crystalline and physically stable 
[128]. Immunoblotting revealed that the protein-adjuvant conjugates remained intact after 
spray drying [39]. Intra-tracheal delivery of both protein-adjuvant conjugates stimulated 
protective T cell responses in the lungs of the vaccinated C57BL/6 mice [39]. Using a similar 
approach, Jin et al. spray dried adenoviral-vectored vaccine (AERAS-402) in combination with 
mannitol, cyclodexrin, trehalose and dextran. The powder was reported to be hydrophobic 
which benefited the survival of the viruses vaccine during both production and storage at 
various temperatures covering 4 - 37°C [98]. These findings indicated dry powder vaccines 
would have a prolonged shelf life in the absence of cold-chain storage, and this would make 
the aerosol immunisation practical globally. 
 
2.1.8 Bacteriophage formulations 
 
Bacteriophage (or phage) therapy is being reappraised as an alternative treatment to antibiotic 
therapy [129, 130]. Mycobacteriophages are viruses that infect M. tuberculosis thereby killing 
the pathogenic bacteria. Phages subsequently lyse the host bacteria, releasing the progeny that 
can infect mycobacteria at other sites of infection allowing continuation of the phage cycle. 
Phages are a promising substitute to antibiotic therapy because resistance to phage infection is 
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unlikely to develop [131]. Some early studies reported successful phage inhalation therapy for 
treating patients with other lung infections [132, 133]. Recently, Liu et al. reported the first 
systematic study on aerosol delivery of mycobacteriophages D29 to mice utilising nebulisation 
mode [134]. Inhalable dry powder containing mycobacteriophages have not been formulated 
for TB therapy, however the optimal excipients and the stability of phage formulations have 
been investigated for other lung infections, such as in cystic fibrosis.  
 
Excipients, including polyethylene glycol, mannitol, lactose, leucine, and trehalose, are used 
for spray drying phages to act as bulking and protectant agents during the process. Trehalose 
is often used to minimise the loss of phages during the processing, and leucine is utilised to 
improve the powder dispersibility in spray drying [135]. The mixture of trehalose, leucine and 
a surfactant can generate a spray dried phage formulation with low processing loss [136]. 
Vandenheuvel and colleagues tested the influence of different excipients, including lactose, 
trehalose and dextran 35 for spray drying the phages [137]. The results revealed that trehalose 
was the most efficient excipient for protecting the phages from mechanical stress and 
temperature during the spray drying process. In a study by Golshahi et al. phages were 
formulated with lactose and lactoferrin using freeze drying instead of spray drying [138]. 
Viability tests after freeze drying showed the loss of one and two log10 titer for phages KS4-M 
and PhiKZ, respectively. The phages also remained viable after a milling procedure for 
deagglomerating the freeze dried powders. Furthermore, Leung et al. compared the phage 
viability and dispersibility of combination powders containing mannitol, trehalose and leucine 
produced via spray drying and spray freeze drying. The spray dried powders caused less loss 
in phage titre and a higher respirable fraction than the spray freeze dried powders. However, 
the spray freeze dried particles were reported to provide a better physical protection to the 
phages than the spray dried counterparts [139]. 
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To develop stable and inhalable formulation of phages, factors such as pH, temperature, 
interfacial adsorption and ionic strength, play a key role in the stability and the feasibility of 
the formulation. Knezeciv and colleagues tested the stability of Pseudomonas aeruginosa-
specific phages in different pH conditions and demonstrated complete survival at pH 7. The 
survival rate dropped slightly to 80 - 100 % at pH 9; however, a significant drop was observed 
at pH 1.5 [140]. Studying the thermal stability of phages revealed their stability at 4°C. 
Nonetheless, they become less stable at elevated temperatures, and this should be avoided in 
processing phage formulations [141]. Another important factor in phage formulation stability 
is ionic strength. Phages may undergo osmotic shock followed by death if there is a substantial 
difference in the osmotic pressure between the interior and exterior of the phage [138]. Hence, 
care should be taken during the drying process in order to reduce the rate of ionic strength 
change. Mechanical stress, such as high speed mixing, centrifugation, and filtration may 
damage the phages causing them to denture [142].  
 
Matinkhoo et al. formulated inhalable phage powder with trehalose and leucine using a 
relatively low spray dryer outlet temperature of 40 to 45°C, and this resulted in less than one 
log10 titer loss after spray drying [136]. The thermal and shear stress during these processing 
parameters did not significantly affect the stability of the phages. By contrast, Finlay’s group 
tested the stability of freeze dried phage formulations designed for inhalation and found no 
significant titer loss when the phage powders were stored at 22 % RH at 4°C and 21°C for three 
months [138]. A recent study demonstrated the stability of spray dried phages with trehalose 
at low temperatures (4°C) and RH (0 %). However, they become increasingly unstable with 
rise in humidity owing to matrix recrystallisation that can damage the phages. In addition, some 
phages become unstable when stored at the relatively high temperature of 25°C [143]. In 
conclusion, formulations and storage conditions need to be optimised for each type of phage to 
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ensure stability. More work is required for examining the long-term stability of phage 
formulations in respirable forms. 
 
2.2 Formulations by freeze drying and spray freeze drying 
 
Freeze drying or lyophilisation is a process of drying frozen material through sublimation and 
desorption under vacuum. This method is ideal for heat sensitive samples including 
immunogenic proteins and peptides, and bacteriophages. The freeze drying of bacteriophages 
KS4-M and PhiKZ with lactose:lactoferin (60:40, w/w) produced a readily dispersible powder 
that did not require milling. The powder demonstrated an acceptable FPF (< 5µm) of 32 – 34 
% when dispersed using an Aerolizer® at 60 L/min [138]. Furthermore, the freeze drying 
technique has often been used for drying liposomal or polymeric formulations [56, 74], and 
this will be discussed in the following sections. For instance, Diab and colleagues produced 
rifampicin-loaded PLGA particles using single-emulsion (oil/water) method, followed by 
freeze drying [79]. Dispersion analysis using a powder insufflator (Model DP-4, Penn Century, 
PA) at 30 L/min showed a high FPF, with approximately 52 % of the powder having 
aerodynamic diameters between 1 - 5 µm.  
 
Another emerging technology in particle engineering that combines spray freezing and freeze 
drying steps is spray freeze drying. The drug solution or suspension is atomised into a cold 
medium (e.g. liquid nitrogen) to snap freeze the droplet, which are then dried under vacuum in 
a freeze dryer to produce large, light and porous particles with enhanced aerosol performance. 
The production yield is almost 100 % [144, 145]. The cost of spray freeze drying can be high 
compared with other conventional processes due to the extensive use of liquid nitrogen. 
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Alternatively, an atmospheric spray freeze drying technology is available which may reduce 
the production cost [146]. 
 
2.3 Formulations by supercritical fluid precipitation 
 
Supercritical fluid precipitation is efficient in producing uniform particles in term of size, 
crystallinity, morphology, and distribution to benefit dispersibility of the powder [147]. The 
technique is based on extraction of solvents from a supercritical fluid containing a dissolved 
compound [148]. A detailed review on application of this technology for pulmonary drug 
delivery is available in Sun [149].  
 
Manion proposed a combination of supercritical fluid precipitation and spray drying to produce 
inhalable capreomycin, kanamycin and isoniazid particles [53]. The particles were corrugated 
spheres and largely amorphous with less than 3 % moisture content. These powders exhibited 
a respirable fraction (< 3.3 µm) of 21.6 % determined via the Puffhaler® at a flow rate of 28.3 
L/min. Importantly, the processed formulations of these drugs as well as other anti-TB drugs, 
such as rifampicin, moxifloxacin and ciprofloxacin, retained in vitro anti-M. tuberculosis 
activity, confirming that the technique does not affect the anti-mycobacterial activities of the 
drugs [53, 150]. Alternatively, Ober et al. manufactured rifampicin/lactose microparticle 
composites using supercritical antisolvent drug-excipient mixing technique. Fourier transform 
infrared spectroscopy analysis demonstrated no chemical interaction between rifampicin and 
lactose [68]. The potential drawbacks of the technique include the requirement for high 
pressure and complicated scale-up procedures.                   
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3. OTHER INHALABLE DRY POWDER PRODUCTION APPROACHES 
 
3.1 Liposomal formulations 
 
Liposomes are small spherical shaped vesicles created from a variety of non-toxic 
phospholipids. First described in the mid-60s [151, 152], the advantages of liposomes include 
the ability to achieve narrow particle size distribution and a high drug loading [153, 154]. 
Furthermore, encapsulating poor water soluble drug in liposomes resolves the solubility issues 
and negates the need for potentially toxic solubilising agents [155]. The slow release property 
of the liposomes also prolongs the drug residence in the lung and facilitates uptake by 
macrophages [156, 157]. For drugs that have an unpleasant taste or cause cough after 
inhalation, liposomes can effectively reduce these effects [155].  
 
Among liposome formulations, distearyl phosphatidylcholine (DSPC), was the most suitable 
phospholipid to ensure vesicle stability and minimise lipid–drug interactions [153]. These 
liposomes are also suitable to encapsulate two or more drugs in a single liposomal formulation 
because of their hydrophobic and hydrophilic characteristics. For instance, Gursoy and 
colleagues successfully encapsulated hydrophilic isoniazid and hydrophobic rifampicin into a 
single formulation [158]. They even showed that co-encapsulation augmented the entrapment 
of the individual drugs.  
 
The latest development in this field is cell-specific targeting in which the liposomes are coated 
with ligands to facilitate targeting of specific cells, such as alveolar macrophages [159]. 
Intermittent delivery of rifampin encapsulated liposomes grafted with macrophage activator 
tetrapeptide tuftsin was 2,000-fold more effective than the free drug in lowering the bacterial 
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burden in the lungs of M. tuberculosis-infected mice [160]. However, this study used liquid 
liposomal formulations that are typically unstable for long-term storage and require 
nebulisation for inhaled therapy [161]. The nebulisation process may cause significant loss of 
encapsulated drug and alteration in the physical integrity of the liposomes [155]. To overcome 
the instability and delivery constraints, liposomes can be dried using spray drying, freeze 
drying or spray freeze drying into proliposomes [144]. Proliposomes are free flowing particles 
that immediately form liposomes when in contact with aqueous media [162]. Rojanarat et al. 
developed levofloxacin and pyrazinamide proliposomes using spray drying [62, 67]. The 
aerodynamic analysis using an in-house dispersion device at 60 L/min showed an FPF (< 4.4 
µm) and MMAD of approximately 30 % and 4 µm, respectively. Furthermore, repeated 
intratracheal treatment with the levofloxacin proliposome powder in rats showed no significant 
renal and liver toxicity. On the other hand, Shah and Misra prepared amikacin liposomes as a 
dry powder by freeze drying and blended them with lactose coarse carrier in varying mass 
ratios with or without fines to evaluate the influence of carrier on in vitro deposition 
performance [49]. Delivery with the Rotahaler® at a flow rate of 60 L/min showed that a lactose 
carrier containing 10 % fines (w/w) provided the optimum blend at 1:5 mass ratio of 
liposome:lactose having a FPF of 29 % [49]. Alternatively, Changsan and colleagues 
encapsulated rifampicin into liposomes and freeze dried these either with mannitol, trehalose 
or lactose as a cryoprotectant [75, 76]. Among the excipients tested, mannitol was the most 
suitable cryoprotectant, and it was crystalline after being freeze dried. The aerosol performance 
evaluation using an in-house dry powder inhaler at 60 L/min displayed a high FPF of 66.8 % 
(< 5 µm) with a low MMAD of 3.4 µm, which is suitable for inhalation. The cytotoxicity assays 
showed rifampicin-loaded liposomes were nontoxic to bronchial epithelial cells, small airway 
epithelial cells, and alveolar macrophages. Rifampicin in the liposomal dry powder formulation 
was also found to be more stable compared to rifampicin aqueous solution and rifampicin 
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liposomal suspension.  
 
Furthermore, Bhardwaj et al. successfully produced freeze dried isoniazid, rifampicin and 
pyrazinamide sub-micron liposomes using sucrose as the matrix. Scanning electron microscopy 
demonstrated that the liposomes adhered to the sucrose particles. The flowability of the powder 
was expressed by angle of repose that ranged between 18 - 20˚, and this was considered 
excellent for inhalation [93, 163]. Although these results demonstrate the  suitability of 
liposomal vesicles for pulmonary delivery of anti-TB drugs, the high production cost and 
complex processing provide potential barriers to large scale production.    
 
3.2 Polymeric formulations 
 
Polymer-based carriers offer numerous advantages for inhalation delivery because of their 
ability to increase the solubility of hydrophobic compounds, the sustained release of the 
incorporated drugs, the potential to modifiy particle surface properties and protect the 
incorporated drugs from degradation [164]. As mentioned above, polymeric particles also 
increase uptake by macrophages. Hydrophobic PLA and PLGA have been among the most 
attractive candidates studied for inhalation delivery, owing to their biocompatibility and 
biodegradability and extended release profile. Further, they are FDA-approved polymers for 
systemic delivery [165, 166] but these are yet to be approved for inhalation. Therefore 
pulmonary delivery systems based on these polymers are of experimental nature. The 
accumulation of polymeric materials in the lungs over long-term inhalation use and the acidity 
of degradation products of these polymers may be of safety concerns. 
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Traditional methods of producing drugs encapsulated in PLA and PLGA particles utilised 
single (oil-water) or double (water-oil-water) emulsion techniques. In the single-emulsion 
method, a hydrophobic drug and polymer are dissolved in an organic phase (oil phase), and 
this solution is emulsified with a surfactant (water phase). By contrast in the double-emulsion 
method, a hydrophilic drug solution (water phase) would first be emulsified in an organic 
solvent containing a hydrophobic drug and polymer (oil phase), followed by a second 
emulsification in a surfactant (water phase). The resulting suspensions are stirred for several 
hours to allow evaporation of the organic solvent and hardening of the particles. The hardened 
particles are then washed and dried through spray drying, freeze drying or spray freeze drying 
techniques. Muttil and colleagues encapsulated two anti-TB drugs (hydrophilic isoniazid and 
hydrophobic rifabutin) within PLA microspheres through double-emulsion and spray drying 
[94]. The powder showed a high FPF (< 4.6 µm) of 78.91 % when dispersed at 20 L/min into 
an animal nose-only exposure chamber for delivering drugs to mice via pulmonary route [94]. 
Using a similar approach, Lu et al. produced inhalable PLGA powder encapsulating M. 
tuberculosis antigen 85B (Ag85B) with the adjuvant trehalose dibenate (TDB). The dispersion 
analysis was performed using a Insufflator DP-3 (Penn Century, PA) at a flow rate of 60 L/min 
and showed a respirable fraction of 68.9 % (< 5 µm) [101].  
 
Size distribution and drug loading of emulsified polymeric particles are highly dependent on 
the shear forces and formulation conditions, such as surfactant concentration, polymer viscosity 
and concentration, and the volume of the aqueous phase. Studies have suggested more 
advanced methods to achieve high drug loading with monodisperse particles, such as pre-mixed 
membrane emulsification and supercritical anti-solvent precipitation [73, 74, 83]. However, 
these technologies are not practicable for bulk production as they are expensive and labor 
intensive. Alternatively, a direct spray drying of the organic solvent containing polymer and 
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drug is a rapid and less laborious approach to achieve a high drug loading [80, 81, 91]. A 100 
% drug loading efficiency can be attained from this technique because the drug cannot partition 
into the secondary water phase. Coowanitwang and colleagues produced inhalable rifampicin 
PLA and PLGA powders using a spray drying and reported MMAD of 4.65 - 5.11 µm and 2.22 
- 2.86 µm, respectively, upon dispersion using a Cyclohaler® at 28.3 L/min [80]. O’Hara and 
Hickey, however, showed that direct solution spray drying resulted in higher concentrations of  
rifampicin on the surface of the PLGA particles [81], and this caused a greater initial release 
of drug compared to single emulsion particles.  
  
Other polymeric formulation techniques include iontrophic gelation for preparation of 
tripolyphosphate-crosslinked chitosan microspheres with approximately 50 % isoniazid 
loading and an FPF of 67 % using Cyclohaler® at 28.3 L/min [60]. In another study, Pai et al. 
showed intratracheal instillation of rifampicin and rifapentine loaded chitosan particles 
suspended in phosphate buffer saline (PBS, pH 7.4) only caused mild changes in the lung 
pathology, compared to the severe peribronchiolar infiltration of inflammatory cells caused by 
free drug treatment in rats [86]. These findings suggest chitosan polymer dry powder is a 
potential platform for pulmonary treatment of TB. 
 
Polymeric nanoparticles have also attracted considerable interests as drug carriers for 
pulmonary drug delivery systems. Nano-sized particles are readily internalised by alveolar 
macrophages and provide a sustained release reservoir in the vicinity of the target [167-172]. 
However when inhaled as a dry powder, nanoparticles can be readily exhaled because of the 
small aerodynamic diameter of the particles. They are also nearly impossible to deagglomerate 
and will aggregate quickly upon inhalation due to van der Waal forces [173]. One approach to 
overcome this problem is to blend the nanoparticles with coarse carriers. For example, 
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Vadakkan et al. produced spray dried spherical rifampicin cationic lipopolymeric nanomicelles 
and blended them with inhalation grade lactose (Inhalac 230). It was found that the spherical 
nanomicelles were adsorbed on the asperities of the lactose crystals that acted as “active sides”. 
The powder was also in an inhalable range with a FPF (1-5 µm) of 67.9 % and a MMAD of 
2.31 - 2.45 µm, when aerosolised with a Rotahaler® at a flow rate of 28.3 L/min [84]. However, 
this formulation was too bulky for inhalation owing to the addition of lactose carrier. 
Nonetheless, the findings suggest that dry powder nanoparticles for pulmonary treatment of 
TB are feasible. 
 
4. DRY POWDER DELIVERY DEVICES 
 
For effective anti-TB pulmonary regimen, patients may need to inhale a large dose of 
antibiotics. In Phase 1 clinical study, administration of an inhaled dose of 300 mg capreomycin 
(12 capsules of 25 mg powder each)  using a capsule-based handheld device resulted in a 
systemic concentration equal to or higher than the minimum inhibitory concentration (MIC) of 
the drug against M. tuberculosis [29]. These findings suggest that the patient may need to inhale 
repeatedly a large dose of drugs for an effective treatment outcome.  
 
Both the nebuliser and dry powder inhaler (DPI) are capable of delivering large doses. The 
most common nebuliser is the conventional air-jet nebuliser that generates aerosol medication 
from liquid or suspension formulations using a compressed gas. Jet nebulisers are relatively 
cheap but bulky, noisy and cause wastage of medication owing to retention of drug liquid in 
the dead space of the device. Other newer air-jet nebulisers are breath enhanced devices, such 
as the Pari LC®, which minimise the drug wastage by mechanically controlling the delivery of 
the aerosol dose during the inspiratory phase [174].  A different type of nebulisers is based on 
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vibrating-mesh technology, which generates the aerosol by extruding the drug solution through 
a vibrating mesh containing an array of tiny pores. Examples are the Aeroneb® and Aerogen®, 
which are more handy to use and operate silently [175]. However, these nebulisers are 
relatively expensive and there is currently no data on dose adjustment to prevent overdose of 
medications that are already optimised for jet nebulisers [175, 176]. The DPIs are breath-
activated devices for powder aerosol generation and delivery. The powder is dispersed into 
particles by the patient’s inspiratory flow and in general the device is inexpensive, hence 
suitable for application for TB [177]. Figure 1 depicts some of the currently available DPI 
products. 
 
Currently, marketed DPIs that can deliver more than 100 mg of dry powder are the Novartis 
TOBI Podhaler® (112 mg of tobramycin) and Pharmaxis Bronchitol® (400 mg of mannitol), 
both for the treatment of cystic fibrosis [104, 178]. One of the rate-limiting factors for these 
devices is that patients are required to load and inhale multiple capsules, and  this may reduce 
patient adherence to the therapy, especially in the context of the lengthy anti-TB regimen [179, 
180]. To overcome this limitation, we modified the Aerolizer® device to accommodate the size 
0 capsule. Similar to Aerolizer®, the dispersion mechanisms of the modified device involves 
air turbulence and impaction inside the swirling chamber for deagglomeration of the powder 
[181]. The performance of the device to deliver needle-like crystalline rifapentine powder in a 
single capsule (with loading of 30 mg) with multiple manoeuvres was tested at 60 L/min using 
multi-stage liquid impinger [88]. The dispersion analysis showed an FPF (< 5 µm) of more 
than 50 % with less than 10 % device and capsule retention, suggesting that the 
deagglomeration had occurred before the powder exited the device [182]. Traini and colleagues 
investigated the OrbitalTM, a breath-actuated (passive) and a single use disposable DPI [183]. 
This device consists of a sample compartment puck that releases the powder by centrifugal 
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force through one or more orifices into a deagglomeration chamber, where the powder breaks 
into inhalable size before delivery into the respiratory system. In vitro aerosol analysis reported 
that the device is capable of delivering a high quantity of mannitol co-spray dried ciprofloxacin 
or azithromycin formulations (ranging up to 400 mg) via multiple inhalation manoeuvres [183, 
184]. For example, the mannitol-ciprofloxacin combination powder at a loading of 200 mg 
showed a FPF (< 5 µm) of 42.0 ± 1.8 % at 60 L/min, which was equivalent efficiency to the 
commercially available RS01 device (FPF < 5 µm, 38.4 ± 2.0 %) [183]. However, as the 
OrbitalTM empties a relatively large amount (i.e. 100 mg) of powder with each actuation, it may 
cause side effects such as coughing or wheezing. Nevertheless, the potential of using the 
OrbitalTM for TB therapy is being explored [185].  
 
A device with a “open-inhale-close” routine would be preferred for inhaled drug delivery for 
TB. In addition to important requirement of delivering a large dose, the device should have a 
simple operation process with flexible dosing to promote patient compliance. A possible 
example is TwinCaps®, a single-dose and disposable passive device used to deliver 40 mg of 
Inavir® (laninamivir octanoate, a long-acting neuraminidase inhibitor) for the treatment of 
influenza [176, 186]. The device has been approved for children under 10 years old [176, 186]. 
TwincerTM is another single-use disposable passive device that consists of three plastic plates 
which can be simply stacked and clicked together. The device showed good dispersion and 
moisture protection of pure micronised colistin sulfomethate at doses up to 25 mg for the 
treatment of cyctic fibrosis [187]. Further optimisation of the TwincerTM (Cyclops) increased 
the loading dose of spray dried tobramycin to at least 50 mg [188]. Besides drug delivery, these 
devices are also applicable for pulmonary vaccination that requires a limited number of doses. 
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Most passive DPIs require a sufficient inspiratory flow rate (e.g. 30 - 60 L/min) to aerosolise 
powder from DPI, restricting their use for children (< 6 years old) and elderly patients [189, 
190]. Therefore, active DPIs open a new window for pediatric and geriatric inhaled therapies. 
Unlike passive devices, the dispersion of active devices is independent of inspiration flow. 
Dispersion is usually achieved by utilising external energy sources such as: (1) the piezoelectric 
system to facilitate the aggregation of drug from dosing chamber (e.g. MicroDose Therapeutx 
Dry Powder Inhaler); (2) embodiment with compressed air or spring to actively disperse the 
powder (e.g. Exubera® and Aspirair®); and (3) battery-driven motors to enable aerosolisation 
of powder (e.g. SpirosTM) [176, 186, 191-194]. Although these developments are proven to 
increase the lung deposition independent of the inspiratory flow, these alterations may reduce 
the portability and incur additional production costs.  
 
TB patients may require admission to an intensive care unit (ICU) because of acute respiratory 
or multi-organ failure [195]. Unfortunately, DPIs are generally regarded as unsuitable for 
patients in ICU owing to their cumbersome administration. Recently, Tang et al. developed a 
novel dry powder delivery system for intubated patients that utilises a ventilation bag, a one-
way duck-billed valve and an Osmohaler® [196]. The setup was capable of delivering Relenza® 
(Zanamivir dry powder) with a reasonable FPF (< 5 µm, 13.6 %) in vitro [197]. The clinical 
safety of the system was also established using dry powder mannitol [198]. The findings 
support the potential of this strategy for inhaled therapy to intubated TB patients. 
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Figure 1. Photographs of some currently available dry powder inhaler devices; (a) 
Osmohaler®, (b) HandiHaler®, and (c) Aerolizer®. 
 
5. PRE-CLINICAL AND CLINICAL TRIAL EVALUATIONS OF INHALED TB 
DRUG POWDERS  
 
5.1 In vitro studies 
 
Several in vitro cell culture models have been used to examine the anti-mycobacterial activity 
of inhaled drug formulations. Although primary alveolar macrophages are the most relevant 
cells for intracellular infection with M. tuberculosis, they are not readily accessible and may 
be heterogeneous. Therefore immortalised, macrophage cell lines, such as THP-1 cell line-
derived macrophages are used to provide a homogeneous population that mimics the behavior 
of primary human alveolar macrophages [199]. Lawlor and colleagues used PLGA 
encapsulation to develop rifampicin, PAS and capreomycin dry powders that allowed a high 
respirable dose with Spinhaler® and Diskhaler® at a flow rate of 100 L/min [55]. Treatment of 
THP-1-derived macrophages infected with M. tuberculosis H37Ra with the capreomycin and 
PAS microparticles resulted in a significant mycobacterial killing. A more recent study showed 
that rifampicin-loaded freeze dried liposomes released the drug in a controlled manner, and the 
a c b 
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uptake of encapsulated rifampicin into macrophages was more rapid than the free drug 
treatment [200].  
 
The potential cytotoxicity of the dry powder drugs may also be determined using lung-derived 
cell lines, such as alveolar macrophages or lung epithelial cells. For example, a pyrazinamide-
proliposome formulation was not toxic to human bronchial epithelial (Calu-3), human lung 
adenocarcinoma (A549) and rat alveolar macrophage (NR8383) cell lines. Further, the 
proliposomes did not activate macrophages to release inflammatory mediators in vitro [67]. 
 
An in vitro model using lung epithelial cells has proved useful to study the kinetics and 
mechanism of transepithelial transport of inhaled drugs. A detailed review on this model to 
assess the pulmonary absorption and disposition of drug particles is available in Sakagami 
[201] and Steimer et al. [202]. Salomon et al. tested the permeability of CPZEN-45, a 
capramycin derivative with anti-TB activity, using Calu-3 monolayers. The permeability 
coefficients in absorptive and secretive directions were in the acceptable range of 0.43 ± 0.20 
× 10-6 cm/s and 0.38 ± 0.12 × 10-6 cm/s, respectively [203].  
 
5.2 In vivo studies 
 
Several animal models have been established to study pulmonary TB as reviewed by 
McMurray et al. [204]. Over the past five years, in vivo studies using mice [30, 58], guinea pigs 
[52, 64, 205], rats [206], and monkeys [95] have investigated the efficacy of dry powder 
formulations for treatment of TB.  Verma’s group used infection in Swiss mice to compare the 
efficacy of microparticles containing clofazimine delivered via the aerosol and oral routes. 
Aerosol delivery reduced M. tuberculosis colony forming units (CFU) in the lungs by log10 2.6 
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compared to a reduction of log10 0.7 in the orally treated group [58]. In another study, crystalline 
rifapentine was administered by either intratracheal or intraperitoneal to BALB/c mice to study 
the pharmacokinetics of the drug [30]. The intra-tracheal delivery resulted in 38-fold higher 
concentrations of rifapentine in the lung than the plasma. Similar results were also reported 
using inhalable amorphous rifampicin in a rat model [206]. In addition, Garcia-Contreras et al. 
showed that guinea pigs receiving a high dose of inhaled PA-824 particles had lower degree of 
inflammation, tissue damage and bacterial burden after M. tuberculosis infection than the 
untreated or placebo-treated animals [64]. Aerosol delivery of BCG vaccine to guinea pigs 
subsequently challenged with virulent M. tuberculosis significantly reduced bacterial burden 
(log10 3.2 reduction) and lung pathology compared to both untreated guinea pigs and animals 
immunised with standard parenteral BCG (log10 1.1 reduction) [21]. The major advantage of 
using mice, rat or guinea pig model is that there are similarities in the pathophysiology of TB 
with human and their immune system is well characterised. In addition, the purchase, 
husbandry and housing are less costly than for nonhuman primates.  
 
Misra et al. investigated the biodistribution and pharmacokinetics of isoniazid and rifabutin 
delivered as PLA microparticles in monkeys via either inhalation or intravenous routes [95]. 
The elimination half-life of isoniazid and rifabutin were higher when the drug was inhaled. 
Moreover, the drug concentration in the lung was twice that of the liver and four times that of 
the kidney. Previously, low dose infection of monkeys with M. tuberculosis was shown to 
closely resembled the pattern of disease in humans [207]. Despite the costly nature of the 
nonhuman primate infection, this model can be extremely beneficial in testing safety and 
efficacy of new formulations of drugs and vaccines, especially for late-stage preclinical studies. 
Nonetheless, the in vivo studies consistently show that drug administration by inhalation has 
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the potential to increase selectively therapeutic efficacy at site of lung infection as well as to 
minimise systemic exposure and possible toxicity. 
 
5.3 Clinical trial 
 
Over the past ten years, only one paper has been published on a clinical trial using inhalation 
therapy targeting for pulmonary TB treatment. Dharmadhikari and colleagues conducted a 
Phase I clinical study examining the safety and tolerability of capreomycin in 20 healthy 
subjects and measured the pharmacokinetic parameters [29]. Capreomycin was formulated by 
spray drying with leucine and administered at single doses of 25 mg, 75 mg, 150 mg, or 300 
mg. Five subjects experienced temporary mild/moderate cough, but overall, the inhaled drug 
was well tolerated. No changes in pulmonary, renal and liver functions were detected post-
inhalation. Rapid drug adsorption through the lung was detected as evidenced by the plasma 
concentration within 20 minutes. The inhalation of 300 mg of powder permitted a systemic 
Cmax of 2.3 µg/ml compared with 32.0 µg/ml when 1.0 g of drug was administered 
intramuscularly [117]. However, a higher drug concentration was expected in the lungs after 
inhalation than after intramuscular delivery. The half-life (t1/2) of capreomycin was also 
extended to 4.8 h compared with 2 to 3 h after intramuscular administration [208]. These 
findings are significant, demonstrating that the inhaled capreomycin can achieve high drug 
concentrations at the infection site and longer drug retention in the systemic circulation, which 
would have the potential to reduce the drug dose and dosing frequency, and consequently drug-
associated adverse effects. However, these inhaled pharmacokinetic data should be interpreted 
with caution as the studies were performed on healthy volunteers and they may not necessarily 
be replicable in TB patients. For example, in cystic fibrosis the increased bronchial circulation 
and pulmonary inflammation enhanced the absorption rate of inhaled drugs so that the dose-
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normalised Cmax value of inhaled dry powder tobramycin was higher in cystic fibrosis patients 
than in healthy volunteers [209-211]. There is still a lack of understanding on respiratory 
physiology of TB patients, and this aspect clearly needs further clinical investigations to 
address the fate of particles deposited in the lungs.      
 
The Clinical Trials Registry reports one ongoing clinical trial in Thailand on the safety of 
inhaled delivery of rifampicin, isoniazid, pyrazinamide and levofloxacin as individual dry 
powders [212]. 
 
6. RISK RELATED TO INHALED REGIMEN IN THE TREATMENT OF TB 
 
Despite the potential benefits of inhaled therapy compared to the conventional regimen, there 
are also risks associated with direct deposition of particles in the lung. The lung has a complex 
biological defense system rich with immune cells, such as macrophages and leukocytes, and 
its vital role of gas exchange is dependent on the lipid-rich surface layer of surfactant and lung 
fluid homoeostasis. Any damage to these components could be life threatening. Clinical trials 
with large number of subjects are yet to be performed to determine the safety profiles of inhaled 
aerosol therapy for TB.  
 
Besides the concern of drug toxicity, a potential risk of pulmonary drug delivery is 
inflammation of the respiratory tract caused by repeated deposition of inhaled particles. This 
may be more critical when treating pulmonary TB patients because of prior inflammatory 
changes in the lungs and the recruitment of mutiple immune cells, including monocytes, T and 
B lymphocytes and natural killer cells [213, 214]. Furthermore, the deposition of foreign 
materials in the lungs may cause allergic inflammatory response and reduce lung function. 
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Misra and team demonstrated that intracellular delivery of inhalable microparticles loaded with 
anti-TB drugs activated M. tuberculosis infected macrophages [35, 215]. These included up-
regulation of cytokines TNF-α, interleukin-12 (IL-12)), reactive nitrogen and oxygen radicals, 
and caspase-independent apoptosis [35, 215-217]. These products could potentially cause 
severe immunopathology through inflammation and oxidative stress [218]. These 
microparticles were intended for a slow drug release profile indicating they could stay in the 
lungs for some time [95]. Therefore, such a prolonged adverse immunological phenomenon 
may also lead to hapten-specific immunoglobulin E (IgE) responses and extensive mast-cell 
degranulation [218].  
 
Unlike delivery of drugs, vaccines do not require multiple doses over a long period, but there 
are still potential risks of immunopathological reactions. Adjuvants do induce some 
inflammatory response as part of their immune stimulation, but excessive inflammation may 
be harmful. For example, Simecka and colleagues showed that intranasal immunisation with 
cholera toxin adjuvant caused a massive pulmonary airway inflammation characterised by IgE 
production and significant infiltration of mononuclear cells into the lungs, exclusively around 
pulmonary airways and vessels [219, 220]. This phenomenon resulted in bronchoconstriction 
of the airways and/or airway blockage with exudates leading to reduction in the airflow [220]. 
Similarly, pulmonary vaccination may induce significant immune response characterised by 
hypersensitivity reactions in the lungs which possibly contributing to pathologic changes in the 
lung. In addition, aberrant host innate immune responses characterised by dysregulation of 
cytokine or “cytokine storm” in the lungs can be dangerous [221]. The best example is the 
influenza pandemic of 1918 where the high degree of mortality was caused by the up-regulation 
of inflammatory chemokines and recruitment of neutrophils in the bronchi [222]. A similar 
scenario can occur when antigents directly deposited in the highly immunogenic lung region. 
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Rational approaches need to be developed to avoid serious immunogenic or inflammatory 
reactions associated with pulmonary delivery.  
 
For drug delivery, a minimum proportion of a non-toxic excipient or carrier is critical to achieve 
desired therapeutic outcome with good aerosol performance [223]. A balance between 
maximum drug loading and carrier system is critical for inhalation product. The α-lactose 
monohydrate is the only FDA approved sugar that can be used as a carrier in dry powder 
formulation to enhance the flowability and dispersion of the powder [48]. However, as 
mentioned earlier, this approach is not very practical for TB because of the requirement of high 
doses. Other dispersion enhancer including 10 - 20 % leucine, is often used to balance the 
maximum drug loading and aerosol performance [51, 224]. Administration of a single dose of 
300 mg capreomycin:leucine at 8:2, which is equivalent to 60 mg of leucine, showed good 
tolerability in healthy volunteers [29]. The safety of multiple deposition of leucine in the lungs 
is still unknown.  
 
The inhalable vaccine formulations must stimulate immune responses without causing 
pathological damage. One successful adjuvant was the positively-charged chitosan particles 
that contained a DNA vaccine encoding HLA-A*0201-restricted T-epitopes of M. tuberculosis. 
The chitosan acted as an adjuvant to promote the secretion of Interferon-γ by T cells recruited 
to the lungs following pulmonary immunisation without lung damage [36, 225]. By contrast, 
PLA and PLGA microspheres induced pro-inflammatory responses following phagocytosis by 
macrophages [226] and these may limit the benefit of T cell responses induced by the 
encapsulated agents. Furthermore, drug containing PLA and PLGA particles were reported to 
provoke TNF-α, IL-12, and reactive oxygen and nitrogen radical production in macrophages 
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recovered from infected mice [215], while induction of apoptosis in infected THP-1 derived 
macrophages [216]. 
 
7. EXPERT OPINION ON FUTURE DEVELOPMENT 
 
The promising results from various in vivo studies and the Phase 1 human clinical trial provide 
evidences for performing larger scale efficacy and safety inhaled anti-TB clinical trials. 
Nonetheless, there are a number of challenges that need to be addressed. 
 
1. Physiology of TB patients and particle deposition. There is a lack of understanding of lung 
and airways physiology of TB patients. The airflow of patients may differ from healthy 
population and this could affect the deposition of particles and their fate in the lungs. The 
intended region for powder deposition is also determined by the formulation and device 
designs. Tuberculous granulomas may be distributed throughout the lung and therefore more 
diffused deposition of the drug aerosol in the lungs is desirable. Thus, a greater understanding 
of the lung and airways of TB patients and the correlation with the aerosol deposition is crucial 
to facilitate successful inhaled anti-TB therapies [227].   
 
2. Dosing consideration and strategies. Currently, prolonged therapy with a combination of 
anti-TB drugs for at least 6 months is essential for optimal clinical outcomes and to prevent the 
emergence of drug-resistant M. tuberculosis strains. Inhaled antibiotics may play a role as an 
adjunct to the existing oral therapy by providing high concentration of drugs at the site of 
infection [228]. Multiple dosing may be needed for an optimal pulmonary drug concentration, 
depending on the powder formulation and pharmacokinetic of the drug. The frequency of 
dosing and the long-term effects of pulmonary delivery remain to be investigated.    
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3. Screening of drug/vaccine candidates. Not all drugs/vaccines are ideal for inhaled therapy 
and there should be careful selection of the drugs/vaccines for testing by the pulmonary route. 
These candidates should be highly efficacious and able to reduce the dosing frequency when 
given via inhalation compared to the conventional route of administration. Cheaper 
manufacturing and packaging procedures along with inexpensive inhaler devices will be 
advantageous. 
 
4. Medication cost and feasibility. If the medication is expensive to be manufactured into an 
inhalable form, it will impact the global accessibility, especially to the resource-poor countries 
with a high burden of TB. Furthermore, a correct inhaler handling technique is important for 
an optimal benefit from inhaled therapeutics. This will require training for the TB clinic staff 
on proper usage of the inhaler to educate the patients, and this may incur additional costs. The 
lower development costs and ease of oral administration probably make many organisations 
including WHO, favour the discovery of new anti-TB drugs for oral administration instead of 
reformulations of approved anti-TB drug into an inhalable dosage form [227]. The Phase 1 trial 
of an inhaled pharmacokinetic study with capreomycin addressed the benefits and barriers of 
progressing the preclinical studies of inhalation therapies to practical treatment for TB [29]. 
Therefore cost-benefit and feasibility studies are necessary to justify the global implementation 
of inhaled therapy for TB [227].   
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8. CONCLUSIONS 
 
Pulmonary administration using powder aerosols is a relatively new approach for the treatment 
of/or vaccination against, pulmonary TB especially targeting for MDR and XDR cases. An 
optimised powder formulation coupled to a suitable inhaler device is critical for effective 
pulmonary delivery and intended clinical outcomes. A substantial amount of powder 
formulation works has been undertaken over the past two decades aiming at delivering inhaled 
TB therapeutics to the lungs. A common theme is to develop carrier-free formulations to 
increase the drug load required for high-dose antibiotics. They also avoid any carrier-associated 
toxicity. Combination drug formulations are necessary for effective treatment of TB and for 
reducing the emergence of drug resistance strains. Formulations of micro- or nano-particles 
with a slow release profile will promote phagocytosis by M. tuberculosis-infected alveolar 
macrophages. An inhaler device with an “open-inhale-close” routine will enhance patients’ 
compliance for the treatment, but both the generation and administration of a high powder dose 
remain a challenge to be tackled satisfactorily. It is also a prerequisite for the 
formulation/device to be cost-effective for countries with high burden of TB cases. While the 
formulation development and preclinical evaluation are in their advanced stage, clinical trials 
are significantly lagging behind, and this is partly due to the safety concerns of administering 
inhaled drugs or vaccines to the infected lungs that are already inflamed. However, if the 
biosafety hurdles can be mitigated and the TB drugs or vaccines efficiently delivered to TB 
patients, then inhaled TB therapy has potential to contribute to the global elimination of TB. 
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CHAPTER 2 
 
 
IN VITRO EVALUATION OF INHALABLE  
VERAPAMIL-RIFAPENTINE PARTICLES FOR 
TUBERCULOSIS THERAPY 
 
 
 
 
 
 
 
This chapter has been published in Molecular Pharmaceutics, 2016; 13: 979-989, with the title 
‘In vitro evaluation of inhalable verapamil-rifapentine particles for tuberculosis therapy’. 
Authors: Parumasivam T, Chan JGY, Pang A, Quan DH, Triccas JA, Britton WJ, Chan H-K.
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ABSTRACT 
 
Recent studies have demonstrated that drug efflux pumps of M. tuberculosis provide a crucial 
mechanism in the development of drug resistant to anti-mycobacterial drugs. Drugs that inhibit 
these efflux pumps, such as verapamil have shown the potential in enhancing the treatment 
success. We therefore hypothesised that the combined inhaled administration of verapamil and 
a first-line rifamycin antibiotic will further improve the treatment efficacy. An inhalable dry 
powder consisting of amorphous verapamil and crystalline rifapentine with L-leucine as an 
excipient was produced by spray drying. The in vitro aerosol characteristic of the powder, its 
microbiological activity and stability were assessed. When the powder was dispersed by an 
Osmohaler®, the total fine particle fraction (FPFtotal, wt. % of particles in aerosol < 5 µm) of 
verapamil and rifapentine was 77.4 ± 1.1 % and 71.5 ± 2.0 %, respectively. The combination 
drug formulation showed a minimum inhibitory concentration (MIC90) similar to that of 
rifapentine alone when tested against both M. tuberculosis H37Ra and M. tuberculosis H37Rv 
strains. Importantly, the combination resulted in increased killing of M. tuberculosis H37Ra 
within the infected macrophage cells compared to either verapamil or rifapentine alone. In 
assessing cellular toxicity, the combination exhibited an acceptable half maximal inhibitory 
concentration (IC50) values (62.5 µg/mL) on both human monocytic (THP-1) and lung alveolar 
basal epithelial (A549) cell lines. Finally, the powder was stable after 3 months storage in 0 % 
relative humidity at 20 ± 3°C. 
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1. INTRODUCTION 
 
Tuberculosis (TB) caused by the intracellular pathogen Mycobacterium tuberculosis is an 
ancient lung infectious disease that remains a major cause of global mortality. In 2013, the 
World Health Organization (WHO) reported that there were 1.5 million deaths attributed to the 
disease and 6.1 million people with active infection [1] with a further estimated 2 billion people 
have latent TB [2]. In addition, there are alarming rates of multi-drug resistant (MDR) and 
extensively drug resistant (XDR) M. tuberculosis and HIV-TB co-infection that contributed to 
the increased rates of TB [3]. Despite the limitations of long-term oral chemotherapy and 
inadequate compliance to the current treatment regimen, only two new anti-TB drugs, 
bedaquiline and delamanid have been successfully approved in the past 50 years [4, 5]. 
Therefore, the repurposing of existing drugs into advanced drug delivery systems could be an 
effective approach to improve the existing arsenal of TB treatments.  
 
In recent years, the role of bacterial and macrophage efflux pumps in promoting M. tuberculosis 
drug resistance has gained significant attention. First, M. tuberculosis utilise these pumps to 
extrude ‘toxic’ compounds including anti-TB agents from the interior of the bacterial cell into 
their extracellular environment. Overexpression of these pumps leads to reduced drug 
concentration in the bacterial cytoplasm thus enabling intrinsic and acquired drug resistance in 
M. tuberculosis [6-8]. For instance, Rodrigues et al. demonstrated that the overexpression of 
bacterial efflux pumps alone can result in isoniazid-resistance in M. tuberculosis without 
requirement of genetic mutations [8]. Second, M. tuberculosis within the infected macrophages 
are protected from high antibiotic concentrations because the macrophage efflux pumps also 
extrude anti-TB agents to provide a low intramacrophage drug concentration [7, 9]. For 
example, Adams et al. revealed that exposure to non-lethal concentration of rifampicin within 
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the macrophage environment transcriptionally induced M. tuberculosis efflux pump Rv1258 
expression which allowed the bacteria to become resistant [10]. These mechanisms were also 
further confirmed in macrophages infected with several drug sensitive and resistant M. 
tuberculosis strains in which the rapid development of tolerance to various anti-TB agents, 
including isoniazid, moxifloxacin, linezolid, PA-824, and bedaquliline was established [11]. 
These bacterial and macrophage efflux pump-mediated resistant mechanisms may prolong the 
treatment duration for TB and requires a multi-drug regime for cure [12].  
 
Adjunctive therapy with a drug that inhibits these efflux pumps could be a promising treatment 
approach against TB. The efflux pump inhibitor could: (1) directly block the efflux system of 
M. tuberculosis and reduce the development of bacterial phenotypic resistance [7, 13]; (2) 
block the efflux pump of infected macrophages thereby reducing intracellular drug level [7, 
13]; and (3) inhibit the calcium and potassium efflux pump of the phagolysosome, that causes 
acidification of the phagolysosome to activate hydrolytic enzymes to degrade the intracellular 
M. tuberculosis [14]. Hence, these three mechanisms of action have the potential to shorten the 
current TB oral drug regimens and reduce the emergence of new MDR and XDR-TB strains. 
 
Verapamil, a calcium-channel blocker is a most potent mycobacterial efflux pump inhibitor 
both in vitro and in vivo TB models [10, 15-18]. Verapamil has been approved by Food and 
Drug Administration (FDA) since 1982 for oral treatment of cardiovascular disorders [19]. In 
vitro studies have highlighted the capacity of verapamil to significantly improve the anti-
mycobacterial activity of many drugs including rifampicin, streptomycin, isoniazid, ofloxacin, 
bedaquiline, and clofazimine [11, 13, 17, 18, 20]. Verapamil also reduces drug tolerance in the 
macrophage environment and amplifies the intracellular activity of isoniazid and rifampicin 
against M. tuberculosis by enhancing the accumulation of these drugs inside the macrophage 
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[10, 11]. Furthermore, an in vivo study by Louw et al. demonstrated that verapamil can restore 
M. tuberculosis susceptibility to first-line drugs and prevent the development of further drug 
resistance of mice infected with MDR-TB isolate [21]. Their study also showed that the 
incorporation of verapamil in the treatment of first-line anti-TB drugs significantly reduced the 
bacillary load in the lungs compared to the anti-TB drugs alone. Similarly, Gupta et al. 
demonstrated accelerated bacillary clearance and reduced relapse rates of standard anti-TB 
therapy in M. tuberculosis infected mice when verapamil was co-administered [16]. These 
findings are promising, but clinical studies investigating verapamil as an adjunctive anti-TB 
agent are limited.  
 
The under-utilisation of verapamil may be due to its limitations when administered orally with 
rifampicin; a key first-line oral anti-TB drug that induces verapamil-metabolising enzyme 
CYP3A4 [16, 22-24]. Thus, concomitant oral administration of these two drugs leads to 
variable pharmacokinetics of verapamil [16, 22, 23] and severely reduces its clinical efficacy 
[25]. There is also a significant variation in bioavailability of verapamil even in rifampicin 
naïve subjects after oral administration due to high plasma protein binding of verapamil nearly 
90 % [26, 27]. These metabolic and protein binding limitations can be overcome by inhaled 
delivery of verapamil in combination with rifamycin. Apart from avoiding first-pass 
metabolism by the liver, pulmonary delivery offers additional advantages. First, targeted 
delivery to the primary site of infection may increase local therapeutic concentration and anti-
TB activity. Second, high doses of efflux inhibitors at the site of infection could also enhance 
the activity of other orally-administered anti-TB drugs, including the accumulation into 
infected macrophages. This dual mechanism has the potential to shorten the treatment duration 
and reduce the side effects associated with prolonged drug usage.  
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The current study describes the manufacture of a combination inhalable dry powder consisting 
of verapamil and rifapentine. Rifapentine was selected as it is a first-line anti-TB drug similar 
in action to rifampicin, but has a longer pulmonary half-life and stronger anti-mycobacterial 
activity [28, 29]. The inhalable formulation of verapamil and rifapentine was produced at a 
drug mass ratio of 1:3, respectively based upon current recommended oral dosages [30, 31]. 
The physiochemical, in vitro aerosol performance and storage stability, and in vitro 
microbiological activities including pulmonary cytotoxicity are reported.  
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2. MATERIALS AND METHODS 
 
Materials 
 
Verapamil hydrochloride, L-leucine, potassium dihydrogen orthophosphate, dimethyl 
sulfoxide (DMSO), and phosphate-buffered saline (PBS) were obtained from Sigma-Aldrich, 
Castle Hill, Australia. Rifapentine was from Hangzhou ICH Imp & Exp Company Ltd., 
Hangzhou, China. Acetonitrile, methanol, tetrahydrofuran, and orthophosphoric acid were 
purchased from Ajax Finechem Pty Ltd., Taren Point, Australia.  
 
Bacterial strain and cell culture 
 
M. tuberculosis H37Ra (ATCC 25177), M. tuberculosis H37Rv (ATCC 27294), human 
monocytic cell line (THP-1), and human alveolar basal adenocarcinoma epithelial cell line 
(A549) were purchased from American Type Culture Collection (ATCC) (Manassas, VA). The 
M. tuberculosis strains maintained in Middlebrook 7H9 media (enriched with 10 % albumin, 
dextrose and catalase (ADC) supplement) with 20 % glycerol stock at -80°C. The THP-1 and 
A549 cells were grown in complete RPMI-1640 media (RPMI-1640 medium, 0.05 mM 2-
mercaptoethanol, 10 % fetal bovine serum) at 37°C in 5 % CO2. 
 
Formulation design 
 
The single drug formulation of verapamil (Vrp_Leu) was produced by spray drying a solution 
containing 2.7 mg/mL verapamil hydrochloride and 0.7 mg/mL L-leucine (equivalent to 20 %, 
w/w) in distilled water. For the rifapentine only (Rpt) powder, a rifapentine crystalline 
90 
 
suspension was prepared as previously described [32]. Briefly, a rifapentine solution at 
concentration of 4 mg/ml was prepared in a co-solvent consisting of acetone:water (1:1, v/v). 
The solution was then heated to 67°C for evaporation of acetone to form a crystalline 
suspension. This suspension was homogenised at 10 000 rpm for 2 minutes (Silverson L4RT 
High Shear Mixer, Silverson, Chesham, UK) and then spray dried. For the combination 
formulation (Vrp_Rpt_Leu), verapamil hydrochloride (at 1:3; verapamil:rifapentine, w/w) and 
L-leucine (20 %, w/w) were solubilised in the homogenised rifapentine suspension and the 
mixture was spray dried. 
 
The spray drying process was carried out using a B-290 Mini Spray Dryer (Buchi Labortechnik 
AG, Flawil, Switzerland) in an open-loop configuration using the following settings: inlet 
temperature of 60°C, atomiser of 60 mm (approximate 742 L/h), aspirator of 100 % (40 m3/h), 
and feed rate of 5 % (equivalent to 2 mL/min). A spray dried L-leucine powder was also 
produced through spray drying a L-leucine aqueous solution at a concentration of 0.7 mg/mL 
using the same parameters. 
 
Physico-chemical characterisation 
 
Particle morphology 
 
Particle morphology was imaged using scanning electron microscopy (SEM) (Zeiss Ultra Plus 
scanning microscope, Carl Zeiss, Oberkochen, Germany) at 5 kV acceleration voltages. 
Powders were deposited onto carbon tape and sputter coated with 15 nm of gold using a K550X 
sputter coater (Quorum Emitech, Kent, UK).  
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Particle sizing 
 
Equivalent volume diameter was determined using laser diffraction coupled with a Scirocco 
dry powder module (Mastersizer 2000, Malvern Instruments, Worcestershire, UK). The dry 
powder was dispersed at a pressure of 3.5 bar. All the measurements were performed in 
triplicate. The refractive index (RI) was set at 1.54, 1.63 and 1.60 (average RI of verapamil and 
rifapentine at ratio 1:3) for Vrp_Leu, Rpt and the Vrp_Rpt_Leu, respectively.  
 
X-ray power diffractometry 
 
The crystalline property of the dry powders was analysed using x-ray powder diffractometry 
(XRPD) (D500; Siemens, Karlsruhe, Germany). The powder was spread into the cavity of the 
XRPD glass slide, and analysis was performed using Cu-Kα radiation at a generator voltage of 
40 kV and a current of 33 mA. The data were collected by the 2θ scan method with a scan rate 
of 0.04°/sec from 5-40°. 
 
Thermal analysis 
 
Differential scanning electron calorimetry (DSC) and thermogravimetric analysis (TGA) 
(Mettler Toledo, Melbourne, Australia) were used to study the thermal profile of the dry 
powders. For DSC, 5 mg of each powder was evenly spread into an aluminium crucible which 
was then crimped with a perforated lid and heated from 30 to 300°C at 10°C/min under a 
continuous flow of nitrogen gas. For TGA, 5 mg of each powder was weighed into an alumina 
crucible and then gradually heated at 10°C/min from 30 to 300°C under a dynamic nitrogen 
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gas flow. Both sets of thermal data were recorded and analysed through STARe software 
V.9.0x (Mettler Toledo, Greifensee, Switzerland).   
 
Dynamic vapour sorption 
 
The moisture sorption behaviour of the powders was assessed using a dynamic vapour sorption 
(DVS) instrument (DVS-1, Surface Measurement Systems, London, UK) operated at 25°C 
with continuous nitrogen gas flow. The powders were exposed to a dual moisture ramping 
cycle of 0 to 90 % with 10 % increments of RH. The mass changes were recorded over time 
and equilibrium moisture content determined by dm/dt of 0.02 % per minute.  
 
Dissolution profile 
 
The dissolution profile of the dry powders was studied using a Franz-cell dissolution system 
coupled with a heating stirrer station (Perm Gear Inc., Bethlehem, USA). The method was 
adapted from Chan et al. [33]. Each cell reservoir was filled with 23 mL of PBS (pH 7.4) with 
2 % ascorbic acid as an antioxidant, to form a positive liquid meniscus. Magnetic stirrers were 
used to provide solute uniformity within the reservoirs. The cells were connected to a water 
bath to maintain the internal liquid temperature at 37°C.  
 
Prior to dissolution, a capsule was filled with 20 mg of powder and actuated (Osmohaler® 
(Plastiape, Italy) dry powder inhaler at an airflow of 100 L/min for 4 secs) into a next generation 
impactor (NGI) containing cellulose filter papers (Whatman® qualitative filter paper Grade 5) 
in stages 3 and 4 that has cut-off diameter of 2.2 and 1.3 µm, respectively. The filters holding 
the deposited powder were then placed in between the buffer meniscus and the top 
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compartment of the Franz-cell reservoir. Sampling (500 µL) was performed at predetermined 
time points (15, 30, 45, 60, 90, 120, 180, 240, and 300 min) and replaced with an equivalent 
amount of fresh buffer. At the final time point (5 h), the filter was removed and washed 
thoroughly with 3 mL of fresh buffer solution.          
 
Drug quantification was performed using a validated high-performance liquid chromatography 
(HPLC) method [32]. A µBondapakTM C18 (3.9 × 300 mm2) column (Waters, Milford, 
Massachusetts) was coupled with a HPLC (Model LC-20, Shimadzu, Kyoto, Japan) operated 
at a detection wavelength of 250 nm (SPD-20A UV/VIS detector, Shimadzu) and an injection 
volume of 20 µL. The mobile phase was a 50 mM phosphate buffer (pH 
3.0):acetonitrile:tetrahydrofuran at a ratio of 53:42:5 (%, v/v). The mobile phase was run at an 
isocratic flow rate of 1.0 mL/min. Calibration curves with R2 values of 1.0 for verapamil and 
rifapentine were obtained using standard solutions with concentrations ranging from 0.0005 to 
0.1 mg/mL. The data were expressed as a percentage of drug mass in the buffer solution relative 
to the total mass recovery. Each formulation was tested in triplicate.          
 
In vitro aerosol performance 
 
In vitro aerosol performance of the spray dried powders was analysed using the Pharmacopeia 
method of the multi-stage liquid impinger (MSLI) (Apparatus C, British Pharmacopeia 2012, 
Copley, Nottingham, UK) connected to a USP throat with a silicone mouthpiece adapter [32]. 
The rinsing solvent consisted of ascorbic acid (0.2 mg/mL) in methanol:water at 3:1. The MSLI 
was filled with 20 mL of rinsing solvent in stages 1 to 4 and fitted with a glass fibre filter in 
stage 5. Size 3 hydroxypropyl methylcellulose capsules (Capsugel, Greenwood) were filled 
with 10 ± 0.5 mg of powder. A capsule was punctured in an Osmohaler® (Plastiape, Italy), and 
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actuated for 4 secs at 100 L/min (calibrated using airflow and flow controller (TSI 3063 airflow 
meter, TSI Instruments Ltd., Buckinghamshire, UK and Flutus Air, Novi Systems Ltd., 
Dulverton, UK, respectively)). Following the dispersion, the components were washed with 
rinsing solvent as follows: 5 mL for the adaptor, and 10 mL each for the capsule, device, throat 
and filter. Dispersions were performed at 20 ± 3°C and a relative humidity (RH) of 50 ± 5 %. 
Each formulation was tested in triplicate and the drug mass was quantified using HPLC as 
mentioned previously. The lower cut-off diameters for stages 1-4 of the MSLI at 100 L/min 
are 10.4, 4.9, 2.4, and 1.2 µm, respectively. 
 
The total fine particle fraction (FPFtotal) was expressed as a mass percentage of particles with 
an aerodynamic diameter less than 5 µm relative to the total recovered drug mass. The emitted 
fine particle fraction (FPFemitted) was calculated as a mass percentage of particles with an 
aerodynamic diameter less than 5 µm relative to the total recovered drug mass excluding the 
capsule and device. Mass median aerodynamic diameter (MMAD) and geometric standard 
deviation (GSD) were calculated from the log-probability plot of the MSLI data. 
 
Storage stability studies 
 
Storage stability of Vrp_Leu and Vrp_Rpt_Leu was studied at 0 % and 60 % RH at 20 ± 3°C 
for 1 and 3 month intervals. These study conditions were chosen because the powders absorb 
significant amount of water at a RH above 60 % at 25°C as shown by the DVS analysis. The 
stability of Rpt formulation has been reported in a previous study [32]. The spray dried powders 
were stored in loosely capped scintillation vials in a desiccator at 20 ± 3°C and protected from 
light. To maintain RH close to zero, the desiccator contained gel desiccant beads and was under 
vacuum. For a 60 % RH and 20 ± 3°C environment, the powders were stored in a climate 
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controlled cabinet. At predetermined time points a known quantity of powder was dissolved in 
MSLI rinsing solvent and quantified using HPLC to study the chemical stability of verapamil 
and rifapentine. The drug content was expressed as a mass percentage of each drug. Aerosol 
performance was also assessed on samples at these time points using the aforementioned 
methods.  
 
In vitro microbiological and cytotoxicity studies 
 
Resazurin assay 
 
The resazurin assay was performed in 96-well plates. The antibiotic powders were dissolved 
in DMSO and serially diluted to the desired concentration in Middlebrook 7H9 media 
supplemented with 10 % ADC supplement, 0.05 % glycerol, 0.05 % Tween-80 and 1 % 
tryptone. Subsequently, mid-exponential phase (OD600 0.4 - 0.8) M. tuberculosis H37Ra or 
M. tuberculosis H37Rv cultures were added and incubated for 5 days in a humidified incubator 
at 37°C. After the incubation, a mixture of 0.02 % resazurin solution (30 µL) and 20 % Tween-
80 (12.5 µL) was added to each well, then further incubated for 48 h. Fluorescence was 
measured using a BMG Labtech Polarstar Omega (BMG Labtech, Ortenburg, Germany) at an 
excitation wavelength of 530 nm and emission wavelength of 590 nm. Growth percentage was 
determined in comparison to the growth of the untreated negative control after subtracting the 
background fluorescence. Minimum inhibitory concentration (MIC90) was measured as the 
lowest concentration that showed 90 % growth inhibition compared to the untreated cells. 
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Intracellular inhibition assay 
 
THP-1 cells were grown in complete RPMI-1640 media (RPMI-1640 medium, 0.05 mM 2-
mercaptoethanol, 10 % fetal bovine serum) at 37°C in 5 % CO2. The media containing 50 
ng/mL of phorbol 12-myristate 13-acetate and 1 × 105 cells/well were added to 96-well plates 
and incubated for 48 h for the cells to adhere and differentiate. The cells were then infected 
with M. tuberculosis H37Ra at a multiplicity of infection (MOI) of 5. After 4 h of infection, 
cells were washed 3 times with PBS, replaced with fresh media and further incubated overnight 
for the cells to recover. The verapamil and rifapentine in combination with various 
concentrations were dissolved in DMSO and then further diluted in complete RPMI-1640 
media to achieve the desired concentration. Diluted solutions were added and incubated for 48 
h. To determine the intracellular bacterial load, cells were lysed and bacterial number (colony 
forming units, cfu) were determined after plating onto Middlebrook 7H11 (Bacto Laboratories, 
Mt. Pritchard, NSW, Australia) supplemented with 10 % oleic acid, albumin, dextrose and 
catalase (OADC) enrichment, and 0.5 % glycerol using standard procedures [34].  
 
Cytotoxicity assay 
 
The toxicity of the combination formulation and its individual components were tested on THP-
1 and A549 cell lines. A concentration of 5 × 105 cells/well was seeded to a 96-wells plate and 
incubated for 48 h to allow cell adherence and differentiation. The drug powders were dissolved 
in DMSO and diluted in complete RPMI-1640 media. Drugs (concentrations ranging from 
0.00196 - 1.0 mg/mL) were added into the wells in two-fold dilutions and incubated for 4 days. 
On day 4, 10 µL of 0.05 % (w/v) resazurin was added and incubated for 4 h. Fluorescence 
readings were then taken at a wavelength of 590 nm following excitation at 544 nm using the 
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FLUOstar Omega Microplate Reader (BMG Labtech, Ortenburg/Germany). The half maximal 
inhibitory concentration (IC50) was determined through comparison to the untreated cells.        
 
Statistics 
 
All data were expressed as mean ± standard deviation with n=3. The statistical differences were 
analysed using Microsoft Excel, t-test analysis of variance (Microsoft Office Excell 2007) and 
p values < 0.05 were considered statistically significant.   
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3. RESULTS 
 
Physico-chemical characteristics 
 
Particle morphology 
 
SEM analysis on the physical morphology of various powders is presented in Figure 1. The 
raw verapamil was irregularly shaped, while processed Vrp_Leu was relatively spherical with 
a highly corrugated surface. The rifapentine (Rpt) particles consisted of needle-like structures. 
A mixture of nearly spherical and elongated particles was observed in the combination 
formulation. The geometric size of verapamil particles were in the range of 1 - 3 µm while the 
rifapentine crystals were about 10  2  2 µm of length  width  height. 
  
  
 Figure 1. Scanning electron micrographs of powder samples: (a) raw verapamil, (b) Rpt, (c) 
Vrp_Leu, and (d) Vrp_Rpt_Leu. 
 
a b 
c d 
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Particle sizing 
 
Equivalent volume median diameter (D50) of the raw verapamil powder was about 7.39 ± 1.70 
µm, which was reduced to 1.42 ± 0.02 µm after being solubilised and spray dried with L-
leucine in Vrp_Leu (Table 1). The D50 of the Rpt (1.41 ± 0.06 µm) was similar to Vrp_Leu. A 
slight increase in size was observed for the combined Vrp_Rpt_Leu particles (1.61 ± 0.03 µm) 
and the particles were within the inhalable range of less than 5 µm. 
 
Table 1. Particle size distribution of the formulations (mean ± SD, n=3) 
 D10 (µm) D50 (µm) D90 (µm) 
Raw verapamil 2.27 ± 0.04 7.39 ± 1.70 24.37 ± 0.04 
Rpt 0.74 ± 0.04 1.42 ± 0.02 2.72 ± 0.08 
Vrp_Leu 0.80 ± 0.03 1.41 ± 0.06 2.66 ± 0.09 
Vrp_Rpt_Leu 0.91 ± 0.03 1.61 ± 0.03 2.89 ± 0.05 
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X-ray powder diffractometry 
 
Raw verapamil was shown to be crystalline as numerous diffraction peaks were observed, 
notably at 10.59°, 14.45°, 17.07°, 18.1°, 18.84°, 20.29°, 21.32°, 23.06°, 23.75°, and 26.29° 
(Figure 2), similar to those reported in the literature [35]. The Vrp_Leu showed a typical “halo” 
pattern indicating the powder is largely amorphous. The Rpt powder demonstrated crystallinity 
with peaks at 5.68°, 6.52°, 7.56°, 8.48°, 9.08°, 10.04°, 13.16°, 15.68°, 17.8°, 20.76°, and 
23.52°. The Vrp_Rpt_Leu powder also demonstrated crystalline peaks in similar regions as in 
Rpt but at lower intensities. Crystalline peaks were also observed in the spray dried L-leucine.   
 
 
Figure 2. X-ray diffractograms of various powder formulations. Crystalline peaks were 
demonstrated by Vrp_Rpt_Leu, Rpt, raw verapamil and spray dried L-leucine. Vrp_Leu was 
largely amorphous.   
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Thermal properties of the Vrp_Rpt_Leu were compared to their individual components as 
shown in Figure 3. The raw verapamil exhibited a broad endotherm from 25°C to 130°C 
followed by a sharp endotherm peak at 146.65°C. In contrast, Vrp_Leu showed a broad 
exotherm from approximately 80°C to 225°C and an endotherm peak at 246.93°C. Slight 
enthalpy changes were observed in the DSC curves of Rpt and Vrp_Rpt_Leu from 25°C to 
160°C, followed by an endothermic peak at 174.90°C and 174.84°C, respectively. The spray 
dried L-leucine showed an extended endotherm between 25°C and 275°C with a melting point 
of 293°C. 
 
 
Figure 3. DSC thermograms of the spray dried combination formulation and its individual 
components. The samples were heated from 30°C to 300°C under a dynamic flow of nitrogen 
gas. 
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Figure 4 shows the TGA dynamic curves of the powders. Almost complete water evaporation 
during the spray drying was observed because the measured weight loss was very low (< 0.5 
%) for all samples after heating from 25°C to 120°C. In addition, raw verapamil and Vrp_Leu 
begin to degrade at around 225°C, while Rpt and Vrp_Rpt_Leu at 204°C and 162°C, 
respectively. Decomposition of spray dried L-leucine began after 240°C. 
 
 
Figure 4. TGA profiles of the spray dried formulation and its individual components. The 
samples were heated from 30°C to 300°C under a dynamic flow of nitrogen gas. 
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Dynamic vapour sorption 
 
The dynamic water sorption behavior of Vrp_Leu, Rpt and Vrp_Rpt_Leu showed the 
formulations experienced a maximum mass change of 18.05 %, 13.70 % and 10.30  % (w/w), 
respectively at 90 % RH (Figure 5). All formulations exhibited a similar reversible moisture 
sorption trend at both the first and second moisture sorptions with no moisture-induced 
recrystallisation. A double sigmoid profile was observed during both moisture sorption and 
desorption cycles of Rpt; whereas only a slight sigmoid profile was noticed in desorption cycles 
Vrp_Rpt_Leu which appeared after 60 % RH.  
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Figure 5. Moisture sorption isotherms for (a) Vrp_Leu, (b) Rpt and (c) Vrp_Rpt_Leu. 
Humidity ramped from 0 % to 90 % RH for 2-cycles. 
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Dissolution profile 
 
Figure 6 shows the dissolution properties of the Vrp_Leu, Rpt and Vrp_Rpt_Leu. Verapamil, 
a hydrophilic drug, reached its maximal rate of dissolution within an hour in both Vrp_Leu and 
Vrp_Rpt_Leu. However, the release rate of rifapentine was reduced by 20 % in Vrp_Rpt_Leu 
compared to Rpt.   
 
 
Figure 6. Dissolution profile of Vrp_Leu, Rpt and Vrp_Rpt_Leu using Franz-cell dissolution 
method over a period of 5 h (mean ± SD, n=3). 
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In vitro aerosol performance 
 
The FPFtotal, FPFemitted, MMAD, and GSD of each formulation are displayed in Table 2. Figure 
7 presents the drug deposition of Vrp_Leu, Rpt and Vrp_Rpt_Leu powders after MSLI 
dispersion. 
 
The MMAD and GSD of Vrp_Leu were 2.8 µm and 1.6, respectively, which resulted in an 
FPFtotal of 67.3 ± 1.2 %. The FPFtotal of verapamil was increased to 77.4 ± 1.1 % in 
Vrp_Rpt_Leu, which corresponds to MMAD and GSD of 2.10 - 2.16 µm and 1.65 - 1.66, 
respectively. In both formulations, a higher percentage of verapamil was deposited in stage 3 
and 4 compared to the other stages of the impinger.  
 
The FPFtotal and FPFemitted of Rpt were 83.9 ± 0.6 % and 93.9 ± 0.3 %, respectively. Notably, 
Rpt also consists of approximately 24.5 ± 1.0 % of particles aerodynamically less than 1.32 
µm, demonstrated by the drug deposited in the filter stage. Rifapentine in Vrp_Rpt_Leu showed 
FPFtotal and FPFemitted that was significantly reduced to 71.5 ± 2.0 % and 76.8 ± 2.2 %, 
respectively (p < 0.05).  
 
More importantly, for the combination formulation no significant differences were observed in 
the deposition percentage between the two drugs in various stages of the MSLI (p > 0.05), 
indicating uniform distribution of verapamil and rifapentine. 
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Table 2. FPFtotal, FPFemitted, MMAD, and GSD for Vrp_Leu, Rpt and Vrp_Rpt_Leu over 3 
months in 0 % RH (mean ± SD, n=3) 
Vrp_Leu 0 months 1 month 3 months 
FPFtotal (%) 67.3 ± 1.2 68.6 ± 0.7 65.2 ± 2.9 
FPFemitted (%) 73.6 ± 2.0 74.2 ± 0.6 71.1 ± 2.9 
MMAD (µm) 2.87, 2.86, 2.80 2.93, 2.94, 2.58 2.86, 2.71, 2.94 
GSD 1.60, 1.58, 1.59 1.61, 1.61, 1.60 1.58, 1.56, 1.58 
Rpt 0 months   
FPFtotal (%) 83.9 ± 0.6 - - 
FPFemitted (%) 93.9 ± 0.3 - - 
MMAD (µm) 1.76, 1.81, 1.79  - - 
GSD 1.69, 1.70, 1.69 - - 
Vrp_Rpt_Leu 0 months 1 month 3 months 
verapamil rifapentine verapamil rifapentine verapamil rifapentine 
FPFtotal (%) 77.4 ± 1.1 71.5 ± 2.0 77.4 ± 1.1 71.8 ± 4.2 76.7 ± 1.5 69.6 ± 1.8 
FPFemitted (%) 85.7 ± 1.1 76.8 ± 2.2 85.7 ± 1.1 78.2 ± 4.0 84.8 ± 1.2 77.8 ± 1.8 
MMAD (µm) 2.11, 
2.16, 2.10 
2.29, 2.29, 
2.19 
2.21, 
2.19, 2.16 
2.39, 2.35, 
2.34 
2.10, 
2.17, 2.19 
2.35, 2.33, 
2.32 
GSD 1.66, 
1.65, 1.65 
1.66,1.64, 
1.66 
1.57, 
1.61, 1.56 
1.64, 1.63, 
1.62 
1.64, 
1.62, 1.60 
1.65, 1.63, 
1.62 
*MMAD and GSD from each replicate 
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Figure 7. In vitro aerosol deposition profile for (a) Vrp_Leu and Rpt, and (b) Vrp_Rpt_Leu 
following MSLI dispersion at a flow rate of 100 L/min at 0 months using Osmohaler® (mean 
± SD, n=3). 
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Storage stability studies 
 
Figure 8 shows the SEM images of Vrp_Leu and Vrp_Rpt_Leu exposed to 60 % RH for a 
month. The particles in both formulations were observed to be fused into a non-dipersible solid 
aggregate. On the other hand, intact morphology (as in Figure 1) was observed in the powders 
stored at 0 % RH. Therefore, further characterisation was only carried out using powders stored 
at 0 % RH.   
 
Table 3 shows the theoretical and actual drug content of verapamil and rifapentine in 
Vrp_Rpt_Leu stored at 0 % RH over 3 months. The composition of the individual drugs 
remained unchanged after 3 months of storage (p > 0.05). In regard to their aerosol 
performance, no significant changes were seen in their FPFtotal, FPFemitted, MMAD and GSD as 
shown in Table 2 (p > 0.05). The aerosol deposition profiles of Vrp_Leu and Vrp_Rpt_Leu 
stored at 0 % RH up to 3 months (Figure 9) did not demonstrate any significant difference from 
their initial MSLI profile (p > 0.05). 
 
  
Figure 8. Scanning electron microscopy observation of (a) Vrp_Leu and (b) Vrp_Rpt_Leu 
exposed to 60 % RH for a month. 
 
a b 
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Table 3. Theoretical versus actual drug content of Vrp_Rpt_Leu over 3 months of storage in 
0 % RH at 20°C (mean ± SD, n=3)  
Duration of storage  Drug content (%) 
Verapamil Rifapentine 
Theoretical 25 75 
0 month 27.7 ± 1.5 72.3 ± 2.0 
1 month 28.5 ± 3.2 71.5 ± 3.0 
3 months 26.0 ± 2.5 73.0 ± 2.5 
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Figure 9. In vitro aerosol deposition profile for powders stored at 20 ± 3ᵒC in 0 % RH for (a) 
1 month and (b) 3 months dispersed at a flow rate of 100 L/min via the Osmohaler® (mean ± 
SD, n=3). 
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In vitro microbiological and cytotoxicity studies 
 
Resazurin assay 
 
The solubilised Rpt showed high degree of activity against M. tuberculosis H37Ra (MIC90 
0.625 ng/mL) and M. tuberculosis H37Rv (MIC90 5.0 ng/mL). By contrast, the solubilised 
Vrp_Leu has no anti-mycobacterial activity against both strains. The solubilised Vrp_Rpt_Leu 
demonstrated equivalent activity against M. tuberculosis H37Ra (MIC90 0.625 ng/mL) and M. 
tuberculosis H37Rv (MIC90 5.0 ng/mL) as Rpt. Furthermore, when the ratio of verapamil to 
rifapentine was increased, a decrease in the anti-mycobacterial activity was observed. The 
excipient, L-leucine did not inhibit mycobacterial growth at the concentrations used in the 
combinations of Vrp_Leu and Vrp_Rpt_Leu.     
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Table 4. Minimum inhibitory concentration (MIC90) against M. tuberculosis H37Ra and M. 
tuberculosis H37RV of the three drug formulations and the individual compounds using the 
resazurin assay 
Compound  MIC90 (µg/mL)* 
M. tuberculosis 
H37Ra 
M. tuberculosis 
H37Rv 
Vrp_Leu 250 500 
Rpt 0.000625 0.005 
Spray dried L-leucine > 62.5 > 1000 
Vrp_Rpt_Leu 
(verapamil:rifapentine,1:3) 
0.000625 0.005 
Verapamil : rifapentine, 1:1 0.00125 0.01 
Verapamil : rifapentine, 3:1 0.005 0.01 
Verapamil : rifapentine, 10:1 0.01 > 0.02 
*Mean MIC90 of three independent experiments performed in triplicate. 
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Intracellular inhibition of M. tuberculosis H37Ra 
 
In light of the efficacy of the solubilised Vrp_Rpt_Leu against M. tuberculosis, we investigated 
whether verapamil and rifapentine at a ratio of 1:3 could restrict the mycobacterial growth 
within the host THP-1 cell. This assay was only conducted with M. tuberculosis H37Ra due to 
biosafety constraints on using virulent M. tuberculosis H37Rv strain.   
 
As shown in Figure 10, the combined verapamil and rifapentine showed a dose-dependent 
bactericidal activity on M. tuberculosis H37Ra growth over 2 days of infection. Furthermore, 
a statistically significant (p < 0.05) difference was observed between the individual drug 
treatments compared to the combination. For example on day 1, treatment with the combination 
(verapamil 0.05 µg/ml + rifapentine 0.15 µg/ml) resulted in 35 % and 20 % increased bacterial 
killing compared to verapamil (0.05 µg/ml) or rifapentine (0.15 µg/ml) alone, respectively. A 
similar trend was also observed at the other two concentrations tested. These findings indicated 
that the intracellular activity of rifapentine was enhanced by the presence of verapamil.  
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Figure 10. Bactericidal effects of verapamil (VRP) and rifapentine (RPT) at ratio of 1:3 on 
intracellular infection of M. tuberculosis H37Ra in THP-1 cell treated for (a) 24 h and (b) 48 
h (mean ± SD, n=3). The vertical dotted lines separate the different concentrations tested. 
Differences between treatments were evaluated by analysis of variance (*p < 0.05, **p < 0.01). 
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Cytotoxicity assay 
 
The safety of the formulations was investigated by determining the cytotoxic half maximal 
inhibitory concentration (IC50) against THP-1 and A549 cell lines (Table 5). The IC50 of all 
solubilised antibiotic powders were in the range of 62.5 µg/mL and 250 µg/mL. L-leucine did 
not have any cytotoxic effect on either cell line.      
 
Table 5. Half maximal inhibitory concentration (IC50) of the inhalable dry powder formulations 
on human monocytic (THP-1) and human alveolar basal carcinoma epithelial (A549) cell lines 
Compound IC50 (µg/mL) 
THP-1 A549 
Vrp_Leu 125 250 
Rpt 62.5 62.5 
Vrp_Rpt_Leu 62.5 62.5 
Spray dried L-leucine >1000 >1000 
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4. DISCUSSION 
 
To the best of our knowledge, this is the first study on the development of inhalable formulation 
of efflux pump inhibitor, verapamil and rifapentine. The inhaled combination formulation is 
uniquely composed of corrugated amorphous verapamil attached to elongated crystalline 
rifapentine particles. This distinct combination showed a promising aerodynamic performance 
for both verapamil and rifapentine. When verapamil alone was spray dried with L-leucine 
(Vrp_Leu), it had an FPFtotal above 65 % and the MMAD was 2.8 µm. The corrugated surface 
morphology of these amorphous particles reduces the interparticle cohesive forces which 
concomitantly lead to lower particle adhesion forces and superior FPF compared to smoother 
particles [36, 37]. The addition of L-leucine also reduces intermolecular interaction between 
the drugs for enhanced dispersion performance [38]. When verapamil and L-leucine were 
further combined with elongated rifapentine (Rpt) and spray dried (Vrp_Rpt_Leu), the FPFtotal 
of verapamil increased to more than 75 % and the MMAD was reduced to 2.1 µm (p < 0.05). 
This was due to a larger deposition of the particles on stage 4 compared to stage 3 in Vrp_Leu, 
indicating that the elongated Rpt particles act as a carrier for the amorphous verapamil to 
enhance the powder dispersibility. A similar observation was also reported in an inhaled 
formulation that contained colistin and rifapentine [39]. On the other hand, lower deposition of 
rifapentine on the final filter stage (aerodynamically < 1.32 µm) reduced the respirable fraction 
of rifapentine in the combination powder reduced to 70 % (p < 0.05) compared to 83 % in the 
rifapentine alone formulation. However, this reduction may not be clinically significant as the 
particles likely to be submicron, hence exhaled due to negligible impaction and gravitational 
sedimentation in the lung airways [40]. More importantly, Vrp_Rpt_Leu also showed a 
uniform dose distribution of both drugs at their intended dose (p < 0.05) in stages 1 - 4 of the 
MSLI, suggesting a potential homogeneous pulmonary deposition of both drugs. Therefore, 
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the Vrp_Rpt_Leu combination demonstrates suitability for pulmonary delivery at the intended 
dose with high lung deposition profile.  
 
Another advantage of the Vrp_Rpt_Leu formulation was a slower in vitro dissolution rate of 
Rpt particles. Raula et al. demonstrated a similarly slow dissolution rate for L-leucine coated 
salbutamol sulphate (produced via spray drying) compared to pure drug particles [41]. This 
phenomenon was explained by the relatively low water solubility of L-leucine (approximately 
24 g/L) [41]. On the basis of their finding, it could be deduced that during the spray drying 
process L-leucine coated onto the surface of the Rpt and slows the dissolution of the particles. 
In the context of TB treatment, the slow release of anti-TB drugs may allow less frequent 
dosing as well as longer retention of physical drug particles to enhance internalisation by 
macrophages [42].  
 
The stability of the formulations was also addressed. A previous study has demonstrated that 
amorphous rifapentine was chemically unstable after a month of storage at ambient (60 % RH) 
and dry (0 % RH) conditions [32]. A unique crystalline form of rifapentine was therefore 
developed and shown to be chemically stable for up to 3 months of storage under the 
aforementioned conditions [32]. In contrast, spray dried verapamil (without L-leucine) was 
very hygroscopic leading to immediate caking after being spray dried at ambient RH (45 ± 5 
%). In a recent Phase 1, single-dose study by Dharmadhikari et al. used inhalable capreomycin 
spray dried with 20 % L-leucine (w/w) with no severe adverse effects up to administration of 
300 mg [43]. Hence, a similar proportion of L-leucine was used to stabilise verapamil alone 
formulation.  
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The DVS moisture sorption profile demonstrates the Vrp_Leu still absorbs a significant amount 
of water at elevated RH above 60 %. Nonetheless, the reversible water absorption and 
desorption pattern as indicated by the identical reversible moisture sorption trend at both first 
and second moisture sorption cycles suggesting absence of recrystallisation. This could be due 
to the presence of L-leucine, which has been reported to prevent water-induced recrystallisation 
of amorphous pyrazinamide in an inhalable antibiotic formulation consisting of rifapentine, 
moxifloxacin and pyrazinamide [44]. Furthermore, a similar reversible sorption profile was 
observed in Vrp_Rpt_Leu with an additional sigmoid profile after 60 % RH. The presence of 
a sigmoid profile is attributable to the crystalline rifapentine, which forms a monohydrate 
followed by a dehydrate [32]. 
 
Both Vrp_Leu and Vrp_Rpt_Leu can be stored at validated conditions for long-term stability. 
Vrp_Leu and Vrp_Rpt_Leu powders stored for a month at 60 % RH absorbed a significant 
amount of water to become a non-dispersible cake. In contrast, Zhou et al. have shown that co-
solvent spray drying hygroscopic colistin with hydrophobic rifampicin at 1:1 protected the 
powder from storage moisture. They proposed that this was due to the coating of the rifampicin 
onto the surface of the colistin [45]. Although, Vrp_Rpt_Leu consists of 75 % of hydrophobic 
rifapentine, it was crystallised first before the addition of verapamil prior to spray drying which 
resulted the drugs present as two distinctive forms. The water absorption of Vrp_Rpt_Leu 
during storage therefore, could be mainly attributed to the relatively hygroscopic verapamil 
particles. In contrast, the formulations stored for up to 3 months in a moisture-free (vacuum) 
condition retained their physical morphology when observed under SEM. No statistical 
difference was observed in the dispersion profile of these powders up to 3 months. Drug 
quantification analysis also indicated the individual components of the combination remained 
at the intended mass ratio after storage. The HPLC data revealed drug recovery of 95 – 105 % 
120 
 
and no extra peaks that would indicate oxidation or other unwanted chemical reactions. Thus, 
both Vrp_Leu and Vrp_Rpt_Leu should be in moisture protective packaging for long term 
storage.   
 
Verapamil and rifapentine in combination did not show synergistic inhibitory activity against 
M. tuberculosis in vitro. The solubilised Vrp_Rpt_Leu formulation was anticipated to show a 
lower MIC90 than the rifapentine alone formulation owing to efflux pump inhibition by 
verapamil. Unexpectedly, the MIC90 value did not decrease even with an increase in the 
proportion of verapamil. In contrast, Gupta et al. reported that the MIC of bedaquiline and 
clofazimine against the laboratory H37Rv strain and clinical isolates was reduced by 8 to 16 
times in the presence of verapamil [17]. Another study demonstrated verapamil resulted at least 
a 4-fold reduction in the in vitro MIC of isoniazid against M. tuberculosis H37Rv [8]. 
Rodrigues et al., who studied the contribution of efflux mechanism on isoniazid resistance in 
M. tuberculosis complex highlighted that activation of efflux pumps depends on the genotype 
of the strain tested rather than the drug alone [8].  
 
Nevertheless, the killing of M. tuberculosis H37Ra within the macrophage host environment 
was enhanced by the combination of verapamil with rifapentine when compared to treatment 
with the individual drugs. This result could be due to verapamil that appears to inhibit the 
macrophage-induced M. tuberculosis efflux pumps, leading to the increased killing of 
intracellular mycobacteria [10, 17].  
 
The cytotoxicity profiles were also studied to examine the tolerance of pulmonary cells to these 
formulations. As the drugs are shown to accumulate in macrophages, tolerability was assessed 
in THP-1 derived macrophages. The tolerability was also assessed on a lung epithelial cell line 
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due to the non-specific nature of pulmonary delivery. For both cell lines, solubilised 
Vrp_Rpt_Leu demonstrated greater toxicity than the Vrp_Leu solution, but this was similar to 
Rpt alone. This could be because the majority (75 %) of the formulation was rifapentine. 
However, the cytotoxicity of solubilised Vrp_Rpt_Leu may underestimate the potential 
pulmonary toxicity of the formulation as the Rpt particles may not undergo rapid dissolution 
following lung deposition. In a previous study, Chan et al. reported the solubilised Rpt alone 
was well tolerated in vitro by the macrophage and epithelial cell line models up to 50 µM, 
compared 71.3 µM in the present study [32]. Additionally, pharmacokinetics analysis 
following a single pulmonary dose of Rpt at 20 mg/kg showed that intratracheal delivery can 
achieve Cmax of 321 µg/ml in the lungs with no adverse event in the animals during the 
treatment. This suggests that the pulmonary tolerability of rifapentine may be even higher. 
Further pulmonary safety studies of Vrp_Rpt_Leu are warranted.     
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5. CONCLUSION  
  
In this study, we formulated a novel inhalable verapamil and rifapentine combination dry 
powder that demonstrates excellent aerosol performance, enhanced activity against 
intracellular growth of M. tuberculosis in macrophages relative to the single drugs, and a 
promising in vitro cytotoxicity profile. Murine studies are underway to ascertain in vivo 
efficacy of this formulation.  
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CHAPTER 3 
 
 
IN VITRO EVALUATION OF NOVEL INHALABLE DRY 
POWDERS CONSISTING OF THIORIDAZINE AND 
RIFAPENTINE FOR RAPID TUBERCULOSIS TREATMENT 
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2016; 107: 205-214, with the title ‘In vitro evaluation of novel inhalable dry powders consisting 
of thioridazine and rifapentine for rapid tuberculosis treatment’. Authors: Parumasivam T, 
Chan JGY, Pang A, Quan DH, Triccas JA, Britton WJ, Chan H-K. 
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ABSTRACT 
 
Thioridazine is an orally administered antipsychotic drug with potential for treatment of drug-
resistant tuberculosis (TB). However, drug-induced adverse cardiac effects have been reported 
when thioridazine was used at an efficacious oral dose of 200 mg/day to treat TB. Pulmonary 
delivery of thioridazine could be a rational approach to reduce dose-related side effects while 
enabling high drug concentrations at the primary site of infection. The present study compares 
in vitro aerosol performance, storage stability, and in vitro antimicrobial activity and 
cytotoxicity of two inhalable powders composed of thioridazine and a first-line anti-TB drug, 
rifapentine. Formulation 1 is a combination of amorphous thioridazine and crystalline 
rifapentine, while Formulation 2 consisted of both drugs as amorphous forms. Both 
thioridazine-rifapentine formulations were found suitable for inhalation with a total fine 
particle fraction (< 5 µm) of 68 - 76 %. The two powders had similar MIC90 to rifapentine 
alone, being 0.000625 µg/mL and 0.005 µg/ml against M. tuberculosis H37Ra and M. 
tuberculosis H37Rv, respectively. In contrast, thioridazine alone had a MIC90 of 12.5 µg/mL 
and 500 µg/mL against M. tuberculosis H37Ra and M. tuberculosis H37Rv, respectively, 
demonstrating no synergistic anti-TB activity. However, thioridazine and rifapentine in a ratio 
of 1:3 enhanced the killing of M. tuberculosis H37Ra within the human monocyte-derived 
macrophages (THP-1) compared to the single drug treatments. Both powders showed an 
acceptable half maximal inhibitory concentration (IC50) of 31.25 µg/mL on both THP-1 and 
human lung epithelial (A549) cells. However, Formulation 1 showed greater chemical stability 
than Formulation 2 after three months of storage under low humidity (vacuum) at 20 ± 3 °C. 
In conclusion, we have demonstrated a novel inhalable powder consisted of amorphous 
thioridazine and crystalline rifapentine (Formulation 1) with a good aerosol performance, 
potent anti-TB activity and storage stability, which deserves further in vivo investigations. 
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1. INTRODUCTION 
 
Tuberculosis (TB) is predominantly a pulmonary disease caused by Mycobacterium 
tuberculosis. Despite M. tuberculosis was identified since the evolution of medical 
microbiology, TB remains a global burden responsible for high rates of morbidity and mortality 
[1]. The current anti-TB chemotherapy recommended by the World Health Organization 
(WHO) consists of a combination of at least three first-line antibiotics, along with direct 
observation of patient adherence to ensure effective treatment [2]. However, premature 
termination of treatment due to the long duration (at least six months) and associated adverse 
effects contributed to an alarming rate of drug-resistant cases. The treatment of drug-resistant 
TB demands second-line or third-line drugs that are often expensive, less effective, and 
potentially fatal [3]. Unfortunately, progress in developing new anti-TB drugs is insufficient to 
address the rampant emergence of multi-drug resistant (MDR) and extensively drug-resistant 
(XDR) M. tuberculosis strains [4-6]. Repurposing of drugs approved for other diseases could 
be a promising and rapid alternate strategy to achieve new effective anti-TB drugs.    
 
Thioridazine is a phenothiazine drug approved by the U.S. Food and Drug Administration 
(FDA) for the treatment of schizophrenia and psychosis. It is also inexpensive and readily 
available worldwide [7]. Thioridazine has been known for several decades to possess anti-
mycobacterial activity, but it is not currently being used because of its potential toxicity  [8, 9]. 
It has multiple mechanisms of action against M. tuberculosis. First, thioridazine inhibits 
bacterial efflux pump to reduce phenotypic drug resistance in M. tuberculosis [10-12]. Efflux 
pumps are transporter proteins embedded within the cytoplasmic membrane of bacteria to 
extrude toxic substance, including drug molecules from intra-bacterial environment to 
extracellular environment. Over-expression of these pumps reduces the drug concentration in 
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the bacterial cytoplasm that opens a window for drug resistance. The suppression of these 
efflux pumps therefore enriches the drug concentration in the bacterial cytoplasm and hampers 
drug tolerance [10, 11]. Second, thioridazine inhibits potassium (K+) and calcium (Ca2+) efflux 
pumps of M. tuberculosis infected macrophages, thereby activating vacuolar hydrolases within 
the phagolysosome to degrade and kill the phagocytosed bacteria [13]. The inhibition of these 
efflux pumps also enhances the drug concentration within the macrophages for rapid killing of 
entrapped M. tuberculosis without killing the host cells [14, 15]. Third, thioridazine inhibits 
Type-II NADH-menaquinone oxidoreductase, an enzyme that allows M. tuberculosis to persist 
in a dormant/nonreplicating stage in the oxygen- and nutrient-depleted environment of 
granuloma [16, 17]. The inhibition of this enzyme may be effective in the prevention of latent 
TB infection. Finally, as is the case for some other anti-TB drugs, thioridazine interferes with 
DNA replication and damages the bacterial envelope. These pleiotropic activities of 
thioridazine merit its consideration as a potential agent for the rapid treatment of MDR and 
XDR-TB cases.     
 
Various studies have demonstrated that thioridazine can significantly augment the in vitro anti-
mycobacterial activity of many anti-TB drugs [18-20]. However, its efficacy has not been 
replicated in vivo [21, 22] or clinically owing to severe cardiotoxicity at efficacious doses [23, 
24]. For example, de Knegt et al. reported that the addition of thioridazine (4, 8, or 16 mg/L) 
to isoniazid therapy (0.063 mg/L) significantly increased the rate of killing of M. tuberculosis 
(Beijing-1585 strain) and prevented the emergence of isoniazid resistance in an in vitro time-
kill assay [18]. On the other hand, when BALB/c mice infected with the same Beijing-1585 
strain were treated intraperitoneally with isoniazid (25 mg/kg), rifampicin (10 mg/kg) and 
pyrazinamide (150 mg/kg), with thioridazine (3 to 18 mg/kg) no additional efficacy was 
observed compared to the isoniazid, rifampicin and pyrazinamide treatment group  [18]. 
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Similarly, only a modest drug synergism was observed when thioridazine (25 mg/kg) was 
orally administered with isoniazid (10 mg/kg) in BALB/c mice infected with M. tuberculosis 
H37Rv [25]. In contrast, when thioridazine was administered at high oral doses of 32 and 70 
mg/kg with isoniazid (10 mg/kg), rifampicin (10 mg/kg) and pyrazinamide (30 mg/kg) for two 
months, a significant reduction in the number of bacilli was observed in the lungs of the M. 
tuberculosis H37Rv infected BALB/c mice compared to the control and isoniazid, rifampicin 
and pyrazinamide treatment group [21]. Unfortunately, a thioridazine oral dose more than 40 
mg/kg was not well-tolerated in guinea pigs and led to a rapid death which was hypothesised 
due to thioridazine associated cardiotoxicity [22]. Furthermore, adverse cardiac effects have 
been reported in XDR-TB patients administered thioridazine at an efficacious oral dose of 200 
mg/day [24]. Other high dose-related serious side effects of thioridazine include arrhythmia, 
ventricular tachycardia, ventricular fibrillation and sudden cardiac death [7, 26]. Therefore, 
thioridazine appears to be efficacious only at high oral doses that are potentially fatal.  
 
The requirement for high oral dose of thioridazine could be avoided by utilising the inhaled 
route of administration. Apart from achieving significantly higher local thioridazine 
concentrations in the lungs, pulmonary delivery offers additional benefits. First, the targeted 
delivery to the lungs reduces potential degradation of the drug in the acidic environment of the 
stomach and bypasses the first-pass metabolism [27, 28]. Second, pulmonary deposition 
maintains a high drug concentration in the lung which can reduce the frequency of dosing [29]. 
Third, the lung also provides a large surface area for rapid absorption and distribution of drug 
throughout the body to treat any disseminated diseases [27, 28]. These multiple advantages of 
inhalation route may reduce the dose of thioridazine required and related side-effects while 
allowing a rapid cure for TB.  
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The objective of the present work was to prepare and characterise a stable inhalable dry powder 
consisting of thioridazine and a first-line anti-TB drug, rifapentine. Rifapentine is a derivative 
of rifampicin that has a stronger antimicrobial profile and longer pulmonary half-life and has 
gained interest for pulmonary delivery [30]. Two combination powder formulations were 
produced and compared to determine an optimal formulation for further in vivo study: (1) 
Formulation 1 consisted of amorphous thioridazine and crystalline rifapentine where each drug 
existed as distinctive particles, and (2) in Formulation 2 both thioridazine and rifapentine were 
formulated into combination of amorphous particles. The powders were produced at a mass 
ratio of 1:3 which was based on the current recommended oral dosages of thioridazine and 
rifapentine, respectively, with 20 % L-leucine as a stabiliser [24, 31]. The physiochemical 
properties, in vitro aerosol performance and storage stability, and in vitro microbiological 
activities including pulmonary cytotoxicity were compared for these two formulations. 
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2. MATERIALS AND METHODS 
 
Materials 
 
Thioridazine hydrochloride, L-leucine, potassium dihydrogen orthophosphate, dimethyl 
sulfoxide (DMSO), ascorbic acid and phosphate buffered saline (PBS) were from Sigma-
Aldrich, Castle Hill, Australia. Rifapentine was obtained from Hangzhou ICH IMP & Exp 
Company Ltd., Hangzhou, China. Acetonitrile, methanol, and orthophosphoric acid were 
purchased from Ajax Finechem Pty Ltd., Taren Point, Australia. Middlebrook 7H9 and RPMI-
1640 media were from Bacto Laboratories, Mt. Pritchard, NSW, Australia.   
 
Bacterial strain and cell culture 
 
M. tuberculosis H37Ra (ATCC 25177), M. tuberculosis H37Rv (ATCC 27294), human 
monocytic cell line (THP-1), and adenocarcinoma human alveolar basal epithelial cell line 
(A549) were purchased from American Type Culture Collection (ATCC), Manassas, VA. The 
mycobacterial strains were maintained in complete Middlebrook 7H9 media (enriched with 10 
% (v/v) albumin, dextrose and catalase (ADC) supplement) at  37°C  and stored  in 20 % (v/v) 
glycerol at -80°C. The THP-1 and A549 cell lines were maintained in complete RPMI-1640 
media (RPMI-1640 medium, 0.05 mM 2-mercaptoethanol, 10 % (v/v) fetal bovine serum) at 
37°C in 5 % CO2. 
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Preparation of thioridazine and rifapentine formulations by spray drying  
 
For Formulation 1, a crystalline rifapentine suspension was prepared as described by Chan et 
al. [32]. Briefly, rifapentine was dissolved in acetone:water (1:1, v/v) cosolvent at a 
concentration of 4 mg/mL and heated at 67°C to evaporate the acetone to form a crystalline 
rifapentine suspension. The aqueous suspension was then homogenised at 10 000 rpm for 2 
minutes (Silverson L4RT High Shear Mixer, Silverson, Chesham, UK). Thioridazine 
hydrochloride (1:3 of thioridazine:rifapentine, w/w) and L-leucine (20 % w/w) were then added 
and solubilised in the homogenised rifapentine suspension. The combined drug mixture was 
spray dried using a B-290 Mini Spray Dryer (Buchi Labortechnik AG, Flawil, Switzerland) in 
an open-loop configuration using the following conditions: inlet temperature of 60°C, atomiser 
at 60 mm (approximately 740 L/h), aspirator at 100 % (40 m3/h), and feed rate of 2 mL/min.   
 
For Formulation 2, thioridazine hydrochloride, rifapentine and L-leucine at the same ratios as 
Formulation 1 were dissolved in a methanol:water (3:1, v/v) co-solvent. The solution was spray 
dried using similar parameters as described for Formulation 1, but in a closed-loop 
configuration with nitrogen as an inert gas.  
 
Scanning electron microscopy 
 
Particle morphology was examined using scanning electron microscopy (SEM) (Zeiss Ultra 
Plus scanning microscope, Carl Zeiss, Oberkochen, Germany) at a 5 kV acceleration voltage. 
Powders were deposited onto carbon tape and sputter-coated with 15 nm of gold using a K550X 
sputter coater (Quorum Emitech, Kent, UK).  
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Particle sizing 
 
Equivalent volume diameter of the particles was determined using laser diffraction coupled 
with a Scirocco dry powder module (Mastersizer 2000, Malvern Instruments, Worcestershire, 
UK). The dry powder was dispersed at an air pressure of 3.5 bar. All measurements were 
performed in triplicate. The refractive index (RI) was set at 1.61, based on an average RI of 
thioridazine (1.68), rifapentine (1.63) and L-leucine (1.46) at the mass ratio of 1:3:1.  
 
X-ray powder diffractometry 
 
The crystallinity of the powders was analysed using x-ray powder diffractometry (XRPD) 
(D500; Siemens, Karlsruhe, Germany). The powder was spread into the cavity of the XRPD 
glass slide. The analysis was performed using Cu-Kα radiation at a generator voltage of 40 kV 
and a current of 33 mA using a 2θ scan method with a scan rate of 0.04°/sec from 5 - 40°. 
 
Dynamic vapour sorption 
 
A dynamic vapour sorption (DVS) instrument (DVS-1, Surface Measurement Systems, 
London, UK) was used to study the moisture sorption behaviour of the powders. The powders 
were exposed to a dual moisture ramping cycle of 0 to 90 % with gradual 10 % increments of 
relative humidity (RH) at 25°C. The mass changes were recorded over time and equilibrium 
moisture content was determined by a dm/dt of less than 0.02 % per minute.  
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Dissolution profile 
 
A Franz-cell dissolution system (Perm Gear Inc., Bethlehem) was used to study the dissolution 
profile of the powders [33]. Phosphate buffered saline (PBS) (pH 7.4) with 2 % (w/v) ascorbic 
acid as an antioxidant was used as a dissolution medium. Each cell reservoir was filled with 23 
mL of PBS and accommodated with a magnetic stirrer to provide drug uniformity within the 
cell. The cells were connected to a water bath to maintain the temperature of the dissolution 
medium at 37°C. 
 
Prior to dissolution, a capsule filled with 20 mg of powder was actuated using an Osmohaler® 
(Plastiape, Italy) at an air flow of 100 L/min for 4 s into a next generation impactor (NGI) 
containing cellulose filter paper (Whatman® qualitative filter paper Grade 5) in stages 3 and 4 
which have cut-off diameters of 2.2 and 1.3 µm, respectively. The filters holding the deposited 
powder were then placed on the top compartment of the Franz-cell reservoir. Sampling (500 
µL) was performed at predetermined time points (15, 30, 45, 60, 90, 120, 180, 240, and 300 
min) and replaced with an equivalent volume of fresh medium. At the end of the experiment 
(5 h), the filter paper was removed and washed thoroughly with 3 mL of fresh medium.  
 
Each formulation was tested in triplicate and the both drug masses were quantified using a 
validated high-performance liquid chromatography (HPLC) method adapted from previous 
studies [32, 34]. The mobile phase consisted of a 50 mM phosphate buffer (pH 3.0):acetonitrile 
at a ratio of 30:70 (%, v/v) and operated at an isocratic flow rate of 1 mL/min. The stationary 
phase was a µBondapakTM C18 (3.9 × 300 mm2) column (Waters, Milford, Massachusetts). 
The HPLC system (Model LC-20, Shimadzu, Kyoto, Japan) was operated at a detection 
wavelength of 252 nm (SPD-20A UV/VIS detector, Shimadzu) and an injection volume of 20 
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µL. The total running time was 10 min with the retention time of 4.0 min for thioridazine and 
5.1 min for rifapentine. The limit of quantification (LOQ) for thioridazine and rifapentine was 
0.0005 mg/mL and 0.001 mg/mL, respectively. Calibration curves with R2 values of 1.0 for 
thioridazine and rifapentine were obtained with standard concentrations ranging from 0.001 to 
0.1 mg/mL. The dissolution data were expressed as a percentage of drug mass in the buffer 
solution relative to the total mass recovery. 
      
In vitro aerosol performance 
 
In vitro aerodynamic performance of the powders was analysed using a multi-stage liquid 
impinger (MSLI) (British Pharmacopeia 2012, Copley, Nottingham, UK) coupled to a USP 
throat with a silicone mouthpiece adapter [32]. A methanol:water (3:1) co-solvent with 0.2 
mg/mL ascorbic acid was used as a rinsing solvent. Each formulation was tested in triplicate. 
 
Dispersions were performed at 45 ± 5 % RH and 20 ± 3°C. Prior to dispersion, the MSLI was 
filled with 20 mL rinsing solvent in stages 1 to 4 and fitted with a filter paper in stage 5. A size 
3 hydroxypropyl methylcellulose capsule (Capsugel, Greenwood) was filled with 10 ± 0.5 mg 
of powder. The capsule was loaded and punctured in an Osmohaler® (Plastiape, Italy), and 
actuated for 4 s at a flow rate of 100 L/min (Flutus Air, Novi Systems Ltd., Dulverton, UK). 
The dispersion components were washed with rinsing solvent as follows: 5 mL for the adaptor, 
and 10 mL each for the capsule, device, throat and filter. The lower cut-off diameters for stages 
1 - 4 of the MSLI at 100 L/min are 10.4, 4.9, 2.4, and 1.2 µm, respectively. The drug 
quantification was performed using HPLC, as described above. 
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The total fine particle fraction (FPFtotal) was defined as the percentage of particles with an 
aerodynamic diameter less than 5 µm relative to the total recovered drug mass. The emitted 
fine particle fraction (FPFemitted) was defined as the percentage of particles with an aerodynamic 
diameter less than 5 µm in the aerosol relative to the total recovered drug mass excluding the 
capsule and device. Mass median aerodynamic diameter (MMAD) and geometric standard 
deviation (GSD) were calculated from the log-probability plot of the MSLI data. 
  
Storage stability studies 
 
To investigate storage stability, the powders were stored at 20 ± 3°C in loosely capped 
scintillation vials with the glass portion covered with aluminium foil to protect from light. Two 
humidity conditions were studied: 0 % and 60 % RH. For the 0 % RH storage condition, sample 
powders were placed in a desiccator contained silica gel desiccant beads to keep vacuum. For 
a 60 % RH environment, the powders were stored in a climate controlled cabinet. At intervals 
of 1 and 3 months, the in vitro aerosol performance of the powders was assessed using the 
aforementioned methods.  
 
Resazurin assay 
 
The resazurin assay was used to determine the minimum inhibitory concentration (MIC90) of 
the spray dried powders, unprocessed raw drugs in combination and their individual 
components against M. tuberculosis H37Ra (ATCC 25177) and M. tuberculosis H37Rv 
(ATCC 27294). The assay was performed in 96-well plates in triplicate. The powders were 
dissolved in DMSO and serially diluted to the desired concentration in complete Middlebrook 
7H9 media. A log phase M. tuberculosis culture (OD600 0.4-0.8) was added and incubated in 
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a humidified incubator at 37°C for 5 days. On day 5, a mixture of 0.02 % (w/v) resazurin 
solution (30 µL) and 20 % (v/v) Tween-80 (12.5 µL) was added to each well and incubated for 
an additional 48 h. Fluorescence was then measured using a BMG Labtech Polarstar Omega 
(BMG Labtech, Ortenburg, Germany) at an excitation wavelength of 530 nm and an emission 
wavelength of 590 nm. After subtracting background fluorescence, the growth percentage was 
compared to the untreated negative control. Minimum inhibitory concentration (MIC90) was 
measured as the lowest drug concentration that showed 90 % growth inhibition compared to 
the untreated cells. 
        
Intracellular inhibition assay 
 
The human monocytic (THP-1) cells were grown in complete RPMI-1640 media (RPMI-1640 
medium, 0.05 mM 2-mercaptoethanol, 10 % (v/v) fetal bovine serum) containing 50 ng/mL of 
phorbol 12-myristate 13-acetate at a density of 1 × 105 cells/well for 48 h at 37°C in 5 % CO2 
for the cells to adhere and differentiate. The cells were infected with M. tuberculosis H37Ra 
(ATCC 25177) at a multiplicity of infection (MOI) of 5 for 4 h. The cells were then washed 3 
times with PBS, replenished with fresh media and incubated overnight. Thioridazine and 
rifapentine alone and in combination (1:3) were prepared in RPMI-1640 media at various 
concentrations and then added to the plates and incubated for 48 h. At 24 and 48 h incubation, 
the cells were lysed and the viable bacterial number (colony forming units, CFU) was 
determined by plating onto Middlebrook 7H11 agar plates supplemented with 10 % (v/v) oleic 
acid, albumin, dextrose and catalase (OADC) enrichment, and 0.5 % (v/v) glycerol, using 
standard procedures as outlined in [35]. The concentrations were carefully selected, either not 
too high or too low, to show the bactericidal efficacy of the drugs in combination or alone. The 
tested concentrations were also confirmed non-toxic to THP-1 cells through cytotoxicity assay. 
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Cytotoxicity assay 
 
The cytotoxicity profile of the spray dried powders, unprocessed raw drugs in combination and 
their individual components was measured using THP-1 and human alveolar basal carcinoma 
epithelial (A549) cell lines. A 96-well plate was seeded with the cells at a concentration of 5 × 
105 cells/well and incubated for 48 h to allow cell adherence and differentiation. The samples 
were dissolved in DMSO, diluted with distilled water and added into wells in two-fold dilution 
with concentration ranging from 0.00196 - 1.0 mg/mL. The plates were incubated for 4 days at 
37°C in 5 % CO2. A 10 µL aliquot of 0.05 % (w/v) resazurin was added on day 4 and further 
incubated for 4 h. Fluorescence was then measured using a FLUOstar Omega Microplate 
Reader (BMG Labtech, Ortenburg, Germany) with emission at 590 nm following excitation at 
544 nm. The half maximal inhibitory concentration (IC50) was determined by comparing with 
untreated cells after subtracting the background fluorescence.        
 
Statistics 
 
All data are expressed as mean ± standard deviation (SD) with n=3. The t-test analysis of 
variance (Microsoft Office Excel 2007) was performed and the probability (p) values less than 
0.05 were considered significant difference.   
 
 
 
 
 
 
142 
 
3. RESULTS  
 
Particle morphology 
 
Formulation 1 consisted of a mixture of raisin-like particles (thioridazine) and elongated 
crystalline (rifapentine), while Formulation 2 comprised of highly corrugated particles (Figure 
1). The thioridazine particles in Formulation 1 and the particles in Formulation 2 were 
approximately 0.5 to 2.0 µm, whereas the rifapentine crystals in Formulation 1 were roughly 
10  2  2 µm of length  width  height. 
 
  
Figure 1. Scanning electron micrographs of (a) Formulation 1 and (b) Formulation 2. 
 
Particle sizing  
 
Formulation 1 consisted of particles slightly larger than Formulation 2 with equivalent volume 
median diameter (D50) of 1.6 ± 0.03 µm and 1.0 ± 0.03 µm, respectively (Table 1). Both 
formulations have a narrow size distribution as indicated by a span value between 1.1 and 1.2. 
However, the size data of the elongated rifapentine crystals of Formulation 1 should be taken 
a b 
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with caution as the results will depend on the orientation of the non-isometric particles in the 
laser diffraction measurements.  
 
Table 1. Particle size distribution measured by laser diffractiona  
 D10 (µm) D50 (µm) D90 (µm) Span 
Formulation 1 0.9 ± 0.03 1.6 ± 0.03 2.8 ± 0.10 1.2 ± 0.06 
Formulation 2 0.6 ± 0.02 1.0 ± 0.03 1.8 ± 0.06 1.1 ± 0.04 
a(mean ± SD, n=3) 
 
X-ray diffractogram 
 
Formulation 1 showed crystalline peaks at similar angles as previously reported for crystalline 
rifapentine but at lower intensities (Figure 2) [32]. Formulation 2 exhibited a “halo” pattern, 
indicating the powder was largely amorphous.  
 
 
Figure 2. X-ray diffractograms of Formulation 1 and Formulation 2. Crystalline peaks were 
demonstrated by Formulation 1 while Formulation 2 was largely amorphous. 
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Dynamic vapour sorption 
 
Formulation 1 and Formulation 2 absorb a significant amount of water, up to 10.2 and 9.2 %, 
respectively (w/w) at 90 % RH (Figure 3). Both formulations also exhibited a similar reversible 
moisture sorption trend at both the first and second moisture sorptions with no moisture-
induced recrystallisation. A slight sigmoid profile was observed in the desorption cycles of 
Formulation 1 which appeared after 60 % RH, due to crystalline rifapentine which forms 
monohydrate upon exposure to elevated RH [32].  
 
 
 
Figure 3. Dynamic vapour sorption (DVS) isotherm profiles of (a) Formulation 1 and (b) 
Formulation 2 at RH ramped from 0 % to 90 % for 2-cycles. 
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Dissolution profile 
 
The Franz-cell dissolution profiles of the formulations are displayed in Figure 4. Thioridazine 
in Formulation 1 underwent rapid dissolution with about 44.6 % drug released within the first 
30 min and 63.6 % release within 60 min whereas, the release rate of thioridazine in 
Formulation 2 was extremely slow with only about 15.6 % release over 60 min. On the other 
hand, rifapentine in Formulation 1 and Formulation 2 showed a cumulative release of 19.6 % 
and 30.1 %, respectively over 60 min followed by an extended release with a total drug release 
of 54.5 % and 58.2 %, respectively after 5 h.  
 
 
Figure 4. Drug release profiles for Formulation 1 and Formulation 2 determined using Franz-
cell dissolution method over a period of 5 h (mean ± SD, n=3). 
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In vitro aerosol performance  
 
The FPFtotal and FPFemitted of both formulations were acceptable for pulmonary delivery, being 
in the range of 68.1 - 76.4 % and 73.8 - 90.5 %, respectively. However, Formulation 2 showed 
significantly higher FPFtotal and FPFemitted than Formulation 1 (p < 0.05) (Table 2). For example, 
the rifapentine in Formulation 2 had FFPtotal of 76.3 ± 2.0 % and FPFemitted of 90.0 ± 1.3 %, but 
the values were significantly lower (68.1 ± 3.1 % and 73.8 ± 3.4 %, respectively) in 
Formulation 1. These results were also translated into a smaller MMAD of about 1.7 µm in 
Formulation 2 compared to 2.3 - 2.5 µm in Formulation 1. However, the GSD of both 
formulations was around 1.7.  
 
Formulation 2 showed a larger deposition of drugs in stage 3 and 4 and the filter stage while 
Formulation 1 mostly deposited in stages 3 and 4 (Figure 5). Importantly, in both formulations, 
no significant differences were observed in the ratio of the two drugs in various stages of the 
MSLI (p > 0.05), indicating both formulations achieved uniform distributions of thioridazine 
and rifapentine. 
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Table 2. FPFtotal, FPFemitted, MMAD, and GSD of Formulation 1 and Formulation 2 stored in 0 
% RH for 3 months and dispersed using Osmohaler® at 100 L/mina  
Formulation 1 0 month 1 month 3 months 
Thioridazine Rifapentine Thioridazine Rifapentine Thioridazine Rifapentine 
FPFtotal (%) 72.8 ± 3.2 68.1 ± 3.1 73.3 ± 3.9 67.1 ± 2.7 71.5 ± 0.7 66.4 ± 1.2 
FPFemitted (%) 81.2 ± 2.1 73.8 ± 3.4 78.0 ± 4.2 71.7 ± 3.2 79.2 ± 0.8 70.0 ± 2.3 
MMAD (µm) 2.3 ± 0.1 2.5 ± 0.1 2.5 ± 0.2 2.6 ± 0.1 2.5 ± 0.1 2.5 ± 0.1 
GSD 1.7 ± 0.1 1.7 ± 0.1 1.7 ± 0.1 1.7 ±0.1 1.7 ± 0.1 1.7 ± 0.1 
       
Formulation 2 0 month 1 month 3 months 
Thioridazine Rifapentine Thioridazine Rifapentine Thioridazine Rifapentine 
FPFtotal (%) 76.4 ± 2.1 76.3 ± 2.0 79.2 ± 3.0 77.1 ± 1.5 76.6 ± 1.6 76.6 ± 1.2 
FPFemitted (%) 90.5 ± 1.4 90.0 ± 1.3 93.4 ± 1.3  92.4 ± 0.7 92.7 ± 0.7 92.2 ± 0.9 
MMAD (µm) 1.7 ± 0.1 1.7 ± 0.1 1.7 ± 0.2 1.7 ± 0.1 1.7 ± 0.1 1.7 ± 0.1 
GSD 1.7 ± 0.1 1.7 ± 0.1 1.8 ± 0.1 1.8 ± 0.1 1.6 ± 0.1 1.6 ± 0.1 
a (mean ± SD, n=3) 
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Figure 5. MSLI drug deposition profiles of the powders stored in 0 % RH and 20 ± 3°C for 0 
to 3 months and dispersed using Osmohaler® at 100 L/min; (a) Formulation 1 and (b) 
Formulation 2 (mean ± SD, n=3). 
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Storage stability studies 
 
Figure 6 shows the SEM morphology of the powders stored at 60 % RH and 20 ± 3°C for a 
month. In Formulation 1, the thioridazine and rifapentine particles were fused together and 
became non-dispersible larger aggregates while the particles in Formulation 2 were collapsed, 
fused together and caked. This indicated that the powders stored in high humidity were unstable 
and unsuitable for further evaluation. On the other hand, intact morphology (as in Figure 1) 
was observed in the powders stored at 0 % RH. Therefore, the stability dispersion was only 
carried out on powders that were stored in low humidity condition.  
 
No significant differences were measured in FPFtotal, FPFemitted, MMAD and GSD (p > 0.05) 
when the powders were stored in vacuum for up to 3 months (Table 2). Major changes were 
also not observed in the MSLI deposition patterns of the powders, except after 3 months 
storage, Formulation 2 showed greater deposition on stage 4 instead of the filter stage (p < 
0.05) (Figure 5b). There were no significant differences in the MSLI recovery of thioridazine 
and rifapentine in Formulation 1. In contrast, an increase in the proportion of rifapentine 
relative to thioridazine was observed in Formulation 2 after 3 months storage (p > 0.05) (Table 
3). 
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Figure 6. SEM observation of (a) Formulation 1 and (b) Formulation 2 exposed to 60 % RH 
for a month at 20 ± 3°C. 
 
Table 3. Drug percentage recovery from MSLI dispersion of Formulation 1 and Formulation 
2a  
 Formulation 1 Formulation 2 
Thioridazine 
(%) 
Rifapentine 
(%) 
Thioridazine 
(%) 
Rifapentine 
(%) 
0 month 30.3 ± 3.6 69.7 ± 2.7 31.5 ± 3.5 68.5 ± 2.8 
1 month 29.3 ± 4.0 70.7 ± 2.6 32.6 ± 4.8 68.4 ± 3.4 
3 months 30.3 ± 2.9 69.7 ± 4.2 26.3 ± 1.7 73.7 ± 4.2 
a (mean ± SD, n=3) 
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Resazurin assay 
 
Both powder formulations possessed similar MICs against both M. tuberculosis H37Ra 
(0.000625 µg/mL) and M. tuberculosis H37Rv (0.005 µg/mL). The MIC90 was similar to raw 
thioridazine and rifapentine in a combination of 1:3 (Table 4). The MIC90 of thioridazine alone 
was 12.5 µg/mL and 500 µg/mL against M. tuberculosis H37Ra and M. tuberculosis H37Rv, 
respectively. Rifapentine alone had a MIC90 of 0.000625 µg/mL and 0.005 µg/mL against M. 
tuberculosis H37Ra and M. tuberculosis H37Rv, respectively, and this was similar to the 
combination powders. This MIC90 was increased as the proportion of thioridazine to rifapentine 
increased. The excipient L-leucine did not inhibit activity of M. tuberculosis H37Ra or M. 
tuberculosis H37Rv at the concentrations used in the formulations.           
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Table 4. Minimum inhibitory concentration (MIC90) of the combination formulations and their 
individual componentsa   
Compound  MIC90 (µg/mL) 
M. tuberculosis H37Ra M. tuberculosis H37Rv 
Formulation 1 0.000625 0.005 
Formulation 2 0.000625 0.005 
Thioridazine alone 12.5 500 
Rifapentine alone 0.000625 0.005 
Thioridazine:rifapentine (1:3) 0.000625 0.005 
Thioridazine:rifapentine (1:1) 0.0025 0.01 
Thioridazine:rifapentine (3:1) 0.025 0.01 
Thioridazine:rifapentine (10:1) 0.01 > 0.02 
L-leucine > 62.5 > 1000 
aMean MIC90 of three independent experiments performed in triplicate 
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Intracellular assay 
 
To further investigate the efficacy of the formulation against M. tuberculosis-infected 
macrophages, we tested the bactericidal activity of solubilised rifapentine and thioridazine on 
M. tuberculosis H37Ra within macrophages. Figure 7 shows the percentage of viable M. 
tuberculosis H37Ra after treatment with different concentrations of thioridazine and 
rifapentine alone and in combination of 1:3 for 24 h and 48 h.  
 
The intracellular killing activity of thioridazine and rifapentine in combination was 
significantly greater than their respective single drug treatments. On day 1 the drug 
combination (thioridazine 0.05 µg/mL + rifapentine 0.15 µg/mL) exhibited approximately 50 
% and 16 % more bactericidal effect than the thioridazine (0.05 µg/mL) and rifapentine (0.15 
µg/mL) alone, respectively. A similar trend was also observed at the other two concentrations 
tested. Furthermore, thioridazine and rifapentine in combination exhibited a dose-dependent 
bactericidal activity, i.e. on day 1 the combination (thioridazine 0.5 µg/mL + rifapentine 1.5 
µg/mL) resulted in 11 % increased bacterial killing  than the combination at a lower drug 
concentration (thioridazine 0.05 µg/mL + rifapentine 0.15 µg/mL). Complete bacterial killing 
was observed when the concentration of the combination further was increased (thioridazine 
5.0 µg/mL + rifapentine 15.0 µg/mL). 
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Figure 7. Bactericidal effect of thioridazine (THZ) and rifapentine (RPT) at 1:3 on the recovery 
of M. tuberculosis H37Ra from infected macrophages treated for (a) 24 h and (b) 48 h (mean 
± SD, n=3). Differences between treatments were evaluated by analysis of variance (*p < 0.05, 
**p < 0.01). The vertical dotted lines separate the different combination concentrations tested.  
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Cytotoxicity profile 
 
Both Formulation 1 and Formulation 2 showed an IC50 that was two-fold lower than rifapentine 
alone and two-fold higher than thioridazine alone on THP-1 and A549 cell lines (Table 5). A 
similar IC50 value was also observed when unprocessed raw thioridazine and rifapentine were 
tested in a combination of 1:3. L-leucine did not inhibit either cell lines at concentrations up to 
1000 µg/mL. 
 
Table 5. Half maximal inhibitory cytotoxic concentration (IC50) of Formulation 1, Formulation 
2 and their individual components on human monocytic (THP-1) and human alveolar basal 
carcinoma epithelial (A549) cell linesa 
 IC50 
THP-1 A549 
Formulation 1 31.25 31.25 
Formulation 2 31.25 31.25 
Thioridazine alone 15.63 15.63 
Rifapentine alone 62.5 62.5 
Thioridazine:rifapentine (1:3) 31.25 31.25 
L-leucine >1000 >1000 
a Mean MIC90 of three independent experiments performed in triplicate 
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4. DISCUSSION 
 
An inhalable drug combination powder allows deposition of multiple drugs in the pulmonary 
region in a single inhalation [33, 36]. However, formulating drugs with different aqueous 
solubility poses a significant challenge. In the present study, we formulated hydrophilic 
thioridazine hydrochloride and hydrophobic rifapentine into two particulate systems using 
different production methods. In Formulation 1, the crystalline rifapentine particles were pre-
formed and spray dried with solubilised thioridazine to produce amorphous thioridazine 
particles that were physically attached to the elongated rifapentine crystals. In our previous 
study, we produced a similar inhalable formulation consisted of amorphous verapamil and 
rifapentine crystals which showed an FPFrecovered of more than 70 % [37]. In contrast, 
Formulation 2 involved a direct spray drying of thioridazine and rifapentine solubilised in 
methanol:water co-solvent, resulted in corrugated amorphous rifapentine-thioridazine 
particles. Zhou et al. used a similar approach to produce an inhalable powder of colistin 
sulphate (hydrophilic) and rifampicin (hydrophobic) in combination which showed a high 
respirable fraction of more than 90 % [38]. Furthermore, L-leucine that has intermediate water 
solubility was incorporated in both powders to improve powder dispersibility and stability [39, 
40]. L-leucine at 20 % w/w in a spray-dried capreomycin powder has previously been safely 
administered by inhalation in a Phase 1 inhaled clinical study by Dharmadhikari et al. [41]. 
This supports our selection of 20 % w/w L-leucine in the formulations. 
 
Formulation 2 showed superior FPFtotal and FPFemitted compared to Formulation 1 due to higher 
deposition in the filter stage. This also translated into a smaller MMAD for Formulation 2 (1.6 
- 1.7 µm) than Formulation 1 (2.2 - 2.6 µm). The corrugated particles of Formulation 2 likely 
reduced the interparticle cohesive forces to improve deagglomeration of the particles [42]. 
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Furthermore, corrugated particles were reported to increase shape factor (χ) to reduce the 
aerodynamic diameter of the particles [43]. In contrast, in a verapamil-rifapentine formulation, 
it was observed that the elongated rifapentine particles act as a carrier to enhance the 
dispersibility of amorphous verapamil particles [37]. A similar carrier effect was also reported 
in an inhaled formulation consisted of amorphous colistin sulphate and crystalline rifapentine 
[44]. However, this does not appear to be the case in the current study as the respirable fraction 
of thioridazine spray dried with 20 % leucine (FPFtotal 75.2 ± 2.54) (unreported data) was 
similar to thioridazine of Formulation 1 (72.8 ± 3.24), indicating the carrier effect of rifapentine 
crystals may be drug dependent. Furthermore, the results suggest that the corrugated particle 
morphology of Formulation 2 has a greater role for a high respirable fraction than the particle 
carrier system of Formulation 1.   
 
Another important feature of Formulation 2 was the slower in vitro dissolution rate of 
thioridazine than that of Formulation 1, despite the similar dissolution rate of rifapentine in 
both formulations. It is possible that chemical interactions between the compounds could have 
contributed to the difference in the dissolution observed between the formulations. However, 
the FTIR spectrum of Formulation 1 matched that of Formulation 2 (unreported data), 
suggesting the chemical characteristics of both formulations were identical. The peaks also 
matched with that spray dried thioridazine with leucine and rifapentine (unreported data). 
Hence there are no obvious chemical variations or alterations between these two formulations 
which could explain the slow dissolution of thioridazine in Formulation 2. In contrast, Chan et 
al. showed that spray drying of a combination of isoniazid, rifampicin, and pyrazinamide in 
aqueous solution containing ethanol as a cosolvent resulted in the migration of the higher 
molecular weight (MW) and hydrophobic molecules (rifampicin) to the surface of the particles, 
which was reported to slow the in vitro dissolution rate of the particles [33]. Zhou et al. also 
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showed that rifampicin precipitated onto the surface of colistin sulphate which was 
concentrated in the internal core of the particles [38]. On the basis of these findings, in 
Formulation 2, it could be hypothesised that the hydrophobic and high MW rifapentine (MW 
877.0 g/mol) became supersaturated on the surface of the particles and coated the hydrophilic 
and low MW thioridazine (MW 407.0 g/mol). The slower dissolving surface rifapentine 
therefore delayed the elution of thioridazine. This feature of Formulation 2 may encourage the 
phagocytosis of both rifapentine and thioridazine together, which could deliver a high 
concentration of both drugs inside the infected alveolar macrophages. However, this may not 
be the case with Formulation 1 where the thioridazine and rifapentine exist as two distinct drug 
particles. In this formulation, it is likely that thioridazine particles dissolve rapidly in the lining 
of the lungs while the slower dissolving rifapentine crystals are gradually taken up by 
macrophages.   
  
Both formulations required moisture-free conditions for long-term storage stability. Although 
these formulations showed only a 5 % moisture uptake at 25°C and 60 % RH via DVS profile, 
long-term storage at this condition caused formation of non-dispersible larger powder 
agglomerates and caked. Zhou et al. reported that coating by rifampicin can protect hygroscopic 
colistin sulphate from moisture-induced caking [38]. Raula et al. further demonstrated that 
spray drying of salbutamol sulphate with 20 % (w/w) L-leucine protected the particles from 
moisture-induced fusion and recrystallisation when stored at 65 % RH for 7 days [45]. Most 
recently, Li et al. showed that incorporation of 10 - 20 % (w/w) of L-leucine in the spray dried 
disodium cromoglycate offered protection against moisture-induced aerosol deterioration when 
the powder was stored at 60 % and 75 % RH for 24 h [46]. When thioridazine hydrochloride 
was spray dried alone, the powder was very hygroscopic and caked even at the ambient 
humidity (45 ± 5 % RH). In contrast, crystalline and amorphous rifapentine have previously 
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been reported to retain aerosol dispersibility for at least a month when stored at 60 % RH [32]. 
Therefore, the protection conferred by rifapentine and L-leucine may be overwhelmed in the 
present powder formulations by the high hygroscopicity of thioridazine. In contrast, when these 
powders were stored in a moisture-free condition (vacuum) for up to 3 months, they retained 
their physical morphology and dispersibility with no significant changes in FPFtotal, FPFemitted, 
MMAD and GSD. However, the MSLI drug quantification analysis of Formulation 2 showed 
that the mass percentage of thioridazine and rifapentine was changed with a significant shifting 
of drug deposition from filter stage to stage 4 after stored in the vacuum condition for 3 months. 
Further chemical analysis is necessary to study the chemical interactions between thioridazine 
and rifapentine of Formulation 2 which are beyond the scope of the current study. Nonetheless, 
Formulation 1 with reduced chemical interaction would be preferred for further murine studies.  
 
Both formulations showed same MIC90 as the unprocessed raw drugs against M. tuberculosis 
suggesting that both powder production methods did not alter the antimycobacterial activity of 
the drugs. However, the combination did not show any synergistic inhibitory activity against 
the tested M. tuberculosis strains. The inhibition of bacterial efflux pumps by thioridazine was 
expected to increase intra-bacterial accumulation of rifapentine and reduce the MIC90 of 
rifapentine. Unexpectedly, the MIC90 of rifapentine did not decrease even with the increase in 
thioridazine concentration. Rodrigues et al. demonstrated that the activation of bacterial efflux 
pumps on isoniazid-resistant M. tuberculosis strains was highly dependent on the genotype of 
the bacterial strain and not the drug alone [11]. Nonetheless, the efficacy of the thioridazine in 
combination with other anti-TB drug is well established in vivo and in clinical trials [19, 22-
25, 47]. 
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Interestingly, thioridazine in combination with rifapentine enhanced the bactericidal effect 
against M. tuberculosis H37Ra within macrophages compared to the individual drug 
treatments. This result confirms that thioridazine can enhance the accumulation of rifapentine 
inside macrophages to increase the killing rate of the intracellular bacteria [13, 15, 26, 48]. 
Therefore, the combination of thioridazine and rifapentine may have a significant activity 
against the dormant M. tuberculosis for treatment of latent TB [19].  
 
The cytotoxicity of Formulation 1 and Formulation 2 was assessed on THP-derived 
macrophages and lung epithelial cell lines. Both formulations showed a similar IC50 on both 
cell lines, suggesting the particle processing methods did not alter the cytotoxicity profile of 
the powders. The combination formulations (IC50 of 31.25 µg/mL) showed greater cytotoxicity 
than rifapentine alone (IC50 of 62.5 µg/mL) but were lower than thioridazine alone (15.63 
µg/mL). However, it should be noted that the cytotoxicity of the formulations was tested on 
the solubilised form of the drugs. The cytotoxicity of the formulations therefore could be 
underestimated as these particles may not undergo a rapid dissolution after in vivo 
administration. Nonetheless, a murine pharmacokinetic study previously demonstrated that 
rifapentine was well-tolerated when intratracheally administered at a dose of 20 mg/kg with a 
subsequent pulmonary Cmax of 321 µg/mL [29].  
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5. CONCLUSION  
 
We have demonstrated a novel inhalable powder composed of amorphous thioridazine and 
crystalline rifapentine (Formulation 1) with good aerosol performance and potent in vitro 
antimycobacterial activity. The powder required low moisture storage conditions for long-term 
stability. These data warrant further in vivo studies to establish the pharmacokinetic and 
pharmacodynamic profile of this formulation for treatment of TB. 
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CHAPTER 4 
 
 
RIFAPENTINE-LOADED PLGA MICROPARTICLES FOR 
TUBERCULOSIS INHALED THERAPY:  
PREPARATION AND IN VITRO AEROSOL 
CHARACTERISATION 
 
 
 
 
 
 
 
This chapter has been published in European Journal of Pharmaceutical Sciences, 2016; 88: 1-
11, with the title ‘Rifapentine-loaded PLGA microparticles for tuberculosis inhaled therapy: 
preparation and in vitro aerosol characterization’. Authors: Parumasivam T, Leung SSY, Quan 
DH, Triccas JA, Britton WJ, Chan H-K. 
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ABSTRACT 
 
Inhaled delivery of drugs incorporated into poly (lactic-co-glycolic acid) (PLGA) 
microparticles allows a sustained lung concentration and encourages phagocytosis by alveolar 
macrophages that harbouring Mycobacterium tuberculosis. However, limited data are available 
on the effects of physicochemical properties of PLGA, including the monomer ratio 
(lactide:glycolide) and molecular weight (MW) on the aerosol performance, macrophage 
uptake, and toxicity profile. The present study aims to address this knowledge gap, using 
PLGAs with monomer ratios of 50:50, 75:25 and 85:15, MW ranged 24 - 240 kDa and an anti-
tuberculosis (TB) drug, rifapentine. The PLGA-rifapentine powders were produced through a 
solution spray drying technique. The particles were spherical with a smooth surface and a 
volume median diameter around 2 µm (span ~2). When the powders were dispersed using an 
Osmohaler® at 100 L/min for 2.4 s, the fine particle fraction (FPFtotal, wt. % particles in aerosol 
< 5 µm relative to the total recovered drug mass) was ranged between 52 and 57 %, with no 
significant difference between the formulations. This result suggests that the monomer ratio 
and MW are not crucial parameters for the aerosol performance of PLGA. The phagocytosis 
analysis was performed using THP-1 monocyte-derived macrophages. The highest rate of 
uptake was observed in PLGA 85:15 followed by 75:25 and 50:50 with about 90 %, 80 % and 
70 %, respectively phagocytosis over 4 h of exposure. Furthermore, the cytotoxicity analysis 
on THP-1 and human lung adenocarcinoma epithelial cells demonstrated that PLGA 
concentration up to 1.5 mg/ml, regardless of the monomer composition and MW, were non-
toxic. In conclusion, the monomer ratio and MW are not crucial in determining the aerosol 
performance and cytotoxicity profile of PLGA however, the particles with high lactide 
composition have a superior tendency for macrophage uptake.   
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1. INTRODUCTION 
 
Tuberculosis (TB) is most commonly manifested as pulmonary disease caused by 
Mycobacterium tuberculosis, that remains a serious health problem worldwide, especially in 
Asia and Africa [1]. The emergence of multidrug-resistant (MDR) and extensively drug-
resistant (XDR) strains has further contributed to the spread of the disease [1]. In addition, the 
serious side effects of the current regimen of oral drugs, consisting of first-line anti-TB drugs 
isoniazid, rifampicin, ethambutol, and pyrazinamide, and the lengthy treatment course of more 
than six months have contributed to high rates of treatment noncompliance that lead to 
treatment failures and emergence of drug-resistant strains [2]. 
 
The direct delivery of therapeutic agents encapsulated in polymeric microparticles into the 
infection site, the lungs offers several advantages compared to the current oral regimen for 
treatment of TB. These advantages include delivery of high local drug concentration into the 
lungs, absorption of drugs into systemic circulation without undergoing hepatic first-pass 
metabolism, prolonged drug residence in the lungs, and allows uptake by alveolar macrophages 
that harbours M. tuberculosis [3-6]. Particularly, poly (lactic-co-glycolic acid) (PLGA) based 
inhalable dry powders have garnered considerable interest among researchers in recent years 
[7-9]. PLGA is a copolymer chemically synthesised by polymerisation with different ratios of 
lactic acid and glycolic acid. For instance, PLGA 50:50 refers to a copolymer of 50 % lactic 
acid and 50 % glycolic acid composition. The PLGA polymer: (I) has been approved by Food 
and Drug Administration (FDA) for medical purposes due to its biocompatibility and 
biodegradation [10, 11], (II) permits extended release of encapsulated agents [7, 11, 12], and 
(III) it is readily phagocytosed by alveolar macrophages [8, 13]. Moreover, the ability of the 
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macrophages to phagocytose these PLGA particles facilitates the trafficking/transport of the 
drug to other potential mycobacterial infection sites [14]. 
 
Numerous in vitro and in vivo studies have examined the efficacy of inhaled PLGA drug and 
vaccine systems for the treatment of TB. Suarez et al. showed guinea pigs insufflated with 
PLGA rifampicin microparticles (PLGA 75:25, MW 85.2 kDa) resulted in a pulmonary drug 
concentration three times higher than the pure rifampicin treatment persisting 72 h post-dose 
[15]. In a similar study, Yoshida et al. reported a measurable reduction of viable bacillary count 
in the lungs of M. tuberculosis-infected rats that were treated intratracheally with rifampicin-
loaded PLGA microspheres (PLGA 75:25, MW 20 kDa) [16]. On the other hand, the 
recombinant M. tuberculosis antigen 85B (rAg85B) encapsulated in PLGA  microspheres 
(PLGA 75:25, MW 84.7 kDa) triggered a higher level of interleukin-2 production than the free 
soluble rAg85B in vitro T-cell assay [17]. This enhanced immune response is due to efficient 
uptake of vaccine microparticles by macrophages as opposed to the free antigen treatment. 
Furthermore, the PLGA encapsulation was found to protect the immunogenic agents from 
degradation in vivo [18]. The prolonged release of antigens may also negate the need for a 
booster compared to free antigen administration [19].  
 
Of the various monomer composition, PLGA 75:25 has often been chosen owing to its 
amorphous material nature that allows faster drug or protein release than PLGA 85:15 and 
more sustained release compared to PLGA 50:50 [20]. Studies have established that the 
degradation rate of PLGA is influenced by the monomer composition that determines the 
hydrophilicity of the polymer [10, 21, 22]. PLGA 50:50 degrade faster than PLGA 65:35, and 
PLGA 65:35 degrade faster than PLGA 85:15, owing to the higher composition of hydrophilic 
glycolic acid monomer [10, 21, 22]. Similarly, PLGA with high MW requires a longer time to 
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degrade than those with low MW, due to longer polymer chains in high MW PLGA [10]. In 
contrast, the high MW PLGA resulted in gene expression for only three weeks, while the low 
MW polymer extended the expression up to 6 months [23]. Unfortunately, limited data are 
available on the interplay of monomer and MW in the development of inhalable PLGA 
formulation for TB treatment.  
 
To address this knowledge gap, we have compared the aerosol characteristics of various 
rifapentine-loaded PLGA particles with monomer ratio ranging from 50:50 to 85:15 and MW 
between 24 and 240 kDa. The investigated parameters include particulate morphology, particle 
size, thermal property, drug loading, moisture sorption, and in vitro aerosol performance. 
Additionally, the effects of PLGA monomer ratio and MW on dissolution, alveolar macrophage 
uptake, and pulmonary cytotoxicity profiles were investigated. Rifapentine was used because 
it has been recognised as the most potent sterilising anti-TB agent and has a stronger 
bactericidal activity in dormant tubercle cells which makes it a suitable candidate for being 
delivered intracellularly using a polymeric carrier system [24]. Improved understanding of the 
influence of monomer ratio and MW on the aerosol properties of rifapentine polymeric 
microparticles could optimise the PLGA particles for pulmonary delivery to reduce the 
treatment time and side effects of the TB medication. 
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2. MATERIALS AND METHODS 
 
Materials 
 
The following materials were obtained from Sigma-Aldrich, Castle Hill, Australia: PLGA with 
monomer ratio and MW ranging from 50:50 to 85:15 and 24 to 240 kDa, respectively (Table 
1), polyvinyl alcohol (MW 85 000 - 124 000), potassium dihydrogen orthophosphate, dimethyl 
sulfoxide (DMSO), phosphate-buffered saline tablet, and penicillin-streptomycin solution (10 
000 units/mL). Rifapentine was obtained from Hangzhou ICH Imp & Exp Company Ltd., 
Hangzhou, China. Acetonitrile, methanol, tetrahydrofuran, dichloromethane, and 
orthophosphoric acid were from Ajax Finechem Pty Ltd., Taren Point, Australia.  
 
PLGA microsphere preparation 
 
Three batches of PLGA powders were made: Batch (1) spray dried with low drug loading (9 
% w/w), batch (2) spray dried with high drug loading (23 % w/w), and batch (3) oil-in-water 
(O/W) single emulsion solvent evaporation, as summarized in Table 1. The spray drying was 
performed using acetonitrile instead of dichloromethane [25]. In contrast, dichloromethane was 
used to produce emulsion particles due to its immiscibility nature in water. 
  
Spray drying of drug solution 
 
Rifapentine:PLGA at 1:10 (w/w) for Batch (1) and 3:10 (w/w) for Batch (2) were dissolved in 
acetonitrile. The total solid percentage was 2.2 % or 2.6 % (w/v), respectively. The spray drying 
was undertaken with a B-290 Mini spray-dryer coupled with a Buchi-295 inert-loop and Buchi-
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296 dehumidifier (Buchi Laboratories, Flawil, Switzerland) using nitrogen as the drying gas. 
The spray-drying conditions are inlet temperature of 60°C, atomiser of 60 mm (approximately 
672 L/h), aspirator of 70 % and feed rate of 15 mL/min. The end products were kept in a 
desiccator containing silica gel at 20°C until used.    
 
Oil-in-water (O/W) single emulsion solvent evaporation 
 
Rifapentine:PLGA at 1:10 (w/w) were dissolved in dichloromethane, poured into 45 mL of 2 
% PVA continuous phase and probe sonicated (Branson Sonifier 450, Branson Ultrasonics, 
Danbury) at power 4 for 60 sec. The resulted emulsion was continuously stirred at constant 
speed using a magnetic stirrer (C-MAG MS 4, 150 × 105 × 260 mm (width × height × depth), 
IKA®) at 750 rpm for 4 h to thoroughly remove the dichloromethane and hardening of the 
particles. The particles were then recovered by centrifugation (Beckman L90-K 
Ultracentrifuge, Beckman Coulter Australia Pty Ltd, Lane Cove, Australia) at 9183 g-force for 
15 min and washed three times with distilled water. Finally, the particles were reconstituted in 
45 mL distilled water and dried using spray dryer. The spray dryer was operated in an open-
loop mode using compressed air as the drying gas with following parameters:  inlet temperature 
of 60°C, atomiser of 60 mm (approximately 672 L/h), aspirator of 100 % and feed rate of 2 
mL/min. The collected powders were kept in a desiccator at 20°C until used.    
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Table 1. List of poly (lactide-co-glycolide) with lactide:glycolide monomer composition, 
molecular weight, viscosity data and production method 
Formulation Lactide:Glycolidea Molecular weight 
(kDa)a 
Viscosity (dL/g), 0.1 % 
(w/v) 
in chloroform (25°C)a 
Batch (1): Spray dried low drug loading (9 % w/w)  
SP(1)50:50_24k 50:50 24-38 0.32-0.44 
SP(1)50:50_38k 50:50 38-54 0.45-0.60 
SP(1)50:50_54k 50:50 54-69 0.61-0.74 
SP(1)75:25_76K 75:25 76-115 0.71-1.0 
SP(1)85:15_50k 85:15 50-75 0.55-0.75 
SP(1)85:15_190k 85:15 190-240 1.30-1.70 
Batch (2): Spray dried high drug loading (27 % w/w)  
SP(2)50:50_24k 50:50 24-38 0.32-0.44 
SP(2)75:25_76K 75:25 76-115 0.71-1.0 
SP(2)85:15_50k 85:15 50-75 0.55-0.75 
Batch (3): O/W single emulsion solvent evaporation   
EV50:50_24k 50:50 24-38 0.32-0.44 
EV75:25_76K 75:25 76-115 0.71-1.0 
EV85:15_50k 85:15 50-75 0.55-0.75 
a Information obtained from Sigma-Aldrich [26]. 
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Particle morphology 
 
Scanning electron microscopy (SEM) was used to examine the morphology of the particles. 
The powder was sprinkled onto a carbon sticky tape, sputter-coated with 15 nm gold (Quorum 
Emitech, Kent, UK) and viewed under SEM (FESEM, Hitachi S4500) at an acceleration 
voltage of 5 kV.  
 
Microsphere sizing 
 
Equivalent volume diameter of the particle was measured by laser diffraction. The powder was 
dispersed via the Scirocco 2000 dry powder module (Malvern Instruments Ltd., 
Worcestershire, UK) at a dispersive air pressure of 4.0 bars. The measurement was performed 
in triplicate. The refractive index was set as 1.59.  
 
Thermal analysis 
 
Differential scanning calorimetry (DSC) (Mettler Toledo, Melbourne, Australia) was used to 
study the thermal property of the powders. About 5 mg of powder was mounted in an 
aluminium crucible, crimped with a perforated lid and heated from 25 to 300°C at 10°C/min. 
Thermal data were analysed by STARe software V.9.0x (Mettler Toledo, Greifensee, 
Switzerland).  
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Drug loading and drug loading efficiency 
 
About 2 mg of powder was weighed and dissolved in 0.5 mL DMSO. One ml methanol and 
aqueous ascorbic acid as an antioxidant (2 mg/mL) at 75:25 (v/v), respectively was added to 
precipitate out the PLGA. The cloudy suspension was then centrifuged for 15 min at 13.4 k 
rpm (MiniSpin® Eppendorf, Hamburg, Germany) and the supernatant was analysed using 
HPLC. The overall drug loading and drug loading efficiency were calculated using formula 
below:  
 
Drug loading =
The weight of drug in microspheres (mg)
The weight of microspheres (mg)
  × 100 % 
 
Drug loading efficiency =
Actual drug loading (mg)
Theoretical drug loading (mg)
  × 100 % 
 
Dynamic vapour sorption 
 
The moisture sorption profile of the powders was analysed using a dynamic vapour sorption 
(DVS) instrument (DVS-1, Surface Measurement Systems, London, UK). Each sample was 
subjected to dual moisture ramping cycle of 0 to 90 % relative humidity (RH) with 10 % RH 
step increase, and the mass changes were recorded over time. Equilibrium moisture content at 
each RH was defined as dm/dt of 0.02 % or less per minute.   
 
 
 
 
177 
 
In vitro aerosolisation performance 
 
A next generation impactor (NGI) (Copley Scientific, Nottingham, UK) coupled with a US 
Pharmacopeia (USP) stainless steel throat and silicone adapter was used to determine in vitro 
aerosol performance of the powders. Three replicates were carried out for each formulation.  
 
Before the dispersion, all NGI stages were sprayed with silicone grease to reduce particle 
bouncing. An amount of  10 ± 0.5 mg of powder was weighed into a hydroxypropyl 
methylcellulose (HPMC) capsule (size 3) and actuated through an Osmohaler® (Plastiape, 
Italy) for 2.4 sec at an airflow of 100 L/min. The cut-off diameter for stages 1 - 7 of the NGI 
at 100 L/min were 6.24, 3.45, 2.18, 1.28, 0.73, 0.43 and 0.26 µm respectively.  
 
One mL DMSO was used to wash capsule, device, adaptor, throat, and stage 1 - 8, respectively 
followed by addition of 1 mL methanol and ascorbic acid solvent (composition mentioned 
earlier) to precipitate out the PLGA. The suspensions were centrifuged for 15 min at 13.4 k 
rpm (MiniSpin® Eppendorf, Hamburg, Germany) and the supernatants were collected and 
analysed using high-performance liquid chromatography (HPLC). The total fine particle 
fraction (FPFtotal) (wt. % of particles with aerodynamic diameter less than 5 µm relative to the 
total recovered drug mass) and emitted dose (wt. % of particles emitted from capsule and device 
relative to the total recovered drug mass) were calculated. The total recovered mass was the 
amount of powder collected from inhaler, capsule, adaptor, throat and different stages of NGI. 
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In vitro dissolution studies 
 
Approximately 1.5 mg of powder was suspended in a scintillation vial containing 15 mL 
phosphate-buffered saline (pH 7.4) with 2 mg/mL of ascorbic acid. The suspension was 
incubated at 37°C with constant agitation of 100 cycles/min using a water bath shaker (Labec, 
Marrickville, Australia). At predetermined time points, 1 mL sample was withdrawn, and the 
microspheres were sedimented using centrifugation at 13.4 k rpm for 15 min (MiniSpin® 
Eppendorf, Hamburg, Germany). The supernatant was collected for HPLC analysis while, the 
pellet redispersed in an equal volume of fresh media and transferred back into the scintillation 
vial to maintain the sink condition. All powders were tested in triplicate. Results are expressed 
as cumulative percentage drug release over time.  
 
Drug distribution within particles 
 
Prior to the macrophage uptake assay, the distribution of rifapentine within the microspheres 
was examined. About 2 mg of the spray dried low drug loading powder was weighed, added to 
1 ml of methanol containing aqueous ascorbic acid (composition mentioned earlier) and 
vortexed to dissolve the drug on the particle surface. The suspension was then centrifuged for 
15 min at 13.4 k rpm (MiniSpin® Eppendorf, Hamburg, Germany). The supernatant was 
removed and the pellet was dissolved in 0.5 ml DMSO. One ml of methanol and ascorbic acid 
solution was then added to precipitate out the PLGA. The suspension was centrifuged and the 
supernatant was collected. Both supernatants were analysed using HPLC. The drug on the 
external surface (first supernatant) and core (second supernatant) of the polymer matrix were 
expressed in percentage.  
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Macrophage uptake assay 
 
A human monocytic cell line, THP-1 (ATCC, Manassas, VA) were grown in complete RPMI-
1640 media (RPMI-1640 medium, 0.05 mM 2-mercaptoethanol, 10 % fetal bovine serum) at 
37°C in 5 % CO2. The cells were seeded in a 96 wells plate at a density of 10
5 cells/well using 
complete RPMI media containing 50 ng/mL phorbol 12-myristate 13-acetate and incubated for 
48 h for the cells to  differentiate. 
 
Each well was treated with 200 µg of PLGA powders for 1 h, 4 h, and 8 h time intervals. 
Rifapentine at a concentration of 20 µg/ml was included as a control in this study. Prior to 
addition to the plate, the PLGA powders were suspended in a complete RPMI media containing 
1 % streptomycin-penicillin and water bath sonicated for 10 sec to obtain an even suspension. 
Parallelly, the zeta potential values of the suspensions were measured at this stage using 
Zetasizer (Nano ZS, Malvern Instruments, Worcestershire, UK) at 25°C. At a pre-specified 
time point, the cells were washed three times with phosphate-buffered saline to remove 
extracellular PLGA particles adhered to the surface of the cells and lysed with DMSO. The 
samples were collected in an Eppendorf tube, followed by precipitation with methanol and 
ascorbic acid solution as mentioned above. Intracellular drug concentration was expressed as 
the percentage of drug after normalised to the percentage of drug in the polymer core. 
 
Cytotoxicity screening 
 
The cytotoxicity profile was studied on THP-1 and A549, human lung adenocarcinoma 
epithelial cell lines (ATCC, Manassas, VA) as outlined by Pinto et al. [27]. Briefly, freshly 
grown cells dispensed at a density of 5 × 105 cells/well into a 96-well plate and incubated for 
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48 h for the cells adherence. The PLGA powder suspension was prepared as mentioned in the 
previous section and serially diluted with sterile distilled water. The diluted suspension was 
then transferred into the culture plates to obtain a final particle suspension concentration of 
0.01 - 1.5 mg/mL. Two columns on each 96-well microtitre plate were kept for negative 
controls, which contained 10 μL distilled water instead of 10 µL sample. The plates were 
incubated for 4 days. Post-incubation, 10 µL of 0.05 % resazurin was added to each well. The 
plates were incubated for a further 4 h and fluorescence readings taken at 590 nm after 
excitation at 544 nm using an FLUOstar Omega Microplate Reader (BMG Labtech, Ortenburg, 
Germany). After subtraction of background, the survival was calculated as a percentage of 
fluorescence compared with the untreated control. 
 
High-performance liquid chromatography (HPLC) 
 
Samples were analysed using an HPLC system (Shimadzu Corporation, Kyoto, Japan). The 
system consists of CBM-20A controller, LC-20AT pump, SPD-20A UV/VIS detector, SIL-
20A HT autosampler, and LCSolution software. The mobile phase with 53 % 50 mM phosphate 
buffer (pH 3), 42 % acetonitrile and 5 % tetrahydrofuran was run at an isocratic flow rate of 1 
mL/min. The stationary phase was µBondapakTM C18 (3.9 × 300 mm2) column (Waters, 
Milford, Massachusetts). The detection wavelength was 250 nm and the injection volume was 
20 µL. A rifapentine standard curve was plotted from standard solutions with concentrations 
ranging from 0.5 - 100 ug/mL and an R2 value of 0.999 was obtained.   
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Statistic analysis 
 
Data were expressed as mean ± SD with n = 3. The statistical significance of differences 
between groups was calculated using Student’s t-test, and p values < 0.05 were considered 
significant. 
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3. RESULTS AND DISCUSSION 
 
Particle morphology 
 
The SEM micrographs of the particles are shown in Figure 1. Both the low and high drug 
loading spray dried particles were spherical with a smooth surface (Figure 1a-d). The O/W 
single emulsion evaporation method produced a mixture of smooth and slightly corrugated 
particles (Figure 1e-f). It is clear that the PLGA monomer proportion and MW did not translate 
into any visible difference in the particulate physical morphology, but the method of powder 
production has an impact. Jafari-Nodoushan et al. demonstrated electrospraying of PLGA 
50:50, MW 12 kDa dissolved in tetrahydrofuran solution produced irregular particles, and on 
increasing the MW of the polymer to 36 kDa, the particles became shell-like, wrinkled and 
cup-like forms [28]. This was explained by high MW polymer causing stronger chain 
entanglement in the solvent than the low MW polymer [29]. In another similar study, O’Hara 
and Hickey also obtained highly corrugated particles through spray drying dichloromethane 
solution of PLGA 75:25, MW 82.5 kDa with rifampicin [21]. These findings suggest that 
increasing the boiling point or likewise reducing the volatility of the dissolving solvent 
generates smooth particles. The boiling point of acetonitrile (~82°C) is relatively higher than 
tetrahydrofuran (~66°C) and dichloromethane (39.6°C). The slow evaporation of acetonitrile 
therefore allows the polymer chains at the surface of the generated droplets entangled to form 
a strong skin layer that overcomes the contraction pressure of further drying and hence 
produced smooth particles. In contrast, the weak skin layer produced by quick evaporation 
collapses into wrinkled or cup-like under the contraction pressure [30].  
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Figure 1. Morphology of (a) SP(1)50:50_24k, (b) SP(1)75:25_76k, (c) SP(2)50:50_24k, (d) 
SP(2)75:25_76k, (e) EV50:50_24k, and (f) EV75:25_76k. 
 
 
 
 
 
 
a b 
d c 
f e 
184 
 
Particle sizing 
 
Table 2 shows the equivalent volume diameter analysis of the powders. The median diameter 
(d50) of all particles regardless of monomer ratio, MW, and production method was around 1.3 
- 1.5 µm. The d10 of SP(1)50:50_24k was slightly smaller, while d90 of SP(1)85:15_190k was 
slightly higher than the rest of the formulations. This result could be due to higher viscosity of 
SP(1)85:15_190k which potentially caused larger droplets during atomisation of the spray 
drying process compared to other PLGA solutions. Likewise, SP(1)50:50_24k has a lower 
viscosity that resulted smaller particle. A similar observation was previously reported in 
chitosan based particles where a high feeding concentration with high viscosity produced larger 
size particles than the lower concentration solution [31, 32]. Overall, all the spray dried and 
O/W particles were sized within the inhalable range (1 - 5 µm) with an unimodal distribution 
supporting their suitability for respiratory delivery [33].  
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Table 2. Equivalent volume diameter analysis. d10, d50 and d90 represent 10 %, 50 % and 90 % 
of cumulative percentage undersizea  
Formulation d10 (µm) d50 (µm) d90 (µm) 
SP(1)50:50_24k 0.20 ± 0.03 1.34 ± 0.05 2.64 ± 0.16 
SP(1)50:50_38k 0.57 ± 0.06 1.38 ± 0.09 2.66 ± 0.12 
SP(1)50:50_54k 0.67 ± 0.05 1.38 ± 0.10 2.67 ± 0.20 
SP(1)75:25_76K 0.62 ± 0.05 1.34 ± 0.01 2.69 ± 0.02 
SP(1)85:15_50k 0.55 ± 0.09 1.43 ± 0.11 3.21 ± 0.15 
SP(1)85:15_190k 0.52 ± 0.13 1.57 ± 0.05 4.33 ± 0.31 
SP(2)50:50_24k 0.68 ± 0.13 1.45 ± 0.08 2.93 ± 0.23 
SP(2)75:25_76K 0.63 ± 0.02 1.60 ± 0.10 2.93 ± 0.23 
SP(2)85:15_50k 0.60 ± 0.09 1.60 ± 0.08 3.37 ± 0.20 
EV50:50_24k 0.58 ± 0.13 1.51 ± 0.22 3.23 ± 0.24 
EV75:25_76k 0.58 ± 0.02 1.26 ± 0.03 2.54 ± 0.12 
EV85:15_50k 0.53 ± 0.08 1.29 ± 0.04 2.89 ± 0.26 
a mean ± SD, n = 3 
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Thermal characterisation 
 
The glass transition temperatures (Tg) of the powders are summarised in Table 3 (see Appendix 
3, Figure 1 for the thermograms). The Tg endotherm of all the PLGA powders were between 
55°C and 60°C. The Tg higher than the physiological temperature (37°C) suggests the particles 
will have an intact morphology after deposited in the airways which makes them suitable for 
macrophage uptake. In addition, a decrease in Tg was observed as the composition of glycolide 
increased from 15 % to 50 % in all formulations. A similar trend was also observed in the 
unprocessed polymers. The previous study by Lan et al. showed that the incorporation of 
glycolide units in the crystal lattice of lactide units caused lattice defects which decreased the 
overall crystallinity and enthalpy of fusion of PLGA [34]. The thermograms of the present 
study, however, showed that the PLGA powders did not undergo melting and were most likely 
amorphous. Therefore, the slight decrease in the Tg may be associated with plasticiser effect 
caused by increasing the glycine monomer that increases the flexibility of the polymer chain 
[35].  
 
Drug loading and drug loading efficiency 
 
A drug loading efficiency of approximately 100 % was observed for the spray dried particles, 
compared to less than 10 % for O/W emulsion particles (Table 3). The lower drug loading of 
emulsion particles was due to partitioning of the drug from dispersed oil phase into external 
water phase [21]. Studies have proposed various formulation strategies to overcome the 
limitation of low drug loading, such as using low disperse phase to continuous phase ratio and 
rapid solvent removal rate [36]. However, optimisation of these complex binary parameters 
poses a major barrier to achieve large scale production. Alternatively, high drug loading can 
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be easily achieved by spray drying method as it converts the organic solvent containing PLGA 
and drug directly into solid particles [37]. This single-step method is also faster, less laborious 
and produces high yield owing to the absence of an additional washing process to remove the 
surfactant, as required for the O/W method. 
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Table 3. Glass transition temperature (Tg), drug loading and drug loading efficiency of the 
microparticles  
Formulation Glass 
transition 
temperature 
(°C) 
Glass 
transition 
temperature 
(°C) 
(Unprocessed 
PLGA) 
Drug loading 
(%) 
Loading 
efficiency (%) 
SP(1)50:50_24k 55.50 52.33 9.30 ± 0.6 102.0 ± 2.9 
SP(1)50:50_38k 55.22 54.25 8.77 ± 0.8 99.9 ± 2.9 
SP(1)50:50_54k 56.30 55.50 9.05 ± 0.8 102.5 ± 2.4 
SP(1)75:25_76K 58.69 58.03 8.64 ± 0.5 95.0 ± 2.9 
SP(1)85:15_50k 58.33 58.00 8.59 ± 0.1 95.0 ± 1.1 
SP(1)85:15_190k 60.67 60.67 8.62 ± 0.3 94.8 ± 3.3 
SP(2)50:50_24k 55.72 52.33 23.1 ± 0.2 100.1 ± 1.0 
SP(2)75:25_76K 58.56 58.03 21.3 ± 0.9 99.5 ± 2.3 
SP(2)85:15_50k 58.42 58.0 21.6 ± 0.3 99.2 ± 1.3 
EV50:50_24k 52.29 52.33 0.72 ± 0.1 7.89 ± 1.0 
EV75:25_76K 55.92 58.03 0.80 ± 0.0 8.75 ± 0.4 
EV85:15_50k 57.22 58.0 0.89 ± 0.1 9.80 ± 1.3 
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Dynamic vapour sorption analysis 
 
A slightly higher mass change was observed in SP(1)50:50_24k, while the least mass change 
was in both PLGA 85:15 formulations (SP(1)85:15_50k and SP(1)85:15_190k), demonstrating 
the hydrophobicity of the polymer increases as the lactide proportion increased (Figure 2). As 
shown in the literature, the lactic acid and glycolic acid share a similar chemical structure, but 
the presence of pendant methyl group on the alpha carbon of lactic acid makes it slightly more 
hydrophobic than glycolic acid [10, 38]. Therefore, increasing the monomer ratio of lactide 
makes the polymer less hygroscopic. Nonetheless, the minimum water uptake (< 2 %) of the 
powders even at a RH of 90 % suggests that the particles are stable upon exposure to high 
humidity. All formulations regardless of monomer ratio, drug loading, and production method 
also exhibited a reproducible sorption and desorption trend, demonstrating powder’s intact 
physicochemical stability after exposed to humidity.  
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Figure 2. First sorption cycle data from dynamic vapour sorption (DVS) isotherm of 
rifapentine loaded PLGA particles. The powders were exposed to 0 - 90 % RH with 10 % RH 
gradual increments.  
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In vitro aerosol characterisation 
 
 Table 4 compares the FPFtotal, emitted dose, MMAD and GSD of each formulation. 
Representative dispersion profiles are shown in Figure 3. The monomer ratio, MW and drug 
loading were not crucial in determining the aerosol performance of the spray dried PLGA 
particles. The FPFtotal and emitted dose of low and high drug loading spray dried powders were 
acceptable for aerosol delivery, being in the range of 52 - 57 % and 81 - 86 %, respectively. 
The MMAD and GSD were 2.5 - 3.0 µm and 2.0 - 2.5, respectively, showing the particles were 
within the respirable size, mildly polydisperse and suitable for deposition in the lower lung 
regions [39]. There were no significant differences (p > 0.05) in the FPFtotal, emitted dose, 
MMAD and GSD between these formulations and this is likely due to the similar surface 
morphology and particle size of these formulations. Furthermore, the particles were highly 
charged as they readily attracted to the spatula and the storage container during the handling. 
The electrostatic charge on these particles possibly outweighs the influences of the different 
monomer composition and MW of PLGA on the aerosol performance.  
 
Comparing the aerosol performance of powders produced from different methods, it was noted 
that the O/W emulsion formulations showed a lower FPFtotal (40 - 45 %) than the corresponding 
solution spray dried formulations. The majority of the spray dried particles were deposited on 
stages 2 to 4 (Figure 3a), while particles obtained from the O/W emulsion method were 
primarily deposited in stage 1 (Figure 3b). The size of particles produced from these both 
methods was comparable. Therefore, the slightly inferior aerosol performance of the O/W 
emulsion particles could be attributed to the strong cohesive force between the particles. 
Presumably, the turbulence inside device was unable to deagglomerate the powders into 
distinctive particles that resulted in bulky deposition in stage 1 of the impactor [40].   
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Coowanitwong et al. produced rifampicin PLGA (monomer ratio unspecified, MW 40 - 65 
kDa) particles containing the different drug to polymer ratio via spray drying methylene 
chloride solution [7]. An FPF (≤ 5.8 µm) of less than 35 % regardless of drug and polymer 
composition was reported when the powders were dispersed by CyclohalerTM at 28.3 L/min 
[7]. In another similar study, Son et al. produced PLGA (75:25; MW 66-107 kDa) coated 
rifampicin dihydrates crystals by spray drying a rifampicin crystalline suspension and acetone-
PLGA coating solution. The aerodynamic analysis using an Aerolizer® at 60 L/min showed the 
powder has an FPF (≤ 5 µm) less than 45 % [12]. In view of these findings and our data, direct 
solution spray drying using acetonitrile is superior in producing inhalable PLGA powder for a 
higher respirable dose (> 50 %) compared to spray drying chlorinated solvents or other 
production methods.   
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Table 4. Aerodynamic properties of various PLGA microspheres prepared using spray drying 
and O/W emulsion tested at a flow rate of 100 L/min for 2.4 s using an Osmohaler®,a  
Formulation FPFtotal (%) Emitted dose (%) MMAD (µm) GSD 
SP(1)50:50_24k 56.3 ± 3.1 85.7 ± 1.4 2.56 ± 0.1 2.03 ± 0.1 
SP(1)50:50_38k 55.7 ± 3.9 81.4 ± 4.4 2.40 ± 0.4 2.02 ± 0.1 
SP(1)50:50_54k 52.0 ± 1.4 83.1 ± 3.2 2.84 ± 0.2 2.01 ± 0.1 
SP(1)75:25_76K 54.6 ± 1.8 81.9 ± 2.9 2.48 ± 0.4 2.03 ± 0.1 
SP(1)85:15_50k 57.2 ± 1.5 85.8 ± 2.1 2.52 ± 0.4 2.05 ± 0.0 
SP(1)85:15_190k 51.9 ± 1.6 85.4 ± 2.1 3.02 ± 0.2 2.65 ± 0.3 
SP(2)50:50_24k 53.2 ± 4.7 80.5 ± 2.4 2.37 ± 0.1 1.95 ± 0.0 
SP(2)75:25_76K 52.4 ± 3.4 82.7 ± 1.1 2.73 ± 0.1 2.01 ± 0.0 
SP(2)85:15_50k 52.5 ± 1.7 82.4 ± 1.2 2.93 ± 0.1 2.10 ± 0.1 
EP50:50_24k 46.8 ± 2.3 83.1 ± 0.4 2.79 ± 0.1 2.15 ± 0.1 
EP75:25_76K 46.0 ± 1.6 86.3 ± 2.0 2.95 ± 0.2 2.48 ± 0.1 
EP85:15_50k 40.8 ± 2.8 85.3 ± 1.5 3.08 ± 0.2 2.91 ± 0.4 
a (mean ± SD, n = 3). 
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Figure 3. In vitro aerosol deposition profile following next generation impactor (NGI) 
dispersion at a flow rate of 100 L/min for 2.4 s using an Osmohaler® (mean ± SD, n = 3). 
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In vitro dissolution studies 
 
The dissolution profiles of the powders are presented in Figure 4. The dissolution experiments 
were stopped on day 7 before a complete release (100 %) was reached because of the 
degradation of rifapentine in the dissolution medium after 7 days of incubation. In general, all 
formulations underwent a biphasic drug release; an initial burst release from the surface of the 
microspheres involving both dissolution and diffusion mechanisms, followed by a slow 
sustained release by diffusion of drug molecules from the particle core into the medium through 
small pores or channels in microspheres [21].  
 
The low drug loading spray dried particles showed a burst effect in less than an hour with 23 
% to 24 % drug release, while the total release was in the range of 28 % to 35 % until day 7 
(Figure 4a - b). This is different from previous studies which reported more than 20 % burst 
release within 24 h and a total release up to 60 % within 7 days [7, 9, 21]. The much slower 
release observed in the present study was probably attributed to agglomeration of PLGA 
microspheres that reduces the particle surface area exposed to the dissolution medium (see 
Appendix 3, Figure 2). Although, several surfactants including Tween 80, PVA, bovine serum 
albumin and polyethylene glycol at different concentrations were used to minimise the 
formation of PLGA agglomerates during the dissolution, the overall drug release remained 
similar.  
 
The higher drug loading batch showed a slower dissolution rate than the low drug loading batch 
(Figure 4b vs. Figure 4c). For instance, the maximum drug release of SP(1)85:15_50k was 
about 35 %, and this was reduced by more than 2-fold in SP(2)85:15_50k (13 %). This contrasts 
with the finding of Coowanitwong et al. [7] that degradation of high payload rifampicin-PLGA 
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particles was more rapid than the low payload particles prepared by spray drying 
dichloromethane-PLGA solution. A possible reason could be the decrease of the porosity or 
increase of the tortuosity within the particles upon spray drying with acetonitrile [7]. These 
phenomena possibly retarded the diffusion of dissolution media into the polymer matrix that 
delayed the elution of drug from the polymer. Furthermore, any differences in dissolution 
instrumentation setup, agitation rate, temperature or deviations from the sink conditions could 
have contributed to the variations in the results between studies. Currently, there is no standard 
in vitro dissolution method for testing inhaled formulations that can enable a reliable direct 
comparison between studies [41].  
 
The burst release of O/W single emulsion solvent evaporation particles was extended until 8 h 
compared to less than 1 h in their counterparts in the spray dried batch (Figure 4b vs. Figure 
4d). This is not surprising because the production of single emulsion particles involved washing 
step that removes the drugs present on the surface of the particles. However, this is the not the 
case with spray drying as the solvent containing the polymer and drug directly converted to dry 
powder which makes some portion of the drug to precipitate on the surface of the particles. 
This aspect of the spray dried particles is discussed in the following section.         
 
Despite the differences in the production method and drug loading, the dissolution of the 
particles followed a similar trend to that previously reported [22, 42, 43]. The polymer 85:15 
had the slowest drug release followed by 75:25 and 50:50, indicating a decrease in the release 
kinetic with increasing lactide content. This scenario is contributed by preferential degradation 
of monomer glycolic acid due to higher hydrophilicity, as explained previously [10]. This 
observation was more profound in the higher drug loading solution spray dried and O/W 
emulsion formulations. In contrast, no obvious trend was noted for different MW formulations. 
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For instance, all spray dried PLGA 50:50 with different MW showed an approximately 35 % 
rifapentine release at the end of the experiment. 
 
Further in vivo studies are recommended for a complete understanding on the degradation 
property of these polymers. The presence of enzymes and surfactants in the epithelial lung fluid 
perhaps may accelerate the breakdown of PLGA and also prevent agglomeration of the 
particles after deposition in the lungs. In addition, these particles are likely to be engulfed by 
alveolar macrophages, and a faster dissolution rate is expected within the macrophage 
environment because of the  to the chelator-rich environment and acidic pH [44].  
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Figure 4. Rifapentine release profiles of: (a) low drug loading spray dried PLGA powder for 
a duration of 8 h, (b) low drug loading spray dried PLGA powder, (c) high drug loading spray 
dried PLGA powder, and (d) O/W PLGA powder over 7 days (mean ± SD, n = 3).   
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Drug distribution within particles 
 
The distribution of rifapentine in the spray dried, low drug loading PLGA microspheres is 
shown in Figure 5. During the spray drying process, usually the droplet shrinks inward quickly 
carrying any molecules in the solution. However, the study by O’Hara and Hickey [21] showed 
that during spray drying the PLGA molecules moved more slowly than the drug molecules. As 
a result, the drug precipitated throughout the dried polymer matrix, with some part of the drug 
available on the surface and some in the core of the particles [21]. The present study provides 
further insight into this mechanism. The distribution of drug was found to be a function of 
monomer ratio with more drugs incorporated on the surface of the particles as the glycolide 
content increased from 15 % to 50 %. This could be due to the variation in the hydrophobicity 
property of these monomers that affects the drying rate and intermolecular interaction between 
the drug and polymer.  
 
 
Figure 5. The distribution of rifapentine in spray dried PLGA particles. The mass of drug 
precipitated on the surface and within the core of the particles in percentage (mean ± SD, n = 
3).   
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Cellular uptake and toxicity profile 
 
Figure 6 shows the macrophage uptake of spray dried, low drug loading PLGA particles over 
8 h time points. At 1 h incubation period around 50 - 60 % of particle uptake was observed 
regardless of polymer monomer ratio and MW. At 4 h incubation, SP(1)85:15_50k and 
SP(1)85:15_190k exhibited more than 20 % drug internalisation compared to SP(1)50:50_24k, 
SP(1)50:50_38k and SP(1)50:50_54k. A 100 % uptake was observed in all PLGA 
formulations, except SP(1)50:50_24k after 8 h incubation. The phagocytosis of particle is 
affected by the particle size and surface chemistry, including surface charge and 
hydrophobicity [45-47]. In the present study, particle size and zeta potential values (Table 5) 
were identical in each formulation. This confirms that the faster uptake of particles with 
monomer ratio 85:15 and 75:25 is due to their greater hydrophobicity that makes them have a 
higher tendency to adsorb to the surface of the cells [48]. In addition, for an efficient uptake, it 
is essential for the particles to be in nano or low micrometer range and negatively charged [45, 
47]. The generated, rifapentine containing PLGA particles were in the range of 1 - 3 µm and 
negatively charged, and thus, they are suitable for delivering rifapentine into infected 
macrophages.      
 
The lung cytotoxicity was evaluated on THP-1 and A549 cell lines using MTT assay at 
concentrations of 0.01 - 1.5 mg/mL for 4 days. The fact that none of the formulations led to a 
reduction of cell viability below 50 %, indicates that neither the different monomer ratios nor 
the MWs has a significant influence on the cytotoxic property of the PLGA and signifies PLGA 
is non-toxic to respiratory associated cells (see Appendix 3, Figure 3). These results are 
consistent with previous findings that PLGA is not toxic to the pulmonary cell line in vitro [8, 
49].  
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Figure 6. Intracellular uptake of rifapentine loaded PLGA particles by THP-1 cell line over 8 
h time points (mean ± SD, n = 3). The drug recovery was expressed as percentage of total drug 
load after normalisation to the drug in core of the particles. 
 
Table 5. Zeta potential of the PLGA particles dispersed in RPMI-1640 mediaa 
Formulation Zeta potential (mV) 
SP(1)50:50_24k -11.4 ± 0.88 
SP(1)50:50_38k -11.0 ± 1.44 
SP(1)50:50_54k -11.6 ± 0.71 
SP(1)75:25_76K -11.7 ± 0.87 
SP(1)85:15_50k -9.6 ± 1.86 
SP(1)85:15_190k -10.34 ± 0.79 
       a (mean ± SD, n = 3). 
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4. CONCLUSION 
 
The aerosol performance properties of the PLGA-rifapentine particles were independent of the 
PLGA’s lactide:glycoside composition and MW. The highest rate of macrophage phagocytosis 
was observed in PLGA 85:15 followed by 75:25 and 50:50. Furthermore, the cytotoxicity 
analysis demonstrated that PLGA with a concentration up to 1.5 mg/ml, regardless of the 
monomer composition and MW were non-toxic to lung-associated cell lines, including 
macrophages and bronchial epithelial cells. Therefore, the PLGA-rifapentine particles provide 
another option for inhaled therapy for pulmonary TB. 
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CHAPTER 5 
 
 
THE DELIVERY OF HIGH DOSE DRY POWDER 
ANTIBIOTICS BY A LOW-COST GENERIC INHALER 
 
 
 
 
 
 
 
This chapter has been published in The AAPS Journal, 2016; 19: 191-202, with the title ‘The 
delivery of high dose dry powder antibiotics by a low-cost generic inhaler’. Authors: 
Parumasivam T, Leung SSY, Tang P, Mauro C, Britton WJ, Chan H-K.  
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ABSTRACT  
 
The routine of loading multiple capsules for delivery of high dose antibiotics is time consuming 
which may reduce patient adherence to inhaled treatment. To overcome this limitation, an 
investigation was carried out using four modified versions of the Aerolizer® that accommodate 
a size 0 capsule for delivery of high payload formulations. In some prototypes, four piercing 
pins of 0.6 mm each were replaced with a single centrally located 1.2 mm pin and 1/3 reduced 
air inlet of the original design. The performance of these inhalers was evaluated using spray-
dried antibiotic powders with distinct morphologies: spherical particles with a highly 
corrugated surface (colistin and tobramycin), and needle-like particles (rifapentine). The 
inhalers were tested at capsule loadings of 50 mg (colistin), 30 mg (rifapentine) and 100 mg 
(tobramycin) using a multi-stage liquid impinger (MSLI) operating at 60 L/min. The device 
with a single pin and reduced air inlet showed a superior performance than the other prototypes 
in dispersing colistin and rifapentine powders, with a fine particle fraction (FPF wt. % < 5 µm 
in the aerosol) between 62 and 68 %. Subsequently, an Aerolizer® with the same configuration 
(single pin and 1/3 air inlet) that accommodates a size 00 capsule was designed to increase the 
payload of colistin and rifapentine. The performance of the device at various inspiratory flow 
rates and air volumes achievable by most cystic fibrosis (CF) patients was examined at the 
maximum capsule loading of 100 mg. The device showed optimal performance at 45 L/min 
with an air volume of 1.5 – 2.0 L for colistin and 60 L/min with an air volume of 2.0 L for 
rifapentine. In conclusion, the modified size 00 Aerolizer® inhaler as a low-cost generic device 
demonstrated promising results for delivery of various high dose formulations for treatment of 
lung infections.    
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1. INTRODUCTION  
 
Over the last two decades, pulmonary drug delivery has gained considerable interest as a 
promising alternative to conventional routes of drug administration for the treatment of various 
chronic pulmonary diseases, including asthma, cystic fibrosis (CF), and chronic obstructive 
pulmonary disease (COPD) (1-3). Nebulisers are the cornerstone of inhalation therapy which 
can deliver large dosages, but they are time-consuming to use, generally bulky, expensive and 
cause a large amount of drug wastage during continuous operation (4). The pressurised metered 
dose inhaler (pMDI) is compact, portable, optimal for small doses (maximum dose 5 mg), and 
can be used quickly (5). However, delivery efficiency of pMDI depends on the patient’s 
breathing pattern and hand-mouth coordination (4). The device has also suffered a phase-out 
of chlorofluorocarbon (CFC) and difficulties with the new hydrofluoroalkane (HFA) 
reformulations (6). The dry powder inhaler (DPI) is a passive device, known for its convenient 
use and high lung deposition, and does not require a strict hand-mouth coordination (4). 
Because of these advantages, the DPI has garnered significant attention from researchers and 
pharmaceutical companies, and this is reflected by a plethora of dry powder-based commercial 
products and clinical trials (7-9). 
 
There is a wide range of DPI products available on the market, ranging from unit-dose devices 
(e.g. Foradil®/Aerolizer®, TOBI®/Podhaler® and Aridol®/Osmohaler®) to multi-dose devices 
(e.g. Pulmicort®/Turbuhaler® and Advair®/Diskus®). These devices still have some drawbacks 
to deliver higher doses (> 100 mg) of powders, such as patients are required to load and inhale 
multiple capsules. TOBI®/Podhaler® marketed by Novartis for the management of 
Pseudomonas aeroginosa infections in CF patients was designed to deliver a maximum dose 
of 112 mg tobramycin. It requires patients to load four individual capsules of 28 mg each (10). 
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Similarly, Bronchitol® by Pharmaxis for mucocilliary clearance requires patients to load and 
inhale up to 10 separate capsules each containing 40 mg of mannitol to generate a significant 
clinical outcome (11). Real-life studies from asthma and COPD patients proved that the 
multiple capsule refills led to poor patient adherence to inhaled medication and inferior clinical 
outcomes (12, 13). For instance, the Diskus® was heavily preferred over HandiHaler® by 
German and Dutch patients with COPD (aged ≥ 45 years), because the former supplies a month 
of medication in a single drug cargo while the latter requires a capsule loading each time (13). 
To overcome the hurdle of multiple capsule loading, Young et al. introduced a passive dry 
powder device (OrbitalTM) for delivering high dose formulations in a single dosing unit (14, 
15). In vitro dispersion analysis showed the device can aerosolise mannitol co-spray dried with 
ciprofloxacin or azithromycin formulations at a drug loading up to 400 mg via multiple 
inhalation manoeuvres (14, 15). However, the device emptied a large amount of powder (nearly 
100 mg) in each actuation which may cause side effects such as coughing or wheezing. Thus, 
there is a need for an inhaler device that can deliver large doses of medication without the 
requirement for multiple capsule loadings and has good tolerability in clinical settings to 
enhance patient compliance to inhaled treatment.    
 
In this study, we modified the Aerolizer® to accommodate a size 0 or 00 capsule to increase 
the capsule drug loading. The modified Aerolizer® is a simple device consists of a mouthpiece 
and a chamber, therefore it is cheaper to manufacture relative to devices having complex 
designs or many moving parts currently available in the market. The dispersion mechanism of 
these modified devices is similar to the original Aerolizer® which involves air turbulence and 
particle impaction inside the swirling chamber for deagglomeration of the powder (16, 17). 
Upon inhalation, air is drawn through the two air inlets in a tangential flow which rotates the 
capsule in the swirling chamber. This causes the powder to impact on the inside wall of the 
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capsule and forces the powder to empty through the capsule holes. During the exit through the 
holes, the powder agglomerates could be sheared  into smaller fragments or individual particles 
and undergo further impaction with the swirling chamber wall prior to exiting the device (18). 
Previous studies showed that the hole size of the capsule affects the powder emptying 
efficiency and dispersion. Chew et al. has reported that the capsule hole size affects the capsule 
and device retention, powder emptying time, respirable fraction and impaction loss of particles 
at the throat of the impinger using a Dinkihaler® (19). Furthermore, Coates et al. showed that 
the agglomeration-agglomeration interaction during the powder ejection from the capsule 
promotes deagglomeration of the powder using an Aerolizer® (18). The inlet size was shown 
to control the velocity of air entering the device which affects the level of turbulence generated 
inside the inhaler and intensity of the particle collision in the capsule (16, 20).  
 
An initial investigation was carried out with four modified versions of Aerolizer® that can 
accommodate a size 0 capsule with the following modifications (Table 1): (1) a centrally 
located large piercing pin (1.2 mm) or four small pins (0.6 mm each) on each side of the capsule 
chamber facing the ends of the capsule, and (2) fully or 1/3 open air inlet. The dispersion 
performance of these devices was undertaken at a flow rate of 60 L/min and an air volume of 
4.0 L using a multi-stage liquid impinger (MSLI), as suggested by Wong et al. for determining 
aerodynamic performance of high dose formulations (21). To simulate patient multiple 
breathing inspirations, the inhaler was actuated multiple times until the capsule was emptied. 
Based on the obtained results, the inhaler was further optimised to accommodate a size 00 
capsule to increase the capsule payload. The device was then assessed for the effect of various 
capsule loadings and performance at inhalation conditions considered tolerable by most CF 
patients. The experimental design was summarised in Figure 1. 
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Three high-dose formulations were employed to assess the performance of these prototypes. 
(1) Colistin sulfate (also called polymyxin E) is a polymyxin group of antibiotics used for the 
treatment of Pseudomonas infection in CF patients and is often delivered through nebulisation 
(22). (2) Rifapentine is a rifamycin class antibiotic given orally for the treatment of pulmonary 
tuberculosis (TB) and has gained significant interest to be delivered via pulmonary route to 
maximise the drug concentration in the lungs (23). (3) Tobramycin is an aminoglycoside 
antibiotic used to treat lung infections amongst CF patients via inhalation route using both 
nebuliser and DPI (24). The powders were produced with the spray-drying technique and 
characterised in terms of physiochemical properties prior to aerosol evaluation. 
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Figure 1. Flowchart summarising the experimental plan. 
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2. MATERIALS AND METHODS 
 
Chemicals  
 
Colistin sulfate, rifapentine and tobramycin sulfate were obtained from Hangzhou ICH IMP & 
Exp Company Ltd., Hangzhou, China. L-leucine, potassium dihydrogen orthophosphate, 2,4-
Dinitrofluorobenzene, Tris(hydroxymethyl) aminomethane, dimethyl sulfoxide, and 
trifluoroacetic acid were from Sigma-Aldrich, Castle Hill, Australia. Acetonitrile, methanol, 
tetrahydrofuran, and orthophosphoric acid were purchased from Ajax Finechem Pty Ltd., Taren 
Point, Australia. 
 
Modified Aerolizer® designs and resistance measurement  
 
The modified Aerolizer® devices were manufactured by Plastiape S.p.A. (Osnago, Italy) using 
methyl methacrylate-acrylonitrile-butadiene-styrene polymer for the mouthpiece, SLA® resin 
for the main body and mouthpiece base, and stainless steel for the internal springs and piercing 
needles (Figure 2). The modifications included (Table 1): (1) enlarged capsule holder to 
accommodate a size 0 or 00 capsule, (2) 1/3 or fully open air inlet, and (3) one large piercing 
pin (1.2 mm) or four small piercing pins (0.6 mm each) on each side. The original Aerolizer® 
can accommodate a size 3 capsule, has fully open inlet and four pins of 0.6 mm each. 
 
The resistance of the devices was calculated using the formula (∆kPa)0.5 = QR (25). The 
pressure drop (kPa) across the device was measured with a pierced empty capsule at flow rates 
of 30, 45, 60, 80, and 100 L/min using a flow controller (Flutus Air, Novi Systems Ltd., 
Dulverton, UK) in triplicate. The square root of the pressure drop ((∆kPa)0.5 ) was then plotted 
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against corresponding flow rate (Q) and the slope of the line reported as the device resistance 
(R). 
 
 
Figure 2. An image of the modified Aerolizer®, 1pin_HR_0. 
 
Table 1. Summary of Aerolizer® modifications and their resistance characteristics. 
Abbreviation Capsule 
size 
No. of 
pin 
Inlet 
size 
Pin size 
(mm) 
Resistance  
((kPa)0.5 
min/L) 
Pressure drop 
at 60 L/min 
(kPa) 
1pin_HR_0 0 1 1/3 1.2 0.022 1.8 
4pin_HR_0 0 4 1/3 0.6 0.021 1.6 
1pin_LR_0 0 1 Full  1.2 0.017 0.8 
4pin_LR_0 0 4 Full 0.6 0.016 0.7 
1pin_HR_00 00 1 1/3 1.2 0.021 1.6 
Abbreviations: 1pin_HR_0, capsule size 0, 1 pin and 1/3 air inlet; 4pin_HR_0, capsule size 0, 
4 pins and 1/3 air inlet; 1pin_LR_0, capsule size 0, 1 pin and full air inlet; 4pin_LR_0, capsule 
size 0, 4 pins and full air inlet; 1pin_HR_00, capsule size 00, 1 pin and 1/3 air inlet; HR, high 
resistant; LR, low resistant. 
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Dry powder preparation and physicochemical characterisation of the model inhalation 
particle systems 
 
Colistin  
 
Spray-dried colistin powder was prepared as described by Zhou et al. (26). Colistin sulfate was 
dissolved in distilled water at a concentration of 6 mg/mL and spray dried using B-290 mini 
spray dryer (Buchi Labortechnik AG, Flawil, Switzerland) in an open-loop configuration using 
the following settings: inlet temperature of 80°C, atomiser of 60 mm (742 L/h), aspirator of 
100 % (40 m3/h), and feed rate of 2 mL/min. 
 
Rifapentine  
 
A crystalline rifapentine suspension was prepared as described by Chan et al. (27). Briefly, 
rifapentine was dissolved in acetone:water (1:1 v/v) co-solvent at a concentration of 4 mg/mL. 
The solution was then heated 67°C to evaporate the acetone and form a crystalline suspension. 
The suspension was then homogenised at 10 000 rpm for 2 minutes (Silverson L4RT High 
Shear Mixer, Silverson, Chesham, UK). The homogenised suspension was spray dried using 
the aforementioned settings except the inlet temperature set at 60°C.    
 
Tobramycin  
 
The spray-dried tobramycin alone powder was hygroscopic and became sticky at ambient 
relative humidity (RH) of 45 ± 5 %. Therefore, 10 % L-leucine was incorporated as a stabiliser. 
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Tobramycin sulfate (90 % w/w) and L-leucine (10 % w/w) were dissolved in distilled water 
and spray dried using same conditions as the colistin powder.   
 
Scanning electron microscopy 
 
Particle morphology was imaged using scanning electron microscopy (SEM) (FESEM, Hitachi 
S4500, Japan) at an acceleration voltage of 5 kV. Powders were deposited onto a carbon tape 
and sputter coated with 15 nm of gold using K550X sputter coater (Quorum Emitech, Kent, 
UK).  
 
Particle size analysis 
 
The volume equivalent diameters (10th, 50th, and 90th percentile particle diameters) were 
determined using a laser diffraction coupled with a Scirocco dry powder disperser (Mastersizer 
2000, Malvern Instruments, Worcestershire, UK), and the results were translated into particle 
size using Mie theory. The refractive index (RI) was set at 1.58, 1.63 and 1.64 for colistin, 
rifapentine and tobramycin, respectively, and dispersed at an air pressure of 3.5 bars (26-28). 
All measurements were performed in triplicate. 
 
X-ray powder analysis 
 
X-ray powder diffractometer (XRD) (D500; Siemens, Karlsruhe, Germany) was used to study 
the crystalline property of the powders. The analysis was performed using Cu-Kα radiation at 
a generator voltage of 40 kV and a current of 33 mA. The data were collected by the 2θ scan 
method with a scan rate of 0.04°/sec from 5° to 40°. 
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Thermal analysis  
 
Differential scanning calorimetry (DSC) (Mettler Toledo, Melbourne, Australia) was used to 
study the thermal profile of the dry powders. About 5 mg of powder was evenly spread into an 
aluminium crucible, crimped with a perforated lid and heated from 30° to 300°C at 10°C/min 
under a continuous flow of nitrogen gas. The perforated lid avoids explosion due to pressure 
build-up caused by moisture evaporation and/or sample decomposition upon heating. The 
thermal data was recorded and analysed through STARe software V.9.0x (Mettler Toledo, 
Greifensee, Switzerland).   
 
Dynamic vapour sorption analysis 
 
The moisture sorption behaviour of the powders was assessed using a dynamic vapour sorption 
(DVS) instrument (DVS-1, Surface Measurement Systems, London, UK). About 5 - 10 mg of 
powder was exposed to a dual moisture ramping cycle of 0 to 90 % with 10 % increment in RH 
operated at 25°C with continuous nitrogen gas flow. The mass changes were recorded over 
time and the equilibrium moisture content determined by dm/dt of less than 0.002 % per minute.  
 
Bulk and tapped density determination 
 
The powder was filled in a pre-weighed and calibrated glass tube until a volume of ~1 - 2 mL 
was reached. The mass of the powder was measured prior to tapping. The powder was then 
subjected to tapping at room condition (20 ± 5°C, 40 ± 5 % RH) until equilibrium was reached 
(approximately 200 – 250 taps). The tapped volume was noted. The bulk and tapped densities 
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were calculated as the mass (g) of powder divided by the volume (cm3) of powder before and 
after tapping, respectively. 
 
In vitro dispersion analysis 
 
Aerosol performance of devices with full or 1/3 air inlet and one or four pin (s) that 
accommodate a size 0 capsule 
 
The pressure drop and flow rate of 0.7 – 1.8 kPa and 60 L/min, respectively were selected as 
an condition achievable by most CF patients (91 – 97 % of children, 96 – 100 % of adolescents 
and 100 % adults) at the resistance of the modified devices (29). The multi-stage liquid 
impinger (MSLI) (Copley, Nottingham, UK) was operated at a flow rate of 60 L/min for 4.0 
secs in a climate-controlled cabinet: temperature, 20 ± 5°C and RH, 50 ± 3 %. The capsule 
loading for colistin, rifapentine and tobramycin was 50 mg, 30 mg, and 100 mg, respectively 
with each representing an approximately 80 % capsule fill by volume of a size 0 hydroxypropyl 
methylcellulose (HPMC) capsule (Capsugel, NSW, Australia). The 80 % fill representing the 
maximum mass of the powder the capsule can accommodate. The inhaler was actuated several 
times until the capsule was emptied. Prior to actuation, the MSLI was calibrated using a flow 
controller (TSI 3063 airflow meter, TSI Instruments Ltd., Buckinghamshire, UK). Distilled 
water was used as a rinsing solvent for colistin and tobramycin while methanol:water at 3:1 
with 2 % ascorbic acid was used for rifapentine. Each formulation was tested in triplicate and 
the drug mass was quantified using high-performance liquid chromatography (HPLC).  
 
The cut-off diameters for stages 1 - 4 of the MSLI at 60 L/min were 13.0, 6.8, 3.1, and 1.7 µm, 
respectively. The emitted dose is the amount of drug emitted from device and capsule relative 
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to total drug recovery. The recovered fine particle fraction (FPFrecovered) was expressed as a 
weight percentage of drug particles with an aerodynamic diameter less than 5 µm (obtained by 
interpolation to the cumulative percent undersize at 5 µm) respect to the total drug recovery. 
The total drug recovery was the sum of drug powder collected from the inhaler, capsule, 
adaptor, throat and different stages of the MSLI via HPLC quantification. The total drug 
recovery of all dispersions was between 95 and 105 % of the capsule loading. Mass median 
aerodynamic diameter (MMAD) and geometric standard deviation (GSD) were calculated from 
the log-probability plot of the MSLI data. 
 
Aerosol performance of 1 pin and 1/3 air inlet open device that accommodates a size 00 capsule 
(1pin_HR_00) at various capsule loadings 
 
The capacity of 1pin_HR_00 to aerosolise colistin and rifapentine was examined at various 
capsule loadings of 30 mg (rifapentine) or 50 mg (colistin), 75 mg and 100 mg. The size 00 
HPMC capsule reached an 80 % fill by volume at 100 mg for both powders. The 80 % fill 
representing the maximum mass of powder the capsule can accommodate. The dispersion 
conditions were kept the same as mentioned earlier. 
 
Effect of various dispersion conditions using 1pin_HR_00 
 
Patients are less likely to accomplish an inhaled volume of 4.0 L and this is a particular concern 
for CF patients who can only achieve lower inhaled volumes at the given device resistance 
(29). Therefore, the dispersion efficiency of 1pin_HR_00 was tested in a range of inhaled 
volumes achievable by CF patient population (see Appendix 4, Table 2 and 3) at a maximum 
capsule loading of 100 mg colistin and rifapentine. The conditions were based on various 
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inspiratory volumes and flow rates achievable by most CF patients as reported by Tiddens et 
al. (29). In that study, 96 patients with varying degrees of lung disease, ages 6 - 54 years were 
asked to inhale forcefully through different device resistances including the resistance of 
1pin_HR_00 while inspiratory flow (L/min), time (sec) and inhaled volume (L) were measured.  
 
High-performance liquid chromatography (HPLC) 
 
Drug quantification was performed using validated methods with an HPLC (Model LC-20, 
Shimadzu, Kyoto, Japan) and UV detector (SPD-20A UV/VIS detector, Shimadzu). A linear 
calibration curve for colistin, rifapentine, and tobramycin was obtained using MSLI rinsing 
solvents with concentrations ranging from 0.005 – 2.0 mg/mL and a R2 value of 0.999.  
 
Colistin 
 
The method was adapted from Zhou et al. (26). The mobile phase consisted of 0.05 % 
trifluoroacetic acid in Mili-Q water (A) and methanol (B), and the stationary phase was a 
PhenoSphere-Next 5 μm C18 (150 × 4.60 mm2) column (Phenomenex, Torrance, California). 
The flow rate was 1.0 mL/min with a gradient program as follows: 30 % to 80 % (B) for 6 min, 
then 80 % to 30 % (B) for 3 min. The system operated at a detection of 250 nm and the injection 
volume was 50 µL.   
    
Rifapentine 
 
The method obtained from Chan et al. (27). The stationary phase was a µBondapakTM C18 (3.9 
× 300 mm2) column (Waters, Milford, Massachusetts). The mobile phase was consisted of 
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phosphate buffer (pH 3.0):acetonitrile:tetrahydrofuran at 53:42:5 (% v/v). The system was 
operated at an isocratic flow rate of 1.0 mL/min at a wavelength of 250 nm and the injection 
volume was 20 µL. 
 
Tobramycin 
 
The method was adapted from The U.S. Pharmacopeia Convention (30). The stationary phase 
was Nova-Pak® C18 (3.9 × 150 mm2) column (Waters, Milford, Massachusetts). The mobile 
phase consisted of Tris (hydroxymethyl) aminomethane (1 .0 g), mili-Q water (400 mL), 1N 
sulfuric acid (10 mL) and acetonitrile (make up to 1.0 liter). An isocratic flow was set up at 1.2 
mL/min at a wavelength of 365 nm and the injection volume was 20 µL.  
 
Prior to the analysis, pre-column derivatisation was performed on the samples. An amount of 
0.8 mL of samples added to 0.8 mL 2,4-Dinitrofluorobenzene (10 mg/mL in alcohol) and 2 mL 
Tris(hydroxymethyl) aminomethane (3 mg/mL in dimethyl sulfoxide). The mixture heated in 
a water bath at 60 °C for 50 min, allowed to cool to room temperature for 10 min, followed by 
the addition of 2 mL acetonitrile. 
 
Statistical analyses 
 
All data were expressed as mean ± standard deviation (SD) with n=3. The differences were 
analysed using Microsoft Excel, t-test analysis of variance, and p values < 0.05 considered 
significant.   
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3. RESULTS  
 
Physicochemical characterisation of the model inhalation particle systems 
 
Scanning electron microscopy 
 
Spray dried colistin and tobramycin particles were near-spherical with corrugated surfaces 
(Figure 3a & c) (26). The rifapentine particles were elongated (Figure b), similar to that 
reported in the previous study (27). The geometric particle size of colistin and tobramycin 
ranged from 0.3 – 4.0 µm and the rifapentine crystals were roughly 10  2  2 µm of length  
width  height.    
 
 
Figure 3. Scanning electron microscopy observation of spray-dried (a) colistin, (b) rifapentine, 
and (c) tobramycin 
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Particle size analysis 
 
The volume equivalent median diameter of the particles was within the inhalable size of less 
than 5 µm (see Appendix 4, Table 1). However, the size data of the elongated rifapentine should 
be taken with caution as the results will depend on the orientation of the non-isometric particles 
in the laser diffraction during measurements. 
 
X-ray powder analysis 
 
Both colistin and tobramycin showed a single diffuse “halo” pattern, suggesting the powders 
were predominantly amorphous (26, 31). In comparison, multiple crystalline peaks were 
exhibited by the rifapentine powder (see Appendix 4, Figure 1) (27).  
 
Thermal analysis 
 
Colistin and tobramycin underwent dehydration from 40°C to 170°C. Colistin showed 
endothermic peaks at 234.6°C and 263.7°C, responsible for melting and decomposition points, 
respectively. Tobramycin showed formation of a metastable anhydrous tobramycin which 
melted at 240.8°C, followed by melting of a stable anhydrous at 270.3°C (32). Rifapentine 
experienced a broad endothermic change from 30°C to 102°C and a sharp melting peak at 
172.6°C (see Appendix 4, Figure 2) (27).  
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Dynamic vapour sorption analysis 
 
Colistin and tobramycin absorbed a significant amount of water, up to 32 % and 52 %, 
respectively at an elevated humidity of 90 % (see Appendix 4, Figure 3). By contrast, the water 
absorption of crystalline rifapentine was less than 13 % even at 90 % RH. Nonetheless, all 
powders exhibited a similar reversible moisture sorption trend at both first and second moisture 
sorptions with no moisture-induced recrystallisation.     
 
Bulk and tapped density measurement 
 
The bulk and tapped density of the powders follow this rank: rifapentine (0.05 g/cm3 and 0.12 
g/cm3, respectively) < colistin (0.08 g/cm3 and 0.17 g/cm3, respectively) < tobramycin (0.17 
g/cm3 and 0.52 g/cm3, respectively). 
 
Aerosol performance of devices with full or 1/3 air inlet and one or four pin (s) that 
accommodate a size 0 capsule 
 
The results are summarised in Table 2, and the deposition profiles are depicted in Figure 4. The 
data are represented as an average percentage of triplicates (mean ± SD) after single or multiple 
actuation(s).  
 
Colistin  
 
All four prototype devices efficiently dispersed the colistin powder with an emitted dose of 
more than 70 %, and capsule and device retentions ranged between 3 - 5 % and 17 - 24 %, 
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respectively. However, the FPFrecovered of 1pin_HR_0 was significantly higher (61.8 ± 4.2 %) 
than the other devices (51.1 – 56.7 %; p < 0.05). As seen in Figure 4a, the 1pin_HR_0 device 
had a higher deposition in stage 4 and filter stage (about 50 %) compared with other devices 
(< 40 %). The MMAD and GSD values of all devices ranged between 2.71 - 2.97 µm and 1.68 
- 1.89, respectively.  
 
Rifapentine  
 
The highest emitted dose was observed in the 1pin_HR_0 (79.4 ± 1.0 %), followed by the 
4pin_HR_0 (62.4 ± 2.1 %), 1pin_LR_0 (43.8 ± 3.8 %) and the lowest was in the 4pin_LR_0 
(8.6 ± 0.8 %). A similar trend was also noticed in the FPFrecovered with the highest and lowest 
values by 1pin_HR_0 (66.1 ± 2.4 %) and 4pin_LR_0 (6.8 ± 1.4 %), respectively. The low 
respirable fraction of 4pin_LR_0 was caused by a substantial capsule retention of more than 
80 % even after 12 actuations (Figure 4b). In contrast, 1pin_HR_0 showed drug mostly 
deposited in stages 3 to filter stage. The MMAD and GSD for all devices were within the range 
of 2.23 - 2.55 µm and 1.75 - 1.83, respectively. 
 
Tobramycin  
 
All devices emptied more than 80 % of the capsule loading in two actuations. However, in 
contrast to colistin and rifapentine powder, the highest FPFrecovered was observed in the 
4pin_LR_0 device (62.7 ± 1.5 %) (p < 0.03). The calculated MMAD was comparable between 
all devices with the values between 2.13 and 2.23 µm while the GSD gradually decreased from 
2.38 ± 0.12 (1pin_HR_0) to 1.90 ± 0.07 (4pin_LR_0). The MSLI dispersion profiles showed 
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both lower resistance devices (1pin_LR_0 and 4pin_LR_0) had about 18 % device retention 
compared to about 10 % in high resistance ones (1pin_HR_0 and 4pin_HR_0).        
 
Table 2. Emitted dose, recovered fine particle fraction (FPFrecovered), mass median aerodynamic 
diameter (MMAD), geometric standard deviation (GSD), and number of actuations for various 
versions of modified Aerolizer® that accommodate a size 0 capsule tested at a flow rate 60 
L/min and 4.0 L air volume. 
Abbreviation: 1pin_HR_0, 1 pin and 1/3 air inlet; 4pin_HR_0, 4 pins and 1/3 air inlet; 
1pin_LR_0, 1 pin and full air inlet; 4pin_LR_0, 4 pins and full air inlet. (*) indicates a 
significant difference in FPFrecovered with p < 0.05.  
 
Colistin (capsule loading 50 mg) 
 Emitted dose FPFrecovered MMAD (µm) GSD  No. of actuations 
1pin_HR_0 74.5 ± 4.3  61.8 ± 3.2* 2.84 ± 0.02 1.89 ± 0.08 1 
4pin_HR_0 70.4 ± 3.8 51.8 ± 3.7 2.97 ± 0.17 1.72 ± 0.10 1 
1pin_LR_0 68.1 ± 3.5 51.1 ± 3.2 2.94 ± 0.24 1.68 ± 0.04 1 
4pin_LR_0 72.4 ± 3.5 56.7 ± 1.5 2.71 ± 0.12 1.69 ± 0.04 1 
Rifapentine (capsule loading 30 mg) 
 Emitted dose FPFrecovered MMAD (µm) GSD  No. of actuations 
1pin_HR_0 79.4 ± 1.0 66.1 ± 2.4* 2.23 ± 0.10 1.83 ± 0.03 1 
4pin_HR_0 62.4 ± 2.0 55.7 ± 4.1 2.51 ± 0.12 1.75 ± 0.10 2 
1pin_LR_0 43.8 ± 3.8 37.3 ± 3.9 2.55 ± 0.10 1.78 ± 0.03 2 
4pin_LR_0 8.6 ± 0.8 6.8 ± 1.4 2.55 ± 0.20 1.79 ± 0.15 12 
Tobramycin (capsule loading 100 mg) 
 Emitted dose FPFrecovered MMAD (µm) GSD  No. of actuations 
1pin_HR_0 89.4 ± 1.0 56.5 ± 2.8 2.20 ± 0.09 2.38 ± 0.12 2 
4pin_HR_0 90.0 ± 0.6 57.8 ± 2.4 2.13 ± 0.08 2.28 ± 0.07 2 
1pin_LR_0 80.7 ± 4.7 56.1 ± 2.6 2.23 ± 0.05 2.08 ± 0.07 2 
4pin_LR_0 81.1 ± 1.5 62.7 ± 1.5* 2.23 ± 0.02 1.90 ± 0.07 2 
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Figure 4. In vitro deposition profiles of different powders across modified Aerolizer® devices that accommodate a size 0 capsule; (a) colistin, (b) 
rifapentine, and (c) tobramycin at a flow rate 60 L/min and 4.0 L air volume. Abbreviations: 1pin_HR_0, 1 pin and 1/3 air inlet; 4pin_HR_0, 4 
pins and 1/3 air inlet; 1pin_LR_0, 1 pin and full air inlet; 4pin_LR_0, 4 pins and full air inlet. The error bars represent the standard deviation of 
three measurements. 
0
10
20
30
40
50
Capsule Device Adaptor Throat Stage 1 (13.0 µm)Stage 2 (6.8 µm) Stage 3 (3.1 µm) Stage 4 (1.7 µm) Filter (< 1.7 µm)
R
ec
o
v
er
ed
 m
a
ss
 (
%
)
1pin_HR_0
4pin_HR_0
1pin_LR_0
4pin_LR_0
c 
232 
 
Aerosol performance of 1 pin and 1/3 air inlet open device that accommodates a size 00 
capsule (1pin_HR_00) at various capsule loadings 
 
In light of the high respirable fraction produced by the 1pin_HR_0 configuration dispersing 
colistin and rifapentine, a similar device that can accommodate a size 00 capsule was designed 
to increase the drug payload. The performance of the device to aerosolise colistin and 
rifapentine powders at capsule loadings of 30 mg to 100 mg is summarised in Table 3 with 
their respective dispersion profiles shown in Figure 5.  
 
Colistin  
 
Irrespective of drug loading, the device emitted about 75 % of powder and taking 2 to 3 
actuations to empty the capsule. In contrast, FPFrecovered was significantly decreased from 61.1 
± 2.6 % to 51.7 ± 2.8 % and 50.0 ± 1.3 % when the capsule loading increased from 50 mg to 
75 mg and 100 mg, respectively. This trend was also reflected in the MMAD, 2.53 ± 0.07 µm 
for 50 mg loading while 3.04 - 3.05 µm for 75 mg and 100 mg loadings. The GSD was not 
significantly changed between different capsule loadings with values between 1.74 and 1.76 (p 
> 0.50). Regardless of capsule loading, most particles were deposited in stage 3 to filter stage 
of the impinger. Approximately 21 - 25 % of drug was retained in the capsule and device.    
 
Rifapentine 
 
As the loading increased, the emitted dose was slightly reduced from 82.0 - 87.8 % (30 mg and 
75 mg loading) to 74.3 - 80.2 % (100 mg loading) with no significant difference in FPFrecovered 
(55 - 60 %) and MMAD (2.35 – 2.61 µm). The number of actuations required to empty the 
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capsule was increased from 2, 5 to 7 times as the drug loading increased from 30 mg, 75 mg to 
100 mg, respectively, showing a direct relationship between dose emptying and the number of 
actuations. The MSLI aerosolisation profile showed the particles mostly deposited in stages 3 
to filter stage with about 20 % capsule and device retention in all loadings. 
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Table 3. Emitted dose, recovered fine particle fraction (FPFrecovered), mass median aerodynamic diameter (MMAD), geometric standard deviation 
(GSD), no. of actuations and various capsule loadings for the 1 pin and 1/3 air inlet device that accommodates a size 00 capsule (1pin_HR_00) 
tested at a flow rate 60 L/min and 4.0 L air volume. 
              Loading                                                  
……..(mg) 
Performance  
Colistin  Rifapentine  
50 mg 75 mg 100 mg 30 mg 75 mg 100 mg 
Emitted dose (%) 78.0 ± 4.3 74.0 ± 3.0 76.0 ± 0.81 84.9 ± 2.9 83.6 ± 1.0 77.2 ± 3.9 
FPFrecovered (%)  61.1 ± 2.6 51.7 ± 2.8 50.0 ± 1.3 58.9 ± 2.7 60.4 ± 3.0 54.6 ± 2.6 
MMAD (µm) 2.53 ± 0.07 3.05 ± 0.14 3.04 ± 0.05 2.35 ± 0.13 2.36 ± 0.22 2.61 ± 0.15 
GSD 1.74 ± 0.09 1.76 ± 0.04 1.75 ± 0.04 1.82 ± 0.07 2.11 ± 0.13 1.85 ± 0.04 
No. of actuations 2 2 3 2 5 7 
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Figure 5. Aerosol deposition profiles across 1 pin and 1/3 inlet device that accommodates a size 00 capsule (1pin_HR_00); (a) colistin and (b) 
rifapentine following MSLI at a flow rate 60 L/min and 4.0 L air volume. The error bars represent the standard deviation of three measurements. 
0
10
20
30
40
50
Capsule Device Adaptor Throat Stage 1 (13.0 µm)Stage 2 (6.8 µm) Stage 3 (3.1 µm) Stage 4 (1.7 µm) Filter (< 1.7 µm)
R
ec
o
v
er
ed
 m
a
ss
 (
%
)
50mg
75mg
100mg
0
10
20
30
40
50
Capsule Device Adaptor Throat Stage 1 (13.0 µm)Stage 2 (6.8 µm) Stage 3 (3.1 µm) Stage 4 (1.7 µm) Filter (< 1.7 µm)
R
ec
o
v
er
ed
 m
a
ss
 (
%
)
30mg
75mg
100mg
a 
b 
236 
 
Effect of various dispersion conditions using 1pin_HR_00  
 
The optimal flow rates and air volumes tolerable by CF patients at a resistance equivalent to 
1pin_HR_00 (0.021 kPa0.5 min/L) with a capsule loading of 100 mg colistin or rifapentine are 
presented in Table 4. Their respective dispersion profiles are presented in Figure 6. Please refer 
to Appendix 4 (Table 2 and 3) for the results from other dispersion conditions.  
 
Colistin  
 
Optimal inhalation conditions for colistin were 45 L/min for 2.0 sec and 2.7 sec that are 
equivalent to air volumes of 1.5 L and 2.0 L, respectively. Under these conditions, there were 
no significant differences in emitted dose (2.0 sec, 80.6 ± 1.4 %; 2.7 sec, 81.0 ± 3.7 %), 
FPFrecovered (2.0 sec, 46.9 ± 3.3 %; 2.7 sec, 51.0 ± 1.5 %), MMAD (2.0 sec, 3.67 ± 0.09 µm; 2.7 
sec, 3.45 ± 0.17 µm), and GSD (2.0 sec, 2.05 ± 0.02; 2.7 sec, 1.89 ± 0.03 %) (p > 0.05). In 
addition, the device had withdrawn an average of 15.3 ± 5.0 mg and 21.7 ± 10.4 mg of powder 
per puff, respectively and required 6 - 8 actuations to empty the capsule. The MSLI dispersion 
profiles showed the powder largely deposited in stages 3 and 4 of the MSLI. 
 
Rifapentine  
 
As for the rifapentine, optimal performance was observed at 60 L/min for 2.0 sec (inhaling 2.0 
L air) with emitted dose of 83.3 ± 3.7 %, FPFrecovered of 58.4 ± 2.4 %, MMAD of 2.50 ± 0.13 
µm and GSD of 2.01 ± 0.07. About 8 - 9 actuations were required to empty the capsule with 
an average of 9.2 ± 5.2 mg powder dispersed through the device in each actuation.  
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Table 4. Optimal inhalation conditions for efficient performance of 1 pin and 1/3 air inlet 
device that accommodates a size 00 capsule (1pin_HR_00) at a capsule loading of 100 mg 
colistin or rifapentine. 
 
 
                                     Flow rate/volume 
 
Performance 
Colistin  Rifapentine 
45 L/min,  
1.5 L 
45 L/min,  
2.0 L 
60 L/min,  
2.0 L 
Emitted dose (%) 80.6 ± 1.4 81.0 ± 3.7 83.3 ± 3.7 
FPFrecovered (%)  46.9 ± 3.3 51.0 ± 1.5 58.4 ± 2.4 
MMAD (µm) 3.67 ± 0.09 3.45 ± 0.17 2.50 ± 0.13 
GSD 2.05 ± 0.02 1.89 ± 0.03 2.01 ± 0.07 
No. of actuations 8 6 8 - 9 
Powder actuated in the first actuation 
(mg) 
32.0 ± 6.9 17.0 ± 8.9 10.7 ± 3.7 
Average of powder dispersed in each 
actuation (mg)  
15.3 ± 5.0 21.7 ± 10.4 9.2 ± 5.2 
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Figure 6. Deposition profiles using the 1 pin and 1/3 air inlet device that accommodates a size 
00 capsule (1pin_HR_00) with a drug loading of 100 mg colistin or rifapentine at their optimal 
inhalation conditions as specified in the legend. The error bars represent the standard deviation 
of three measurements. 
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4. DISCUSSION 
 
The intrinsic resistance of a DPI, which affects the turbulence across the device, is an essential 
parameter determining how easily patients can generate certain inspiratory flow rates for 
optimal lung deposition (33, 34). The prototype modified Aerolizer® devices are ranked by 
their resistance as 1pin_HR_0 (0.022 kPa0.5 min/L) > 4pin_HR_0 and 1pin_HR_00 (0.021 
kPa0.5 min/L) > 1pin_LR_0 (0.017 kPa0.5 min/L) > 4pin_LR_0 (0.016 kPa0.5 min/L). The 
resistance of these devices is within the range of commercially available DPIs (29, 34, 35). For 
instance, the original Aerolizer®, which is characterised by a low resistance of 0.017 kPa0.5 
min/L, was well tolerated and able to administer a dose of 108 µg/day formoterol to patients 
with mild-to-moderate persistent asthma (36, 37). In contrast, RS01® HRes, a device with a 
high resistance of more than 0.036 kPa0.5 min/L was shown successfully operated by majority 
of CF patients to deliver 40 mg mannitol (11). Therefore, patients should be able to generate 
sufficient flow rates to operate these modified Aerolizer® devices for optimal lung deposition.  
 
The dispersion performance of the modified devices was tested using powders that are 
exhibiting diverse physicochemical characteristics. Both spray-dried colistin and tobramycin 
particles were amorphous with corrugated surfaces and rifapentine were elongated crystals. 
Colistin and rifapentine were pure drug formulations, whereas tobramycin contains 10 % L-
leucine as an excipient. These formulations allowed the devices to be tested with dry powders 
of various chemical and physical properties.         
 
The preliminary investigations showed that the capsule size 0 device with 1/3 air inlet and 
single pin configuration (1pin_HR_0) produced higher FPFrecovered (62 - 66 %) for the colistin 
and rifapentine powders. The comparison of the devices at the same flow rate (60 L/min) 
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resulted in markedly different pressure drops among these devices due to the different 
resistance - 1/3 air inlet high resistance devices produced larger pressure drop (1.6 - 1.8 kPa) 
than the fully open inlet low resistance devices (0.7 - 0.8 kPa). These differences in pressure 
drop are a strong component that drives powder fluidisation and dispersion. This is correlated 
with the computational fluid dynamics (CFD) analysis of the original Aerolizer® with 1/3 air 
inlet which was shown to generate greater turbulence, integral scale strain rate (ISSR) and 
velocity than the full air inlet counterpart. This combined effects therefore increased the 
capsule impaction inside the swirling chamber that enhanced the powder deagglomeration and 
generated higher respirable fraction (16, 20). On the other hand, the single piercing pin of 1.2 
mm diameter was found to be more efficient in discharging powder from capsule than the four 
pins of 0.6 mm diameter each, although the total aperture area of both designs was same (0.36 
mm2). A prominent example is the 4pin_LR_0 (fully open air inlet and 4 pins) retained nearly 
80 % of the rifapentine in the capsule even after 12 actuations which was attributed to the 
elongated shape and larger surface area of the particles (38). In contrast, when the colistin and 
rifapentine powders were dispersed with the original Aerolizer® at 100 L/min, FPFrecovered of 
about 83 % has been reported in both powders (26, 27). The original Aerolizer® due to its 
smaller size could generate a stronger flow field at the given dispersion condition which may 
have caused stronger powder deagglomeration and higher respirable fraction (26, 27). 
Furthermore, the modified devices showed higher capsule and device retention (19 - 24 % 
colistin and 18 - 23 % rifapentine) compared to the original Aerolizer® (~ 10 % colistin and ~ 
15 % rifapentine) due to the larger size of these components. 
 
In contrast, when tobramycin powder was dispersed using the 1pin_HR_0 device, the 
FPFrecovered was significantly reduced to 56.5 ± 2.8 % (p < 0.05). The MSLI dispersion profile 
showed higher drug deposition in the throat and stage 1 compared to the other devices. This 
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observation suggests an incomplete deagglomeration of the powder, and this could be due to a 
larger fraction of the powder exiting the device before a maximum level of turbulence and 
impaction was generated in the swirling chamber (19, 20). Studies have reported that during 
spray drying, L-leucine is coated onto the surface of the drug particles to improve the 
flowability of the powder (39, 40). This may aid the premature emptying of the tobramycin 
powder prior to the maximum flow and impaction development. Note that the bulk density of 
tobramycin (0.17 g/cm3) powder is also higher than that of the colistin (0.08 g/cm3) and 
rifapentine (0.05 g/cm3), and this potentially has contributed to less powder fluidisation 
resulting in higher deposition of tobramycin in the throat and stage 1 of the MSLI (41). The 
tobramycin powder was therefore not used for further optimisation with the device having a 
similar configuration as the 1pin_HR_0 but can accommodate a size 00 capsule (1pin_HR_00).   
 
Using the 1pin_HR_00 device for the dispersion of colistin and rifapentine showed that the 
number of actuations was significantly increased as the capsule loading increased from 30 mg 
to 100 mg. When the drug loading was 100 mg a slower capsule spinning was noticed, 
suggesting the turbulence at the given flow rate was not strong enough to efficiently spin the 
heavier capsule. The slow spinning of the capsule could have reduced the powder-capsule 
impaction and the deagglomeration of large aggregates/clumps that resulted in less powder 
coming out from the capsule. Similarly, at the low loading dose the powder has more room in 
the rotating capsule for impaction which breaks up the large agglomerates of powder to easily 
emit from capsule (18). This observation is consistent with the CFD analysis of the original 
Aerolizer® shown that the higher particle-capsule impaction enhanced the deagglomeration 
potential in the flow field and improved the dispersion (18, 42). Furthermore, this impaction 
has caused a significant increase of FPFrecovered in colistin (50 mg vs. 75 mg and 100 mg, p < 
0.01), but only a slight increase in rifapentine (30 mg vs. 75 mg and 100 mg, p > 0.05). This 
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could be due to the amorphous and more cohesive characteristics of colistin compared to 
rifapentine, which is crystalline and less cohesive (14, 38). These results also suggest that the 
performance of the device depends on powder properties (i.e. morphology and crystallinity), 
and therefore if different powders to colistin and rifapentine are tested the outcome could be 
different. Nonetheless, the FPFrecovered of both powders were still within the acceptable 
respirable fraction of 50 - 61 %, implying that irrespective of capsule loading the device is 
capable of aerosolising these powders. 
 
When colistin was dispersed using 1pin_HR_00 at patient-tolerable inhalation conditions, an 
optimal performance was observed at a flow rate of 45 L/min and an air volume of 1.5 - 2.0 L. 
Tiddens et al. reported that nearly all CF patients can achieve 45 L/min at a resistance 
equivalent to that of the  1pin_HR_00. Furthermore, about 51 - 77 % of adults (> 18 years), 29 
- 62 % of adolescents (11 - 18 years), and 3 - 30 % children (< 11 years) were reported to be 
able to generate an inspiratory volume of 1.5 - 2.0 L (29). At these dispersion conditions, about 
17 - 32 mg powder exited the device in the first actuation, the capsule was emptied in 6 - 8 
actuations, and the FPFrecovered was in an acceptable range of 46.9 – 51.0 %. In contrast, the 
dispersion at same flow rate with a volume of 1.0 L produced a lower FPFrecovered (41.8 ± 1.4 
%), indicating the inspiratory volume must be more than 1.5 L for a high respirable fraction. 
Alternatively, when the flow rate was increased to 60 L/min with an air volume of 1.0 L, a 
larger amount of powder (~62 mg out of 100 mg colistin) was emptied in the first actuation 
(see Appendix 4, Table 2), which may not be tolerable by patients. Therefore, when inhaling 
through the 1pin_HR_00, the flow rate should not be more than 45 L/min to avoid withdrawing 
an excessive amount of colistin powder. A conventional tool to identify and maintain a correct 
air flow includes a trainer inhaler device, such as the Diskus® trainer, which will make a 
whistling noise as a warning to prevent patients from inhaling over 40 L/min (43). Although 
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the trainer devices can provide an objective assessment of inhalation profile (44), it cannot be 
guaranteed that patients will maintain a similar flow rate when inhaling through the actual 
device. To overcome the drawback of high flow rate, a flow-modifying setup with 1pin_HR_00 
and a flow restrictor was proposed. The device exhibited a pressure drop 1.6 kPa at a flow rate 
of 60 L/min without restrictor and 45 L/min with the restrictor, suggesting the spike of flow 
rate more than 45 L/min could be prevented by attaching the device to a restrictor. Additional 
dispersion analysis with this setup showed the performance of the 1pin_HR_00 (FPFrecovered, 
43.3 - 46.9 %) was not significantly affected by the flow restrictor. Thus, this simple flow 
restriction setup opens a window to optimise the performance of 1pin_HR_00 suitable for 
patients. 
 
For rifapentine, an optimal flow rate and volume were 60 L/min and 2.0 L, respectively. The 
percentage of CF patients who can achieve this condition is 51 % of adults, 29 % of adolescents, 
and 3 % of children (29). The FPFrecovered was in an acceptable range of 58.4 ± 2.4 %, an average 
of 10.7 ± 3.7 mg powder exited the device in the first actuation, and required 8 - 9 actuations 
to empty the capsule. In contrast, the dispersion analysis at 60 L/min with a volume of 1.5 L 
reduced the FPFrecovered to 16.0 ± 1.7 % due to high capsule retention (nearly 34 %) even after 
14 actuations. Similarly, a low FPFrecovered of 14.3 ± 1.0 % was observed at 45 L/min and 2.0 L 
with nearly 70 % of drug retained in the capsule after 14 actuations (refer to supplementary 
material Table 3). Reducing the flow rate or air volume must have caused insufficient 
turbulence levels and particle impaction velocities which have significantly reduced the capsule 
emptying and consequently the FPFrecovered. Studies are ongoing to overcome this limitation by 
enlarging the piercing pin size to improve the powder emptying and dispersion.  
 
244 
 
In summary, the 1pin_HR_00 device is capable of aerosolising colistin and rifapentine up to 
100 mg in a single capsule. This negates the need to load multiple capsules and can improve 
patient compliance as they do not have to remember how many capsules they have inhaled. 
The device is more patient friendly compared to other commercial products with a simple 
instruction of “open-load-inhale”. It is also relatively easy to check the remaining dose by 
simply opening the mouthpiece of the device and visually inspecting the capsule. Furthermore, 
the simple design of the device makes it cost-effective and easier for quality control in mass 
production. However, there are also possible drawbacks of this high payload design. (1) If the 
device used for multiple doses, the drug retention/accumulation in the device could adversely 
affect the spinning of the capsule or ‘slough off’ the performance and impart high variability 
between doses. (2) Patients need to inhale multiple times to empty the capsule which may cause 
fatigue during consecutive inhalations.  
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5. CONCLUSION 
 
We have shown that the modified Aerolizer® (1pin_HR_00) as a low-cost generic device can 
efficiently aerosolise powders with different physiochemical properties up to a maximum dose 
of 100 mg per capsule. This device can also perform well at the inhalation conditions 
achievable by CF patients. Therefore, using this device can prevent the need for multiple 
capsule loadings and ease the administration of high-dose medications, and this has the 
opportunity to enhance adherence to the inhaled regimen. Further optimisation of the device 
using different capsule aperture sizes to deliver a wider range of high-dose formulations for 
treatment of lung infections is currently underway.    
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CHAPTER 6 
 
 
INHALATION OF RESPIRABLE CRYSTALLINE 
RIFAPENTINE PARTICLES INDUCES PULMONARY 
INFLAMMATION 
 
 
 
 
 
 
 
This chapter has been published in Molecular Pharmaceutics, 2017;14: 328-335, with the title 
‘Inhalation of respirable crystalline rifapentine particles induces pulmonary inflammation’. 
Authors: Parumasivam T, Ashhurst AS, Nagalingam G, Britton WJ, Chan H-K. 
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ABSTRACT 
 
Rifapentine is an anti-tuberculosis (TB) drug with a prolonged half-life, but oral delivery 
results in low concentrations in the lungs because of its high binding (98 %) to plasma proteins. 
We have shown that inhalation of crystalline rifapentine overcomes the limitations of oral 
delivery by significantly enhancing and prolonging the drug concentration in the lungs. The 
delivery of crystalline particles to the lungs may promote inflammation. This in vivo study 
characterises the inflammatory response caused by pulmonary deposition of the rifapentine 
particles. The rifapentine powder was delivered to BALB/c mice by intratracheal insufflation 
at a dose of 20 mg/kg. The inflammatory response in the lungs and bronchoalveolar lavage 
(BAL) was examined at 12 h, 24 h and 7 days post-treatment by flow cytometry and 
histopathology. At 12 h and 24 h post-treatment, there was a significant influx of neutrophils 
into the lungs, and this returned to normal by day 7. A significant recruitment of macrophages 
occurred in the BAL at 24 h. Consistent with these findings, histopathological analysis 
demonstrated pulmonary vascular congestion and significant macrophage recruitment at 12 h 
and 24 h post-treatment. In conclusion, the pulmonary delivery of crystalline rifapentine caused 
a transient neutrophil-associated inflammatory response in the lungs that resolved over 7 days. 
This observation may limit pulmonary delivery of rifapentine to once a week at a dose of 20 
mg/kg or less. The effectiveness of weekly dosing with inhalable rifapentine will be assessed 
in murine Mycobacterium tuberculosis infection.    
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1. INTRODUCTION 
 
Tuberculosis (TB) is a leading cause of death globally and is predominantly a respiratory 
infectious disease caused by Mycobacterium tuberculosis. It is estimated that one-third of the 
world’s population has been exposed to M. tuberculosis with almost 9.6 million new cases and 
1.5 million deaths annually [1]. The current treatment of TB is based on oral administration of 
at least three first-line drugs in combination (i.e. isoniazid, rifampicin, ethambutol, 
pyrazinamide) with direct observation of patient compliance. This strategy has been widely 
promoted and implemented by the World Health Organization (WHO) as DOTS (directly 
observed treatment, short course) [2]. However, the treatment is challenging owing to the 
requirement of at least 6 months therapy with high dose antibiotics and the associated side 
effects that often reduce patient compliance and treatment success. 
 
Inhalation drug delivery, following the natural route of infection, is a rational approach to 
improve the current anti-TB regimen. The advantages of inhalation drug delivery are: (1) it 
delivers the drug directly to the lungs that results in a higher local drug concentration than can 
be achieved by oral or parenteral administration [3, 4], (2) it reduces the systemic exposure of 
the drug [5], and (3) it avoids degradation of the drug by the liver and the acidic gastric 
environment [6]. These features of pulmonary delivery can reduce the drug dose and adverse 
effects, and therefore has the potential to shorten the treatment duration. 
 
Rifapentine is an US Food and Drug Administration (FDA) approved drug administered 
intermittently for treatment of latent TB. Following oral administration, however, rifapentine 
fails to reach effective concentrations in the lungs owing to high plasma protein binding (98 
%)[7]. In addition, the bioavailability of the drug is highly influenced by concomitant food 
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intake and induction of its own metabolism [8, 9]. Studies have shown that these barriers can 
be overcome if rifapentine is delivered directly to the lungs [10, 11]. In a previous study, we 
demonstrated that the intratracheal delivery of inhalable crystalline rifapentine to mice at a 
dose of 20 mg/kg produced a lung Cmax 100-fold higher than the intraperitoneal administration 
at same dose [10]. Furthermore, the lung Tmax was extended to 2 h when the drug was given by 
the intratracheal route compared to 1 h after intraperitoneal delivery [10]. The blood plasma 
and lung drug concentrations were also maintained above the minimum inhibitory 
concentration (MIC) against M. tuberculosis (0.03 – 0.06 µg/mL) [12] for more than 24 h post-
treatment [10]. These findings suggest that the inhalable crystalline rifapentine significantly 
enhances and prolongs the drug concentration in the lungs, and this has the potential to reduce 
the therapeutic dose and the treatment duration whilst maintaining systemic concentrations. 
 
Inhalation therapy is now accepted treatment for a number of respiratory diseases, such as 
asthma and cystic fibrosis,[13] but no inhaled medication has been approved for the treatment 
of TB. One limitation on the use of inhalable antibiotics for treatment of TB is the potential to 
exacerbate inflammation in the lungs. Therefore, in this report, we have examined the effects 
on pulmonary inflammation and cellular influx after intratracheal insufflation of respirable-
size crystalline rifapentine particles at a dose of 20 mg/kg in mice. We report the changes in 
the leukocyte populations in the lungs and the bronchoalveolar lavage (BAL), and the 
histopathological changes in the lungs after drug exposure. Although the cytotoxicity of 
rifapentine on in vitro respiratory cells has been documented [14-17], this is the first study to 
characterise in vivo the effects of pulmonary delivery of respirable-size rifapentine crystals. 
This is a necessary foundation prior to proceeding using the rifapentine in future murine TB 
efficacy studies and human clinical trials. Furthermore, this study contributes to better 
understand the safety of inhaled therapies for TB.  
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2. MATERIALS AND METHODS 
 
Rifapentine dry powder production and characterisation 
 
The rifapentine powder was produced following a method detailed in Chan et al. [17]. Briefly, 
rifapentine (Hangzhou ICH Imp & Exp Co. Ltd., Hangzhou, China) was dissolved in a co-
solvent system consisting of acetone (Ajax Finechem Pty Ltd., NSW, Australia) and 
UltraPureTM DNase/RNase-free distilled water (Thermo Fisher Scientific, NSW, Australia) 
(1:1, v/v) at a concentration of 4 mg/mL. The system was then heated at 67°C to evaporate the 
acetone and formed a crystalline suspension. The suspension was homogenised at 10 000 rpm 
for 2 minutes (Silverson L4RT High Shear Mixer, Silverson, Chesham, UK) and spray dried 
using a B-290 mini spray dryer (Buchi Labortechnik AG, Flawil, Switzerland) in an open-loop 
configuration using the following parameters: inlet temperature of 60 °C, atomiser of 60 mm, 
aspirator of 100 %, and feed rate of 2 mL/min.  
 
The morphology of the particles was examined using scanning electron microscopy (SEM) 
(FESEM, Hitachi S4500, Japan) at an acceleration voltage of 5 kV. The volume equivalent 
diameters of the particles were measured using laser diffraction coupled with a Scirocco dry 
powder disperser (Mastersizer 2000, Malvern Instruments, Worcestershire, UK) at a refractive 
index (RI) of 1.63 and dispersion air pressure of 3.5 bars.  
 
The aerodynamic properties of the powder was tested at flow rates of 60 L/min and 100 L/min 
for 4.0 secs and 2.4 secs, respectively with both representing an air volume of 4.0 L. A capsule 
(size 3, Capsugel, NSW, Australia) containing 10 ± 0.5 mg powder was loaded into an 
Osmohaler® and actuated through a multi-stage liquid impinger (MSLI) (Copley, Nottingham, 
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UK) to simulate an inspiration. The dispersion was performed in triplicate in a climate 
controlled cabinet: temperature, 20 ± 5°C and relative humidity (RH), 50 ± 3 %. 
Methanol:water (3:1, v/v) with 2 % ascorbic acid was used as a rinsing solvent. The drug mass 
was quantified using high-performance liquid chromatography (HPLC) [16, 17]. The mobile 
phase consisted of 50 mM phosphate buffer (pH 3.0):acetonitrile:tetrahydrofuran at a ratio of 
53:42:5 (%, v/v), and the stationary phase was a µBondapakTM C18 (3.9 × 300 mm2) column 
(Waters, Milford, Massachusetts). The system (Model LC-20, Shimadzu, Kyoto, Japan) was 
operated at an isocratic flow rate of 1 mL/min for 10 min. UV detection was performed at a 
wavelength of 250 nm (SPD-20A UV/VIS detector, Shimadzu) and the injection volume was 
20 µL. A calibration curve with a R2 value of 1.0 was obtained with standard concentrations 
ranging from 0.001 to 0.1 mg/mL. The emitted dose was calculated as the amount of drug 
exited the device and capsule relative to the total drug recovery from HPLC. The recovered 
fine particle fraction (FPFrecovered) was represented as the percentage of particles with an 
aerodynamic diameter less than 5 µm relative to the total drug recovery from HPLC. Mass 
median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) were 
calculated from the log-probability plot of the MSLI data, following Appendix XII C of the 
British Pharmacopoeia. 
 
Mice and ethics statement 
 
Female 6 - 10 week old BALB/c mice were obtained from Animal BioResources (Moss Vale, 
NSW, Australia) and were housed in specific-pathogen-free facilities at the Centenary Institute, 
Camperdown, NSW, Australia. The experiment was conducted in accordance with the 
Australian code of practice for the care and use of animals for scientific purpose and approved 
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by the Sydney Local Health District Animal Welfare Committee (protocol number 
2014/031A).  
 
Intratracheal delivery of rifapentine in a murine model 
 
Rifapentine was administered to mice via insufflation (DP-4M, Penn-Century, Philadelphia) at 
a well-tolerated oral dose used in mice and humans (20 mg/kg) [9, 18]. The mouse was 
anaesthesised with ketamine/xylazine (90/10 mg/kg) by intraperitoneal injection and secured 
on an intubation platform. The insufflator was then inserted into the trachea until the tip was 
immediately adjacent to the first bifurcation and the drug directly aerosolised onto the lung 
surface. The insufflator was weighed before and after the aerosolisation to measure the 
delivered dose. The mouse was then injected intraperitoneally with atipamezole (0.0125 mg) 
and rested on a heating pad and monitored until self-righting. Mice were euthanised at 12 h, 24 
h and 7 days post-treatment by CO2 asphyxiation, and lungs (perfused with PBS + 20 U/mL 
Heparin) and BAL were collected. Three lobes of the lungs and BAL were processed for total 
cell counts and immune cell characterisation via flow cytometry. One lobe of the lungs was 
used for histopathological analysis. Another one lobe was used for drug quantification (data 
not reported). The experiments were performed independently twice.  
 
The control mice were untreated (Nil) and did not undergo insufflations to determine basal 
values. Morello et al. reported that insufflation (air only) in female BALB/c mice resulted only 
in a minor congestion and hemorrhage, and resolved over time [19]. Similarly, in the present 
study, no macroscopic indication of significant trauma was observed in the lungs of the 
insufflated/treated mice. In addition, there was no significant increase in total leukocyte counts 
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in the lungs or BAL of the treated mice compared to the untreated group. Therefore, the 
inflammation caused by insufflation alone is likely to be negligible. 
 
Flow cytometry analysis 
 
Lung tissue was digested in RPMI 1640 media (Bacto Laboratories, Mt. Pritchard, NSW, 
Australia) containing fetal calf serum (FCS) (10 %, v/v), collagenase IV (50 U/mL, Sigma-
Aldrich, Castle Hill, Australia) and DNAse I (13 µG/mL, Sigma-Aldrich, Castle Hill, 
Australia) for 30 min at 37°C. After processing the lung tissue and BAL to single cell 
suspensions, erythrocytes were removed utilising ammonium-chloride-potassium (ACK) lysis 
buffer and the cells were then re-suspended in complete media. Fc receptors were blocked by 
incubation of cell suspensions with anti-CD16/CD32 (BD Pharmingen, San Jose, CA) in FACS 
buffer (PBS with 2 % FCS), followed by antibody staining for major leukocyte subsets. 
Antibody panel utilised: anti-CD11b AF700 (M1/70, BD Pharmingen, San Jose, CA), anti-
CD11c PECy7 (HL3, BD Pharmingen, San Jose, CA), anti-F4/80 PE (T45-2342, BD 
Pharmingen, San Jose, CA), anti-MHCII APC (M5/114.15.2, eBioscience, San Diego, CA), 
anti-Ly6G PerCPCy5.5 (1A8, Biolegend, San Diego, CA), anti-B220 APCCy7 (RA3-6B2, BD 
Pharmingen, San Jose, CA), anti-CD45.2 PB (104, Biolegend, San Diego, CA), anti-CD3 FITC 
(145-2C11, BD Pharmingen, San Jose, CA) and live/dead fixable blue dead cell stain 
(Invitrogen, Carlsbad, CA). Data were acquired on the BD LSRFortessa and analysed with 
FlowJo (TreeStar, Ashland, OR).   
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Histopathology examination 
 
The lung lobes designated for histopathology were inflated and immersed in 10 % neutral 
buffered formalin, and stained with hematoxylin and eosin (H & E). Histopathological 
evaluation was measured by microscopy on 5 µm sections of the stained lung. Inflammation 
was scored by two independent histopathologists who were blinded to the treatment conditions.  
 
Statistical analysis 
 
Data were expressed as mean ± standard deviation (SD) or standard error of the mean (SEM) 
as specified. Differences between treatment groups were evaluated by ANOVA with the 
Bonferroni post hoc comparison (GraphPad Prism 6 software), and p < 0.05 was considered 
statistically significant.  
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3. RESULTS 
 
Rifapentine powder characterisation 
 
The rifapentine particles were elongated crystals with physical width × length of at least 0.5 × 
1.0 µm as shown in the scanning electron micrograph (Figure 1), similar to those reported in 
our previous study [15]. The volume median diameter (D50) of the particles measured by laser 
diffraction was 1.47 ± 0.12 µm with a span of 1.56 ± 0.09. When the powder was dispersed at 
flow rates of 60 L/min and 100 L/min with an air volume of 4.0 L, the fine particle fraction 
(FPF < 5 µm) was 69.5 ± 1.3 % and 78.4 ± 1.1 %, respectively (Table 1). This was 
corresponding to a MMAD of 2.21 ± 0.1 µm and 1.85 ± 0.1 µm, respectively. The GSD was 
indifferent at both conditions with values between 1.75 and 1.78. Irrespective of the flow rates, 
the drug mostly deposited in stages 3 and 4, and filter stage (Figure 2). However, significantly 
higher device retention was observed at 60 L/min (22.3 ± 1.3 %) than 100 L/min (12.4 ± 3.3 
%).  
 
 
Figure 1. Elongated crystalline rifapentine particles viewed under scanning electron 
microscope. 
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Figure 2. In vitro deposition profile of the rifapentine following MSLI dispersion at a flow rate 
of 60 L/min and 100 L/min with an air volume of 4.0 L (n = 3). 
 
Table 1. Emitted dose, fine particle fraction (FPF < 5µm), mass median aerodynamic diameter 
(MMAD), and geometric standard deviation (GSD) for rifapentine powder dispersed at 60 
L/min and 100 L/mina. 
Flow rate 60 L/min 100 L/min 
Emitted dose (%) 73.8 ± 0.8 86.6 ± 2.5 
FPF < 5 µm (%) 69.5 ± 1.2 78.4 ± 0.2 
MMAD (µm) 2.21 ± 0.1 1.85 ± 0.1 
GSD 1.78 ± 0.1 1.75 ± 0.1 
amean ± SD, n = 3 
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Flow cytometry analysis 
 
A significant increase in neutrophils was observed in the lungs at 12 h and 24 h after treatment 
(Figure 3), an increase of approximately 20 % and 10 %, respectively compared to the untreated 
control (p < 0.01). However, the neutrophil population returned to normal by day 7. There were 
no significant differences in the other leukocyte populations in the lungs, except there was a 
trend for increase in macrophage/monocyte populations at 12 h and 24 h (p > 0.05), but this 
also returned to baseline by day 7.   
 
Similar cellular changes were also noted in the BAL after treatment (Figure 4). At 12 h and 24 
h post-dosing, there was a significant recruitment of neutrophils so that they comprised 80 % 
and 60 %, respectively of all leukocytes in the BAL (p < 0.05). Again, neutrophil counts 
returned to baseline by 7 days. There was a significant increase in the macrophage/monocyte 
and alveolar macrophage populations in the BAL at 24 h (p < 0.05), along with a small 
reduction in the T-cell, B-cell and dendritic cell (DC) populations at 12 h and 24 h post-dosing 
(p > 0.05).   
 
In summary, pulmonary delivery of rifapentine caused a transient neutrophil-associated 
inflammation in the lungs that had resolved over 7 days. Please refer to the Supporting 
Information for a detailed analysis of immune cell populations in the lungs and BAL (Appendix 
5). 
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Figure 3. Enumeration of leukocyte (CD45.2+) populations in the lungs of untreated mice, or at 12 h, 24 h and 7 days post-treatment. (A) Frequency of 
populations as a proportion of total lung leukocytes. Neutrophils (Ly6G+ CD11b+), B-cells (B220+ CD11c-), dendritic cells (DC) (B220- F4/80- CD11chi), 
combined macrophage/monocyte populations (Mac/mono) (B220- F4/80- CD11b+ CD11c-), alveolar macrophages (B220- F4/80+ CD11b+ CD11c-), 
plasmacytoid dendritic cells (pDC) (B220+ CD11c+), T-cells (CD3+) and others (unidentified cells). Enumeration of (B) neutrophils, (C) combined 
macrophage/monocyte populations (Mac/mono), and (D) alveolar macrophages. Differences between treatment groups were evaluated by ANOVA with 
Bonferroni post hoc comparison (*p < 0.05, **p < 0.01).  
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Figure 4. Enumeration of leukocyte (CD45.2+) populations in the BAL of untreated mice, or at 12 h, 24 h and 7 days post-treatment. (A) Frequency of 
populations as a proportion of total leukocytes in the BAL. Neutrophils (Ly6G+ CD11b+), B-cells (B220+ CD11c-), dendritic cells (DC) (B220- F4/80- 
CD11chi), combined macrophage/monocyte populations (Mac/mono) (B220- F4/80- CD11b+ CD11c-), alveolar macrophages (B220- F4/80+ CD11b+ 
CD11c-), plasmacytoid dendritic cells (pDC) (B220+ CD11c+), T-cells (CD3+) and others (unidentified cells). Enumeration of (B) neutrophils, (C) 
combined macrophage/monocyte populations (Mac/mono), and (D) alveolar macrophages. Differences between treatment groups were evaluated by 
ANOVA with Bonferroni post hoc comparison (*p < 0.05, **p < 0.01).  
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Histopathology examination 
 
Selected photomicrographs from the lungs of mice are depicted in Figure 5 and the 
interpretations are summarised in Table 2. When compared to control mice (Figure 5A), lungs 
of mice taken at 12 h after treatment showed a moderate cytoplasmic vacuolation and blebbing 
of the respiratory epithelium that suggested an epithelial cell degeneration (Figure 5B). 
Furthermore, mild necrosis occurred in the large to small bronchioles on the epithelium lining 
with mucin and karyorrhectic particles adhered to these small eroded surfaces. A mild 
perivascular inflammation characterised by neutrophil influx was also observed (Figure 5C).  
 
The examination at 24 h post-treatment (Figure 5D) showed a severe congestion in the 
parenchyma, compared to that of observed in the control mice or 12 h post-treatment. Extra- 
and intra-pulmonary airways including the terminal bronchiole displayed cytoplasmic 
vacuolation in at least 50 % of the epithelial cells and nearly one-third of the vacuole was 
mainly solitary. Moreover, the epithelial cells had shed and/or proliferated in small bronchioles 
with mononuclear cells in the peribronchial zone. In some airways, particularly in small 
bronchioles, a focal increase of epithelial cells with smaller nuclear to cytoplasmic (NC ratio) 
was present, suggesting early regeneration of cells. A significant recruitment of alveolar 
macrophages and edema was also observed (Figure 5E).  
 
The day 7 post-treatment (Figure 5F) observations showed that at least 60 % of the parenchyma 
was conspicuously congested compared to the untreated lung. The vascular outline of the 
alveolar walls was enhanced by proteinaceous deposits that obscured capillary and its lumen. 
The clumps of granular proteinaceous material also occupied some alveolar sacs together with 
few attached mononuclear and macrophage cells.  
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In summary, a prominent vacuolar cytoplasmic degenerative change occurred at 12 h that had 
intensified by 24 h. In addition, at 24 h a minor focal loss of bronchial epithelium was 
accompanied by an early stage of regenerative hyperplasia. This vascular congestion continued 
up to day 7. Nonetheless, no significant pleural changes were observed.   
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Figure 5. Photomicrographs of hematoxylin and eosin-stained (H & E) lung sections. (A) Lung 
section of an untreated mouse (Nil) (magnification x 10). (B) Lung section examined at 12 h 
after treatment showed a micro-vacuolar cytoplasmic change characterised by congestion 
(black arrow) and blebbing (grey arrow) of the epithelial lining (magnification x 10). (C) At 12 
A B 
C D 
E F 
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h post-treatment, perivascular inflammation characterised by neutrophil influx (blue arrow) 
was also observed (magnification x 10). (D) At 24 h post treatment, lung section showed 
intense congestion (black arrow) when compared to the control and 12 h-post dosing group 
(magnification x 10), and (E) recruitment of alveolar macrophages and occurrence of edema 
(grey arrow) (magnification x 20). (F) Day 7 lung section showed a presence of alveolar 
macrophages, granulomatous inflammation and alveolar vascular congestion (magnification x 
20).       
 
Table 2.  Summary of histopathological findings in the lungs of animals received crystalline 
rifapentine. 
Parameters Control  12 h 24 h Day 7 
Alveolar congestion - + ++ ++ 
Vacuolisation - + + + 
Presence of neutrophils - + ++ ++ 
Presence of monocytes or macrophages - + ++ ++ 
Necrosis of epithelial - + + - 
Edema - - + + 
Pleural change - - - - 
 Abbreviation: (-), within normal limits; (+), mild; (++), severe. 
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4. DISCUSSION 
 
The rifapentine powder was found suitable for aerosolisation with a high FPF between 69.5 % 
and 78.4 %. The elongated morphology of the particles reduced the cohesive van der Waals 
forces and deposited via interception for a high respirable fraction [17]. This is also reflected 
in a minimal deposition in the throat and stage 1, and higher retention in stage 3 to filter stage 
of the MSLI. However, the FPF produced at 100 L/min (78.4 ± 0.2 %) was significantly higher 
compared to when dispersed at 60 L/min (69.5 ± 1.2 %). The inferior FPF was due to 
insufficient powder emptying from the device at 60 L/min, suggesting the elongated particles 
required high energy input to disperse the powder as revealed by the marked pressure drop at 
100 L/min (~4.0 kPa) than that of 60 L/min (~1.4 kPa). Nonetheless, this high device retention 
in clinical application is likely to be optimised by multiple breathing inspirations. Thus, the 
crystalline rifapentine demonstrated in vitro aerosol properties suitable for inhaled 
administration. 
 
In our previous studies, we have established that solubilised rifapentine was tolerated by human 
airway epithelial (Calu-3), human alveolar basal epithelial (A549) and human THP-1 
monocyte-derived macrophage cell lines up to a concentration of 60 µg/mL [14, 16, 17, 20]. In 
contrast, tobramycin, a currently FDA-approved drug for treatment of cystic fibrosis via the 
inhalation route, is non-toxic to lung epithelial cells up to a concentration of 1.0 g/mL [21]. 
However, the cytotoxicity of rifapentine could be overestimated in the in vitro assays as the 
drug was dissolved in an organic solvent (i.e. DMSO) prior to use in the assays, while a gradual 
dissolution is expected after deposited in the lungs. The in vitro assays also differ from the 
actual characteristics of in vivo delivery to the lungs, such as mucociliary clearance of the 
pulmonary region that will have a significant impact on the particle dissolution and retention 
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in the lungs. Therefore, assessing the impact of pulmonary delivery in vivo is essential for 
determining a rational dosage regimen for further preclinical and clinical studies.  
 
A single dose pulmonary insufflation of rifapentine caused a neutrophilic inflammation in the 
lungs at 12 h and 24 h post-exposure that resolved by 7 days. Neutrophils are the first 
leukocytes recruited to phagocytose and denature foreign materials deposited in the lungs 
through the release of reactive oxygen species, defensins, lactoferrin, cathepsins and lysozymes 
[22, 23]. Increased secretion of reactive oxygen species, such as superoxide anion and 
proteolytic enzymes (e.g. neutrophil elastase) can cause significant pulmonary inflammation 
and lung damage. The physiological effect of the inflammation caused by the neutrophil influx 
in the present study is unknown. None of the mice were distressed, suggesting the insufflation 
of rifapentine had not caused any acute lung damage for 7 days after the treatment. The 
histology further revealed that the lung damage was reversible with evidence of some 
regeneration of epithelial cells and no significant pleural changes after 24 h and 7 days post-
treatment. Similar results were reported when a single dose of a cationic lipid suspension was 
administered to BALB/c mice by nasal instillation [24]. This caused a significant influx of 
neutrophils into the lungs and BAL at 1 to 3 days that returned to baseline by 14 days. There 
were also increased levels of the pro-inflammatory cytokines, interleukin-6 (IL-6), tumor 
necrosis factor-α (TNF-α) and interferon-γ (IFN- γ) that peaked at 1 to 2 day post-treatment 
and returned to baseline by 14 days [24]. On the other hand, Patil-Gadhe et al. showed that 
repeated intratracheal insufflations (28 days daily) of rifapentine proliposomes at doses of 1 
and 5 mg/kg in Wistar rats did not elicit pulmonary irritation, as revealed by minimal changes 
in neutrophil populations. However, when the multiple doses were increased to 10 mg/kg which 
is only 50 % of the dose used in this study, there was a significant mortality due to excessive 
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inflammatory responses in the lungs [15]. Therefore, careful attention is required if multiple 
doses of rifapentine at 20 mg/kg are to be delivered via the pulmonary route. 
 
Another important finding was the increased number of alveolar macrophages (~15-20 %) and 
to lesser extent macrophage/monocyte populations in the BAL at 24 h post-exposure, both of 
which resolved by day 7. This was consistent with the lung histology analysis where the 
alveolar spaces were dominated by foamy macrophages at 24 h (Figure 5E). This may be due 
to the activation of the alveolar macrophages to phagocytose the rifapentine particles, as well 
as recruitment of inflammatory monocytes from the peripheral blood that differentiate into 
tissue macrophages [25]. Similarly, Freimark et al. showed an influx of alveolar macrophages 
in the lungs of C57BL/6 mice after intratracheal instillation of liposome suspensions containing 
an immunogenic plasmid. This resulted in enhanced immune responses, possibly through the 
increased cellular uptake of the particles [26]. Therefore, both alveolar and monocyte-derived 
macrophages may have phagocytosed the slowly dissolving rifapentine particles. This has the 
potential to directly target M. tuberculosis residing within macrophages and possibly shorten 
the duration of treatment for TB.    
 
The DC, B-cell and T-cell counts in the BAL were slightly reduced at 12 h and 24 h time points 
and returned to normal by day 7, suggesting the rifapentine deposition likely affected the 
antigen presenting cells (APC) distribution in the lungs. A previous study demonstrated that 
the DCs were efficient at phagocytosing polystyrene nanoparticles (50 nm and 500 nm diameter 
in size) and transporting them from lung to the draining lymph node [27]. Furthermore, the 
inflammation in the lungs prior to the particle insufflation was found to enhance the maturation 
and migration of DCs, and increased the drainage of the particles via the lymphatic system [27, 
28]. A similar study also reported that the footpad injection of polystyrene nanoparticles with 
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a diameter of 20 nm in diameter were taken up by DCs, macrophages and B-cells, and trafficked 
the particles to the lymph node [29]. These findings support the possibility that the rifapentine 
particles trafficked from lungs to the draining lymph nodes. The pharmacokinetic data also 
supports this possibility as intratracheal insufflation of rifapentine at the same dose resulted in 
systemic delivery of the drug with a Tmax of 12 h in the spleen [10]. Presumably, the clearance 
of rifapentine particles from the lungs was driven by a combination of cell-mediated transport 
and drainage via the lymphatic system, and also by macrophages through mucociliary 
clearance.  
 
One of the critical issues in inhalation toxicology is the dose for delivery. Unlike oral and 
intravenous routes, it is difficult to determine the delivered dose following inhalation exposure 
as only a fraction of the inhaled dose will deposit in the lungs. In the present study, an 
intratracheal device (DP-4M® insufflator, Penn-Century) was used which has been proven to 
have high accuracy and reproducibility for delivery of drugs directly to the lungs [30, 31]. This 
delivery technique also widely distributes the powder throughout the lungs of mice, and 
prevents pharyngeal and upper airway losses [31]. However, one limitation of this method is 
that the insufflator is only efficient for delivering a minimum dose of 0.4 mg corresponding to 
20 mg/kg of rifapentine. One of the approaches to overcome this barrier is to reduce the 
proportion of the active ingredient with a carrier, such as lactose or mannitol, in order to 
increase the dry powder mass loaded into the insufflator. The addition of such a carrier, 
however, may alter the pharmacokinetics of the drug after deposition in the lungs [32]. 
Furthermore, the risk of inflammation due to pulmonary delivery of rifapentine may be 
overestimated in this model as the drug was delivered using a DP-4M® insufflators under 
positive pressure which is different to aerosol deposition during tidal breathing. In the present 
study, 200 µL air pulses were utilised as recommended by the manufacturer [33] for delivery 
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of the powder under positive pressure. It is therefore possible that some particles may have 
been deposited in regions of the lungs that are not readily accessible by inhalation under 
ambient pressure. Hoppentocht et al. reported that an air volume of 200 µL was insufficient for 
aerosolisation, with 500 µL and 1000 µL air pulses providing superior deagglomeration of 
powders [34]. However, the maximum air volume that is safe to use for insufflation in mice is 
250 µL [19]. Furthermore, during normal breathing, larger crystals would deposit in the upper 
airways and be eliminated before reaching the lungs. The forcible deposition of these larger 
crystals or agglomerates directly into the lungs by insufflations may have exacerbated the 
neutrophil influx. It has also been reported that even spray instillation of saline, a solution 
considered as “safe” and commonly used in nebulisation caused a transient neutrophil influx 
in rats [35]. Therefore, it would be valuable to assess the pulmonary inflammation when 
rifapentine is delivered via inhalation during tidal breathing in the future. 
 
 
 
 
 
 
 
 
 
 
 
 
 
273 
 
5. CONCLUSION 
 
We have shown that the intratracheal delivery of respirable crystalline rifapentine at a dose of 
20 mg/kg caused a neutrophil-associated transient pulmonary inflammation that resolved over 
7 days period. This may limit the pulmonary delivery of rifapentine to once a week at the given 
dose or less. The efficacy of weekly dosing with inhalable rifapentine in a murine model of M. 
tuberculosis infection is ongoing. Furthermore, this finding suggests that the inhaled antibiotics 
may be more suitable to be administered as an adjunct with an oral regimen where patients may 
require intermittent dosing such as weekly, but this will depend on the powder formulation and 
pharmacokinetic profile of the drug.     
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CONCLUSION 
 
The thesis is comprised of a series of studies that characterise the potential of inhaled therapy 
contribute to the treatment of TB. Novel inhalable dry powder formulations containing efflux 
pump inhibitors (verapamil or thioridazine) and rifapentine were successfully formulated 
(Chapter 2 and 3). These powders demonstrated excellent aerosol performance, enhanced in 
vitro activity against intracellular growth of M. tuberculosis compared to single drug 
treatments, and a promising in vitro cytotoxicity profile. On the other hand, rifapentine-PLGA 
particles regardless of monomer and MW showed good aerosol performance and higher affinity 
for macrophage uptake (Chapter 4). These polymeric particles were also relatively non-toxic 
to lung-associated cell lines, including macrophages and bronchial epithelial cells. These 
chapters have established that the rifapentine-containing inhalable dry powders generated as 
either pure drug or in polymeric formulations are suitable for further in vivo evaluation. 
 
For an effective inhaled anti-TB regimen, patients may need to inhale a large dose of antibiotics 
repeatedly. The modified Aerolizer® (1pin_HR_00) is a low-cost generic device that can 
efficiently aerosolise antibiotic powders with various physiochemical properties, including 
crystalline rifapentine up to a maximum dose of 100 mg in a single capsule (Chapter 5). This 
device has the opportunity to ease the administration of large doses of medication and this may 
enhance patient adherence to the inhaled therapy.  
 
Finally, the potential clinical risk associated with pulmonary drug delivery of high dose powder 
rifapentine was also addressed (Chapter 6). It was found that intratracheal delivery of 
rifapentine (20 mg/kg) triggered a transient neutrophil influx in the lungs which resolved by 7 
days post-dosing. These findings suggest that the inhaled rifapentine dry powder is more 
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suitable for periodic dosing (i.e. weekly) and as an adjunct to the standard oral anti-TB drug 
regimen.  
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FUTURE DIRECTIONS 
 
The results from this thesis provide a strong foundation for the following ongoing or planned 
studies:  
 
1. Single dose and multi-dose murine pharmacokinetic studies using the dry powder 
rifapentine alone, verapamil-rifapentine and thioridazine-rifapentine are ongoing. This will be 
followed by TB therapeutic studies where the mice will be infected with M. tuberculosis strain 
and treated with the drug administered via inhalation route. In parallel, the pulmonary toxicity 
profile of the drugs will be evaluated. The findings from this series of in vivo studies are 
important for determining a rational dosage regimen for TB patients. 
 
 2. The modified Aerolizer® device will be tested for its potential to deliver the anti-TB 
drugs in combination. If necessary, the device will undergo further modifications to enhance 
its performance, for example by increasing the capsule hole size to improve the powder 
emptying. This study will allow the device to be optimised to deliver antibiotics in combination 
as will be required for multi-drug therapy of TB. The device will also be tested for human lung 
deposition studies. 
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FINAL REMARKS 
 
Pulmonary treatment using powder aerosols is a relatively new approach for the treatment of 
TB. Although formulation development and preclinical evaluation for various anti-tubercular 
drugs are in their advanced stage, human clinical trials continue to lag behind. This could be 
due to lack of information on pulmonary physiology of TB patients and safety concern with 
particle deposition in the lungs. Therefore, learning from the application of inhalation 
treatment of other respiratory diseases could contribute to advancing this therapeutic strategy 
for TB. This is a rational and rapid approach to progress inhaled TB regimen from theory to 
clinical reality. 
 
Furthermore, if the anti-TB drugs manufactured into inhalable forms are expensive comparable 
to oral therapy, this will reduce the accessibility of the therapy to countries with the highest 
burden of TB cases which are typically low-income countries. If this hurdle can be mitigated 
satisfactorily, inhaled anti-TB therapy has potential to significantly contribute to the global 
elimination of TB. Although an inhaled drug regimen was not included in the recent WHO’s 
agenda of “END TB Strategy 2015” to eliminate TB by 2030, a global mutual partnership in 
the future will significantly boost the progress of the inhaled therapy for TB. 
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In Vitro Evaluation of Inhalable Verapamil-Rifapentine Particles for Rapid Tuberculosis Therapy 
T. Parumasivam1*, J. G. Y. Chan1, 2, A. Pang3, D. H. Quan4, W. Britton3, J. Triccas4, and H. K. Chan1
1Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Australia 
2JHL Biotech, Inc., Hsinchu County, Taiwan 
3Tuberculosis Research Program, Centenary Institute, Sydney, Australia 
4Infectious Diseases and Immunology, Sydney Medical School, Sydney Medical School, The University of Sydney, 
Australia 
Background 
Drug efflux is a crucial resistance mechanism of Mycobacterium tuberculosis (M. tb) that prolongs treatment 
duration by promoting tolerance to anti-tubercular (TB) drugs and inducing intracellular bacterial survival. 
Compared to existing first-line anti-TB therapy, both verapamil, a FDA-approved hypertension drug that functions 
as an efflux inhibitor, and the first-line anti-tubercular drug, rifapentine, have separately demonstrated treatment-
shortening in mouse models of TB infection. Unfortunately, anti-TB antibiotics, particularly rifamycins, have been 
found to induce metabolism of oral verapamil thereby reducing its bioavailability. Delivering the combination of 
verapamil and rifapentine directly to the lungs would be a rational approach to overcome these barriers. Additional 
advantages of pulmonary delivery include (1) direct targeting of infected granulomas and (2) high drug 
concentration at the primary site of infection. In this study, we produced an inhalable combination antibiotics 
formulation consisting of verapamil and crystalline rifapentine. In vitro aerosol performance and biological aspects 
including toxicity were reported.    
Methods 
A combination dry powder of verapamil and crystalline rifapentine in a mass ratio of 1:3 (based upon orally 
recommend dosage) with 20% L-leucine was produced using co-solvent precipitation and spray drying techniques. 
In vitro aerosol performance of the powder was assessed using a multi-stage liquid impinger (MSLI). The minimum 
inhibitory concentration (MIC) of the powder on M. tb H37Ra was determined via resazurin assay. Intracellular 
killing efficacy of the compounds was tested on THP-1 cells, a human monocyte cell line infected with M. tb
H37Ra. THP-1and human lung epithelial A549 cell lines were used to examine the in vitro cytotoxicity profile of 
the powders.   
Results 
The spray dried verapamil- rifapentine combination dry powder was found suitable for aerosolization. The total fine 
particle fraction (FPFtotal) of verapamil and rifapentine was 77.44±1.07 and 71.49±1.97, respectively. A noteworthy 
synergism was observed as the combination formulation had an MIC of 0.156 ng/mL, which is significantly lower 
than the verapamil (250 ug/mL) and rifapentine (0.625 ng/mL) alone. Rifapentine also augmented the intracellular 
killing of M. tb in the presence of verapamil. All the powders were shown an acceptable half maximal inhibitory 
concentration (IC50) on both THP-1 and A549 cell lines.      
Conclusion 
We have demonstrated a novel inhalable verapamil-rifapentine dry powder with good aerosol performance that 
shows potent activity against M. tuberculosis in in vitro models. This preliminary data warrants further in vivo 
studies. 
The 8th International Conference on Materials Science and Technology
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Tuberculosis (TB) regiment requires relatively long term oral administration of first-line anti-TB drugs 
for curing and preventing emergence of drug-resistance. Recently, inhaled administration of drugs 
encapsulated into micro polymeric particles to the lungs has attracted significant attention, as it offers 
several advantages compared with local and systemic delivery. These include delivering high drug 
concentrations to lung tissues, avoiding hepatic first-pass metabolism, prolonging drug residence in the 
lungs which potentially reduces dosing frequency, as well as targeting alveolar macrophage that 
harbours tubercle cells proliferation. Poly (lactic-co-glycolic acid) (PLGA) is amongst the most 
studied microparticulate systems because it (1) is a FDA approved polymer for medical, (2) allows 
sustained release of the encapsulated drugs to minimize the need for multiple dosing, and (3) is readily 
phagocyted by alveolar macrophage to enhance macrophage intracellular drug concentration. 
Nonetheless, limited data are available in the effects of the physiochemical properties of PLGA, such 
as the monomer (lactide : glycide) ratio and molecular weight, on the aerosol performance. The present 
study aims to address this knowledge gap. PLGA with a monomer ratio of 50:50, 75:25 and 85:15 and 
molecular weight ranged 24-240k was studied using rifapentine (RPT) as a model drug. PLGA and 
RPT were dissolved in acetonitrile at concentrations of 20 mg/ml and 2 mg/ml, respectively. The 
mixture was spray dried using a B-290 Mini spray-dryer in closed-loop with nitrogen as the drying 
gas. The particle morphology and size distribution were examined using scanning electron microscopy 
and laser diffraction respectively. The in vitro aerosol performance of the produced powders was 
assessed using an OsmohalerTM coupled to a next generation impactor (NGI) running at an air flow of 
100L/min for 2.4 sec. Macrophage uptake and cytotoxicity profile of these particles were also 
examined using THP-1 (human monocytic leukemia cell line) and A549 (adenocarcinomic human 
alveolar basal epithelial cells). All produced particles were spherical with smooth surface and a 
volume median diameter (D50) was around 2μm (with a span around 2) which is a suitable size for 
respiratory delivery. The fine particle fraction (FPFtotal) reached above 55% for all formulations. 
Apparently, no significant difference was observed in FPFtotal between all formulations indicating 
PLGA ratio is not a crucial parameter in PLGA inhalation. Nonetheless, the distribution of drug was 
found to be a function of monomer ratio, with more drug incorporated on the external surface for 
particles with higher lactide content. Also, a higher rate of THP-1 phagocytosis was observed for 
PLGA 85:15 followed by 75:25 and 50:50. Furthermore, cell toxicity analysis indicated PLGA itself 
does not have any effect on cell viability. Though the monomer ratio and molecular weight did not 
show any effect in the aerosol performance of particles, the distribution of drugs within the particles 
was found to be affected by these parameters. This finding may have indirect influence on the 
controlled release profile of drugs after they are inhaled into the lungs. 
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INTRODUCTION
Dry powder inhalers (DPIs) are an attractive alternative to nebulizers for high dose inhalation 
medications (≥ 25 mg) because they can be cheaper, more convenient to use, and may reduce 
administration time. The potential of using DPIs to deliver high dose therapeutics to the lungs 
has been recognized [1-4], and may be particularly beneficial for antibiotics [5, 6] and vaccines 
[7]. This work demonstrates the capability of a modified Aerolizer® to aerosolize a wide range of 
high dose carrier-free micronized antibiotics, including colistin for treatment of gram-negative 
bacterial infections, and rifapentine for treatment of tuberculosis.  
MATERIALS AND METHODS
An Aerolizer was modified to accommodate a hydroxypropyl methylcellulose (HPMC) size 0 
capsule (Capsugel, Peapack, NJ) and the original piercing pins were changed from four small pins 
(0.65 mm in diameter) to a single, centrally located large pin (1.19 mm in diameter) on each side 
(Figure 1). In addition, the air inlet size was reduced to 1/3 of the original design based on the 
area of the exterior opening to increase the air velocity and turbulence inside the swirl chamber to 
promote particle deagglomeration. The prototype of the modified inhaler was manufactured by 
Plastiape S.p.A. (Osnago, Italy).
The performance of the modified Aerolizer was evaluated using colistin and rifapentine 
spray dried powders and a multi-stage liquid impinger (MSLI, Copley Scientific Ltd, Nottingham, 
UK). The colistin and rifapentine powders were prepared as reported in [8] and [9], respectively. 
They were of two distinct morphologies: near-spherical with corrugated surface texture (colistin) 
and needle-shaped (rifapentine) (Figure 2). The geometric particle size of colistin powders ranged 
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from 0.5 to 2 µm and the width of the rifa- 
pentine crystals was of the same magnitude. 
The loaded doses for colistin and rifapentine 
were 50 mg and 30 mg, respectively, each rep- 
resenting an approximately 80% capsule fill 
by volume. The airflow conditions of the 
MSLI were 60 L/min for 4 s (4 L) corres- 
ponding to a 4.0 kPa pressure drop across 
the inhaler. The cut-off diameters for MSLI 
stages 1 to 4 are 13.0, 6.8, 3.1, and 1.7 µm, 
respectively. Drug was recovered from the 
MSLI and quantified using high perfor-
mance liquid chromatography using methods 
described in [8, 9].
Figure 2.  SEM images of A) colistin and B) rifapentine.
RESULTS
For both powders, approximately 14% to 18% of powder was retained in the capsule or inhaler 
device after aerosolization (Figure 3). The high emitted dose indicates the modified Aerolizer is 
capable of aerosolizing drugs of different morphologies in the range of 30 to 50 mg. Aerosolized 
colistin and rifapentine powders showed emitted fine particle fractions (FPFemitted) of 65% and 
80%, respectively. These results indicate that deagglomeration of the spray dried antibiotic powders 
occurred before they exited the device. 
CONCLUSIONS
The modified Aerolizer, which can accommodate a size 0 capsule, was found to be able to disperse 
high dose drugs (30 to 50 mg). These preliminary data demonstrate the potential of the modified 
Aerolizer to deliver a wide range of dry powder therapeutics.
Figure 1.  An image of the modified Aerolizer.
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Figure 3. (a) Deposition profile and (b) aerosolization performance of colistin and rifapentine powders dis-
persed using a modified Aerolizer.
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Assessing Murine Immune Response to Pulmonary Delivery of Crystalline Rifapentine Particles 
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Purpose: We have shown that inhalable rifapentine could significantly enhance and prolong the drug 
concentration in the lungs which has the potential to shorten the treatment duration of tuberculosis (TB) (1). The 
present in vivo study characterizes the inflammatory response caused by pulmonary deposition of rifapentine 
particles. 
 
Methods:  6 – 8-week old female BALB/c mice were anesthetized with xylazine/ketamine and rifapentine 
powder was delivered by intratracheal intubation and insufflation at a dose of 20 mg/kg. Mice were euthanized 
at 12, 24 hours and 7 days post treatment, and bronchoalveolar lavage (BAL) and lungs were collected. The 
control was untreated mice (Nil). The left lung and BAL were processed for total cell counts and immune cell 
characterization via flow cytometry. The right lung was fixed by inflation and immersion in 10 % neutral 
buffered formalin, and stained with hematoxylin and eosin (H&E) for histopathological examination. 
 
Results: An inflammatory response characterized by a significant influx of neutrophils was observed in the 
lungs at 12 and 24 hours post-exposure, and the response was resolved by day 7 (Figure 1a). The BAL showed a 
significant recruitment of macrophages at 24 hours (Figure 1b). The histopathological analysis also supports 
these observations, a pulmonary vascular congestion with prominent macrophage recruitment was observed at 
12 and 24 hours, and returned to normal over 7 days.  
 
 
Figure 1. (a) Neutrophil count in the lung and (b) macrophage count in the BAL. Differences between 
treatments were evaluated by ANOVA with Bonferroni post hoc comparison (*p < 0.05, **p < 0.01). 
 
Conclusion: Pulmonary delivery of rifapentine caused a neutrophil-associated inflammatory response in the 
lungs and resolved over 7 days, limiting the pulmonary delivery of rifapentine to once a week at a dose of 20 
mg/kg. Efficacy of weekly dosing inhalable rifapentine in a murine TB model is planned.    
 
References: 
1. Chan JGY, Tyne AS, Pang A, McLachlan AJ, Perera V, Chan JCY, Britton WJ, Chan HK, Duke CC, 
Young PM, Traini D. Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder. Int J 
Antimicrob Agents. 2014;43(3):319-323. 
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APPENDIX 3. SUPPLEMENTARY DATA FROM CHAPTER 4 
 
 
 
Figure 1. DSC thermograms showing glass transition temperature (Tg) (°C) of PLGA-
rifapentine particles. The samples were heated 30-300°C under a dynamic flow of nitrogen gas.  
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Figure 2. Agglomeration of SP(1)85:15_190k exposed to dissolution media for 24 h, viewed 
under scanning electron microscope. 
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Figure 3. (a) THP-1 and (b) A549 cell viability (MTT assay) after 4 days of exposure to 
rifapentine loaded various PLGA particles (mean ± SD, n=3). None of the formulations led to 
a reduction of cell viability below 50 %, indicates that the PLGA particles non-toxic to 
respiratory associated cell lines. 
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APPENDIX 4. SUPPLEMENTARY DATA FROM CHAPTER 5 
 
Table 1. Laser diffraction analysis showing volume equivalent diameters of the particles.  
 D10 (µm) D50 (µm) D90 (µm) 
Colistin  0.77 ± 0.03 1.57 ± 0.04 3.06 ± 0.11 
Rifapentine  0.61 ± 0.13 1.41 ± 0.13 3.07 ± 0.30 
Tobramycin 0.55 ± 0.07 1.31 ± 0.11 2.73 ± 0.10 
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Table 2. Performance of 1pin_HR_00 dispersing colistin at various dispersion conditions. 
Flow 
(L/min) 
Time 
(sec) 
Inhaled 
air 
volume 
(L) 
Amount of powder 
emitted in the first 
actuation 
(mg) 
FPFRecovered 
(%) 
Comments 
30 2.0 1.0 ~ 11.1 19.0 ± 0.1 A low FPF 
30 3.0 1.5 ~ 13.0 n/d A low FPF is 
expected 
30 4.0 2.0 ~ 13.0 n/d A low FPF is 
expected 
45 1.4 1.0 ~ 20.0 41.8 ± 1.4 A low FPF 
45 2.0 1.5 ~ 21.1 46.9 ± 3.3  An acceptable 
FPF and 
emptying dose 
45 2.7 2.0 ~ 32.0 51.0 ± 1.5  An acceptable 
FPF and 
emptying dose 
60 1.0  1.0 ~ 62.1 n/d Emptying a 
relatively large 
amount 
60 1.5 1.5 n/d n/d Emptying a 
relatively large 
amount is 
expected 
60 2.0 2.0 n/d n/d Emptying a 
relatively large 
amount is 
expected 
n/d : not determined 
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Table 3. Performance of 1pin_HR_00 dispersing rifapentine at various dispersion conditions. 
Flow 
(L/min) 
Time  
(sec) 
Inhaled 
air 
volume 
(L) 
Amount of powder 
emitted in the first 
actuation 
(mg) 
FPFRecovered  
(%) 
Comments 
30 2.0 1.0 n/d n/d A low FPF is 
expected 
30 3.0 1.5 n/d n/d A low FPF is 
expected 
30 4.0 2.0 ~ 1.8  3.9 ± 0.1 A low FPF 
45 1.4 1.0 n/d n/d A low FPF is 
expected 
45 2.0 1.5 ~ 5.0 15.9 ± 1.0 A low FPF 
45 2.7 2.0 ~ 7.9  14.3 ± 1.0 A low FPF 
60 1.0 1.0 ~ 8.3 n/d A low FPF is 
expected 
60 1.5 1.5 ~ 8.1  16.0 ± 1.7 A low FPF 
60 2.0 2.0 ~ 10.7 58.4 ± 2.4  An acceptable 
FPF and 
emptying dose 
n/d : not determined 
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Figure 1. X-ray powder diffraction patterns of the spray-dried antibiotics.   
 
 
Figure 2. DSC thermograms of the spray dried-drug powders.  
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Figure 3. Dynamic vapour sorption behaviour of the spray-dried drug powders.  
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APPENDIX 5. SUPPLEMENTARY DATA FROM CHAPTER 6 
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Figure 1. Immune cell subsets in the lungs at 12 h, 24 h and 7 day post-treatment as a 
percentage of CD45.2+ cells. The control mice were untreated (Nil). (A) Neutrophils (Ly6G+ 
CD11b+), (B) B-cells (B220+ CD11c-), (C) dendritic cells (DC) (B220- F4/80- CD11chi), (D) 
combined macrophage/monocyte populations (Mac/mono) (B220- F4/80- CD11b+ CD11c-), (E) 
alveolar macrophages (B220- F4/80+ CD11b+ CD11c-), (F) plasmacytoid dendritic cells (pDC) 
(B220+ CD11c+), and (G) T-cells (CD3+). Differences between treatments were evaluated by 
ANOVA with Bonferroni post hoc comparison (*p < 0.05, **p < 0.01, ***p < 0.001). 
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Figure 2. Immune cell subsets in the bronchoalveolar lavage (BAL) at 12 h, 24 h and 7 day 
post-treatment as a percentage of CD45.2+ cells. The control mice were untreated (Nil). (A) 
Neutrophils (Ly6G+ CD11b+), (B) B-cells (B220+ CD11c-), (C) dendritic cells (DC) (B220- 
F4/80- CD11chi), (D) combined macrophage/monocyte populations (Mac/mono) (B220- F4/80- 
CD11b+ CD11c-), (E) alveolar macrophages (B220- F4/80+ CD11b+ CD11c-), (F) plasmacytoid 
dendritic cells (pDC) (B220+ CD11c+), and (G) T-cells (CD3+). Differences between 
treatments were evaluated by ANOVA with Bonferroni post hoc comparison (*p < 0.05, **p 
< 0.01, ***p < 0.001). 
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“The man who graduates today and stops learning tomorrow is uneducated the day after” 
- Newton D. Baker - 
 
 
 
 
 
 
 
 
 
